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CHAPTER 1: GENERAL INTRODUCTION  
INTRODUCTION 
Metabolite diversity in the Echinacea genus 
The genus of Echinacea (known popularly as purple coneflower, or Kansas snakeroot) 
is a perennial herb that is native to North America and grouped within the Aster family 
(Compositae or Asteraceae).  Historically, Echinacea preparations have been used by Native 
Americans as universal herbal remedies to various ailments ranging from snake bites to burns 
and colds (Foster, 1991; British Herbal Medicine Association, 2003). Today, Echinacea is used 
most widely as prevention or treatment for the common cold, with the proposed mechanism of 
action typically relating to Echinacea’s reported ability to stimulate the immune system 
(Barnes et al., 2005).  Echinacea-containging products were reported in 2004 as the top-selling 
herbal preparations in the United States (Yu, 2004). There are perhaps nine species of 
Echinacea, and three of these species (Echinacea angustifolia DC., E. pallida (Nutt.) Nutt., and 
E. purpurea (L.) Moench.) are commonly used for medicinal purposes; either shoots or roots 
may be used. Both oral and topical preparations have been used. 
A wide range of unusual phytochemicals have been found in Echinacea, some of which 
have been reported to have bioactivity. These include alkamides and ketoalkene/ynes (Bauer, 
2002; Woelkart et al., 2005), caffeic acid derivatives (e.g., chlorogenic acid, caftaric acid, 
cichoric acid, and echinacoside, a caffeic acid glycoside derivative) (Cheminat et al., 1988; 
Hudec et al., 2007), unusual polysaccharides (Bonadeo et al., 1971; Proksch & Wagner, 1987; 
Razina et al., 2007), and glycoproteins (Bodinet & Beuscher, 1991; Egert & Beuscher, 1992; 
Romiti et al., 2008).  
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Echinacea is native to various habitats in the eastern and central United States, with 
minor range extensions into southern Canada. The current state of Echinacea systematics is 
still in disputation. The traditionally accepted taxonomy for Echinacea was proposed in the 
taxonomic monograph of the genus by McGregor (1968), which delimited 9 species and 4 
subspecies.  In contrast, more recently, Binns et al. (2002) lumped these into only 4 species. As 
highlighted by McGregor, many Echinacea species are widely distributed and are highly 
variable morphologically. In addition, species appear to hybridize where their ranges overlap, 
creating hybrid swarms and advanced-generation segregates that are difficult to assign to 
particular species.  Because the Echinacea genus encompasses considerable taxonomic and 
genetic diversity (Kapteyn et al., 2002; Kim et al., 2004), we postulate that the genus also 
contains considerable metabolic diversity, potentially including compounds related to 
bioactivity and human health effects.   
These morphologically-distinct Echinacea groups exhibit differences in phytochemical 
composition (Barnes et al., 2005); however, most studies have been limited to the major three 
medicinally used species. The only studies that attempted to cover all species of Echinacea was 
conducted by Binns et al. (2002), who reported the phytochemical variation in Echinacea from 
roots and flowerheads of wild and cultivated populations. However, in that report, most of the 
alkamides and ketones were identified solely on their UV spectra and their relative retention 
times as compared to the alkamide 8/9 standard. In my research, I have used authentic 
alkamides and ketones as well as structural information obtained by a combination of HPLC-
PDA, GC–MS and HPLC-ESI-MS/MS to provide more comprehensive compound 
identification. 
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 Plants contain a wide variety of specialized (secondary) metabolites, i.e., metabolites 
that are family or species-specific, and often represent adaptive characters that have been 
subjected to natural selection during evolution (Wink, 2003). Echinacea species have a number 
of very unusual specialized metabolites, including the putatively bioactive alkamides, 
ketoalkene/ynes, and phenolics, many of which are exclusive to the genus of Echinacea.  I 
hypothesize that the levels of these putatively bioactive constituents vary greatly between and 
within Echinacea species and this variation is determined by taxonomic differences as well as 
differences in geographical origins.  
Pharmacological activities of Echinacea  
So far scientific studies on the pharmacological activities of Echinacea are mostly 
based on in vitro and animal studies.  The primary focus of most of these studies has been 
immunomodulatory activity (Appendix F; Zhai et al., 2007) and anti-inflammatory activity 
(Speroni et al, 2002; LaLone et al., 2007).  Other activities, such as anti-viral activity 
(Thompson, 1998; Birt et al., 2008), anti-fungal activity (Binns et al., 2000), and antioxidant 
activity (Pellati et al., 2004; Hudec et al., 2007), have also been reported.   
 Clinical trials on human subjects are very limited. A recent review on the effects of 
Echinacea in preventing and treating cold pointed out that to date the clinical data on 
Echinacea are not conclusive and well controlled clinical trials are needed to better evaluate 
Echinacea efficacy as a treatment for colds in humans (Woelkart et al., 2008).   In a review of 
medicinal properties of Echinacea by Barrett (2003), the author concluded that while there is a 
great deal of moderately good quality scientific data demonstrating immunomodulatory 
activities, the effectiveness of Echinacea in treating illness or in enhancing human health has 
not yet been proven beyond a reasonable doubt. One difficulty with the interpretation of these 
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studies is that the plant materials used differ greatly, and the quality and genetic source of the 
materials was not determined in most of the trials. Also, there is great variability in human 
subjects, and appropriate controls were often not used.  In addition, it is not known when to 
apply extracts in relation to exposure to symptoms in human populations. 
Extensive studies indicate that the chemical composition of Echinacea extract is 
complex, including various groups of phytochemicals that have been reported to display 
bioactivity (Barnes et al., 2005). However, it is still uncertain which specific compound(s) are 
primarily responsible for these bioactivities. Among these phytochemicals, phenolics and 
alkamides/ketoalkene/ynes have been the most widely studied. These constituents are found in 
ethanolic liquid extracts, a traditional Echinacea preparation for medicinal purposes. Despite 
the various activities that have been reported from these two groups of compounds, only a few 
bioavailability studies have been reported (Dietz et al., 2001; Jager et al., 2002; Matthias et al., 
2004). According to Matthias et al. (2004), caffeic acid derivatives (caftaric acid, echinacoside 
and cichoric acid) permeated poorly through the Caco-2 cell monolayers, with <5% transported 
after 90 min, while most of the alkamides readily crossed the monolayers, with >50% 
transported after 90 min. The results indicate that alkamides but not caffeic acid derivatives are 
likely to across the intestinal barrier and thus be available to elicit pharmacological effects. 
Inflammation, pain, and calcium signaling 
Inflammation is the complex biological response of organism tissues to harmful stimuli, 
trauma or infection (Libby, 2008).  It is a protective attempt by the immune system to remove 
the injurious stimuli as well as initiate the healing process.  Inflammation and pain are always 
closely interrelated. During inflammation, numerous mediators are produced by inflammatory 
cells and by leucocytes that are recruited to the site of injury. Many of these mediators, such as 
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cytokines, prostaglandins (PGs), lipo-oxygenases and growth factors, can activate or sensitize 
nociceptors which are specialized primary afferent neurons that cause sensation of pain (LeBars 
& Adam, 2002).   
Calcium, a universal signaling molecule, is widely recognized to play a fundamental 
role in the regulation of various biological processes (Berridge et al., 1998).  In the immune 
system, Ca2+ signals regulate the activation, function and gene expression of lymphocytes, 
including T and B cells, NK cells and macrophages (Feske, 2007).  A transient increase in 
cytoplasmic Ca2+ concentration represents a key step for neurotransmitter release and the 
modulation of cell membrane excitability (Pardo, 2001). Accumulating evidence has 
demonstrated the involvement of Ca2+ in regulating pain (Dierssen et al., 1990; Smith & 
Dewey, 1992; Dogrul & Yesilyurt, 1998; Pardo, 2001).   
Echinacea has been historically used by Native American Indians as an herbal 
medicine to treat a number of ailments.  Well known for its characteristic fiery and pungent 
taste, Echinacea produces local anesthesia of the mucous membranes; thus, it has been used 
medicinally since ancient times.  Perhaps the principal use of Echinacea by Native Americans 
was in relation to pain alleviation and the promotion of healing, such as in cases of snake bites, 
pain, burns, cough, sore throats, and toothache (Foster, 1991; Greger, 1984). Despite the 
popularity of the herb and the many pharmacological and clinical studies, the molecular 
mechanism of action of Echinacea remains poorly understood (Woelkart et al., 2005).  With 
the exception of the studies indicating that three alkamides stimulate cannabinoid (CB) 
receptors (Raduner et al., 2006), no studies have scientifically evaluated the action of 
Echinacea on pain, its potential mediation of inflammatory responses via pain receptors, or the 
calcium signaling pathway underlying Echinacea action.  
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The central hypothesis I test in this research is that endogenous compounds present in 
Echinacea activate specific receptors in cells of the immune and central nervous system (CNS) 
to regulate the intracellular Ca2+ signaling pathway, and this regulation underlies the anti-
inflammatory and pain-modulating activities of Echinacea.  The overall goal is to be able to 
determine which compound(s) in Echinacea extracts are bioactive and which receptors these 
compounds are interacting with.  This work is important in gaining a better understanding of 
the central processing of pain and neural-immune interactions. 
DISSERTATION ORGANIZATION 
This dissertation consists of seven chapters and six appendices.  Chapter 1 is the 
general introduction presenting background information on metabolite diversity and 
bioactivities in Echinacea.  Chapters 2 to 6 are chapters modified from published works, 
manuscripts in preparation and unpublished findings. Chapter 2 is a comprehensive evaluation 
of phytochemical variation between roots of forty Echinacea accessions with broad 
geographical and morphological diversity grown under controlled conditions. A dendrogram 
was generated from these metabolite data and was compared with the two existing taxonomic 
treatments of the Echinacea genus, McGregor (1968) and Binns et al. (2002).  Chapter 3 
reports the synthesis and natural distribution of a group of three diacetylenic isobutylamides in 
Echinacea.  Chapter 4 evaluates Echinacea as a regulator of intracellular Ca2+ levels in 
HEK293 cells.  A possible mechanism for Echinacea activation of the Ca2+ signaling pathway 
and how this activation might underlie bioactivities of Echinacea was proposed. Chapter 5 
further investigates the Echinacea-mediated Ca2+ signaling pathway using astrocyte, neuron 
and mixed cultures from rat.  Echinacea stimulated an elevation of intracellular Ca2+ in 
astrocytes and this activation was demonstrated to be related to the CB1 receptor.  Chapter 6 
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reports an indirect interaction of Echinacea with TRPV1 pain receptor using Xenopus laevis 
oocytes as a model system.  All the data in these 5 chapters were collected and analyzed by 
myself, except: Dr. Mark Widrlechner provided the Echinacea seedlings for research in 
Chapters 2 and 3; in Chapter 2, the statistical analysis was kindly provided by Dr. Philip Dixon, 
Department of Statistics; in Chapter 3, the syntheses of these reported alkamides were done by 
Jaehoon Bae, a former graduate student in Dr. Kraus’ lab, Department of Chemistry; in 
Chapters 4 and 5, some of the Echinacea extracts and fractions were provided by Catherine 
Hauck, Department of Food Science; in Chapter 4, the GC-MS analysis was carried out by Dr. 
Ludmila Rizshsky, Department of Biochemistry, Biophysics and Molecular Biology; in 
Chapter 5, the calcium imaging data were obtained by Ksenija Jeftinija, and the primary rat 
hippocampal cells were cultured by Dr. Eric Rowe and Catherine Martens, Department of 
Biomedical Sciences; and in Chapter 6, Dr. Qiang Leng, Department of Cellular and Molecular 
Physiology, Yale University School of Medicine, trained me and guided me with the frog 
oocyte system.  Chapter 7 is a general conclusion summarizing and discussing the results 
presented in chapters 2 to 6.  The Appendices include additional information resulting from this 
work and publications related to this dissertation research. 
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CHAPTER 2.  METABOLIC PROFILING OF ECHINACEA 
GENOTYPES AND A TEST OF ALTERNATIVE TAXONOMIC 
TREATMENTS 
Modified from a paper to be published in Planta Medica 
Lankun Wua, Philip M. Dixonb, Basil J. Nikolauc, George A. Krausd, Mark P. Widrlechnere, 
Eve Syrkin Wurtele a,∗ 
ABSTRACT 
The genus Echinacea is used as an herbal medicine to treat a variety of ailments. To 
better understand its potential chemical variation, forty Echinacea accessions encompassing 
broad geographical and morphological diversity were evaluated under controlled conditions.   
Metabolites of roots from these accessions were analyzed by HPLC-photo diode array (HPLC-
PDA), GC-MS, and multivariate statistical methods.  In total, 43 lipophilic metabolites, 
including 24 unknown compounds, were detected. Weighted principal component analysis 
(WPCA) and clustering analysis of the levels of these metabolites across Echinacea accessions, 
based on Canberra distances, allowed us to test two alternative taxonomic treatments of the 
genus, with the further goal of facilitating accession identification. A widely-used system 
developed by McGregor based primarily on morphological features was more congruent with 
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the dendrogram generated from the lipophilic metabolite data than the system more recently 
developed by Binns et al.  Our data supports the hypothesis that Echinacea pallida is a diverse 
allopolyploid, incorporating the genomes of Echinacea simulata and another taxon, possibly 
Echinacea sanguinea.  Finally, most recognized taxa of Echinacea can be identified by their 
distinct lipophilic metabolite fingerprints. 
Key Words: Echinacea, Asteraceae, Alkamides, Alkylamides, HPLC, GC-MS, PCA 
INTRODUCTION   
Echinacea extracts, particularly from roots, have historically been used by Native 
Americans and, more recently, by Western cultures as herbal remedies to treat ailments ranging 
from snake bites to pain, burns, cough, sore throats and toothache [1], [2], [3].  Echinacea 
products are promoted for immune-system enhancement and are among the best-selling herbal 
preparations in the United States [4]. Many unusual phytochemicals have been found in 
Echinacea, some with reports of bioactivity in animal cells or animals, including alkamides 
and ketones, caffeic acid derivatives, glycoproteins, and unusual polysaccharides (as reviewed 
by Bauer [5]).  Despite its popularity as an herbal dietary supplement, and many pertinent 
pharmacological and clinical studies, little is known regarding the specific compounds 
primarily responsible for observed bioactivity, or whether they are consistently efficacious in 
humans [6].   
Although morphologically-distinct Echinacea groups exhibit differences in 
phytochemical composition [5] and bioactivity [7], most studies have focused on three major 
medicinal species: Echinacea angustifolia DC., E. pallida (Nutt.) Nutt., and E. purpurea (L.) 
Moench. The most comprehensive study to date was conducted by Binns et al. [8], who 
reported on phytochemical variation in Echinacea from roots and capitula of wild and 
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cultivated populations representing all nine Echinacea species recognized by McGregor [9].  
However, in that report, most alkamides and ketones were identified by UV spectra and 
relative retention times compared to one major pair of alkamide standards.  Baum et al. [10], in 
a recent review of the status of Echinacea systematics and phytochemistry, indicated that 
Echinacea taxa are readily distinguishable on the basis of HPLC profiles and that HPLC 
profiles for lipophilic compounds contain more information than those based on caffeic-acid 
derivatives.  This is noteworthy, because of the existence of two alternative taxonomic 
treatments for Echinacea.  The older, developed by McGregor [9], was based on field 
observations, common-garden studies, and cytological and anatomical analyses. McGregor’s 
classification has been widely used by botanists and herbalists [11] and serves as the basis for 
the recent Flora North America treatment [12].  Binns et al. [13] proposed a revision, based on 
morphometric data and phytochemical data from greenhouse-grown and wild plants, using 
canonical discriminant and cladistic analyses.  This revision recognizes all but one of 
McGregor’s taxa, with most significant changes being a reduction in number of species, an 
increase in number of varieties, and in particular, incorporating 5 morphologically diverse 
clades characterized as species by McGregor [9] into a single species.  This Binns et al. [13] 
revision is controversial in the botanical community [11]. 
The current DNA-based molecular marker evidence is not yet refined sufficiently to 
generate accession-level systematics [14] [15].  Even an extensive DNA-sequencing study 
using these identical accessions and based on multiple loci has thus far been unable to 
completely evaluate systematic relationships among these accessions [16].    
Here, we have taken a targeted, metabolite-profiling approach to investigate the 
accumulation of putatively bioactive alkamides and ketones in 40 geographically and 
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morphologically diverse Echinacea populations, which had already been well characterized 
morphologically and as to origin. We used as standards authentic alkamides and ketones that 
were purchased or synthesized by our group [17], [18], [19], as well as structural information 
obtained by a combination of HPLC-PDA and GC–MS, for more comprehensive compound 
identification. Since we lacked reference standards for many of the metabolites reported in this 
study (43 in all), we used relative instead of absolute metabolite concentrations to compare 
overall lipophilic-metabolite profiles across the 40 accessions.  This approach, coupled with 
weighted principal component analysis (WPCA) and clustering analysis based on Canberra 
distances [20], provides an opportunity to test these two taxonomic classifications. 
Furthermore, these metabolic profiles may help standardize Echinacea products, characterize 
plant material of unknown provenance, and identify genetic sources to select for increased 
production of desired compounds. 
MATERIALS AND METHODS  
Plant materials  
We selected 40 well-characterized Echinacea accessions (Table 1) representing a broad 
geographic and morphological sampling of the germplasm conserved by the U.S. National 
Plant Germplasm System, USDA-ARS North Central Regional Plant Introduction Station, 
Ames, IA [21].  Initially we looked at roots of two ages of plants: 6-month-old and 3-year-old.  
We found that the relative levels of metabolites vary, but the same identified alkamides, 
ketones and unknown metabolites are present at both ages (Fig. 1S, Supporting Information); 
therefore, we focused on 6-month-old plants because we are able to grow them under well 
controlled conditions. Characterization data for a broad range of (>40) morphological traits are 
at Germplasm Resources Information Network database http://www.ars-grin.gov/cgi-
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bin/npgs/html/desc_form.pl?221.  Accessions had been keyed to species (or subspecies) during 
initial regeneration on the basis of McGregor [9], and we converted McGregor identifications 
to the treatment of Binns et al. [13] via Table 2 in [10].   Growth conditions, sampling methods 
are in Supporting Information.  
Extraction, HPLC and GC-MS analysis 
Plant extraction, HPLC and GC-MS analyses were performed as [17], [18], [22].   
Compound identification and relative abundance 
In addition to 19 known alkamides and ketones, another 24 unknown lipophilic 
metabolites were also detected and grouped according to their retention times and UV spectra 
(Table. 1S, Supporting Information).  Methods for determination of relative abundance of 
metabolites are provided in Supporting Information.   
Statistical analysis  
Multivariate analyses by WPCA and hierarchical clustering analysis were performed in 
R software, version 2.2.1 (http://www.r-project.org/).  Detailed information is provided in the 
Supporting Information.   
RESULTS AND DISCUSSION  
Most Echinacea extractions use dry materials and rigorous methods that last 1-24 hours 
(e.g. soxhlet extraction [23], ultrasonic extraction [24], shaking [8]).  To minimize possible 
degradation of unstable metabolites during extraction, we used a quick extraction method by 
powderizing a small amount of fresh tissue with liquid N2 and extracting at low temperature 
[17], [18].  By using authentic synthesized standards, combined with GC-MS and HPLC-PDA, 
we evaluated 40 accessions (Fig. 1) and detected 43 UV-absorbing lipophilic metabolites.  Of 
these, 19 metabolites were identified, including 16  alkamides and 2 ketones among those  
  
18
reported so far by the pioneering studies of Bauer and colleagues [5]; and another recently 
reported alkamide, herein referred to as “Chen alkamide” [25] (structures see Fig. 2S, 
Supporting Information).  In addition, we detected 24 unknown lipophilic metabolites, some of 
which (e.g., unknown B5 and unknown 9) are relatively abundant. Five unknowns (unknowns 
A1-A5) have UV spectra similar to the 2, 4-diene alkamides (1, 2, 3, 4, 7, 10, and 11). Six 
unknowns (B1-B6) have UV spectra similar to the monoene alkamides (12, 13, 14, 16 and 17) 
(Table 1S, Supporting Information).  Interestingly, ten unknown metabolites have atypical UV 
spectra. Most of the unknowns (3-10) are highly lipophilic and thus elute at later times. 
Identification of these unknowns is currently being conducted by HPLC-tandem mass 
spectrometry (LC-MS/MS), semi-preparative HPLC, and NMR. 
Our observation of 43 lipophilic metabolites (Table. 1S, Supporting Information) can 
be contrasted with the findings of Binns et al. [8] who distinguished 15 unique alkamides, 2 
pairs of alkamides (alkamide 8/9 and alkamide 5/15), and 3 ketones.   We detected the presence 
of all but 4 of these, 3 of the alkamides and 1 of the ketones. Our ability to distinguish more 
than twice the compounds from these samples is likely attributable to two factors, rapid 
extraction under low temperature, minimizing possible degradation, and a more sensitive 
HPLC separation method with extended retention times.  
To elucidate how Echinacea accessions are related in terms of their overall metabolite 
profiles, two multivariate statistical approaches were used: WPCA and clustering analysis. 
Traditional PCA assumes that all observations of a particular metabolite have the same 
variance, although variances may differ between metabolites. However, for our dataset, 
standard deviations among biological replicates increase with metabolite abundance, i.e., the 
abundant compounds are more variable (Fig. 2).  We used WPCA to account for this pattern.  
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Each element of the data is given a corresponding “weight”, proportional to the inverse of the 
variance. Thus, smaller peaks with smaller errors are given a larger weight, placing more 
emphasis on these less abundant compounds.   
WPCA reveals large quantitative and qualitative differences in lipophilic metabolites 
among Echinacea populations (Fig. 3). Each composite metabolite profile indicates metabolites 
that tend to be present together or absent together (Fig. 3A).  The accession profiles indicate 
relative abundance of corresponding metabolite profiles for each accession (Fig. 3B).    Profile 
1 (WPC1) focuses on the most abundant compounds, primarily amides 8 and 9, with smaller 
amounts of amides 3, 5, 11 and 12.  Profile 1 is most abundant in accessions identified on the 
basis of McGregor [9] as E. angustifolia, E. atrorubens (Nutt.) Nutt., E. purpurea, E. pallida 
and E. sanguinea Nutt.  Profile 2 (WPC2) contains predominantly amides 2, 3, the Chen 
alkamide, ketones 22, 24, and unknown 8.  Profile 2 is most abundant in E. purpurea, also in 
many other species, except E. angustifolia, E. atrorubens and E. tennesseensis (Beadle) Small.  
Profile 3 (WPC3) is almost exclusively composed of amides 12, 13 and 14 and is most 
abundant in E. angustifolia and E. tennesseensis. The three profile solution explains 94.8% of 
the variance of the whole dataset. 
The hierarchical dendrogram constructed from Canberra distances [20] for all pairs of 
40 accessions (3 plants per accession), based on average linkage (Fig. 4), displays phenetic 
relationships among accessions, labeled on the basis of McGregor [9] (Fig. 4A),  and coded for 
the four species recognized by Binns et al. [13] (Fig. 4B).  The primary area of agreement 
between the two taxonomic schemes is the recognition of a distinct species pair, E. purpurea 
and E. laevigata (C. L. Boynton & Beadle) S. F. Blake, which share a distinct stem anatomy, 
leaf shape, and phyllary structure, clustered in adjacent groups in Fig. 4.   
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The major difference between the two treatments centers on the remaining taxa, which 
McGregor [9] treated as seven species with two additional varieties, and Binns et al. [13] 
treated as only two species with six additional varieties.  The dendrogram presented in Fig. 4 
lends little support for the circumscription of the two, diverse species as proposed by Binns et 
al. [13], for two primary reasons.  First, the observed degree of differentiation that distinguishes 
E. laevigata from E. purpurea in Fig. 4, recognized by Binns et al. [13] as a clear distinction at 
the subgeneric level, would support the recognition of three additional subgenera, which we do 
not feel is warranted based on all other relevant data.  In addition, the two inclusive species 
recognized by Binns et al. [13] as E. pallida and E. atrorubens cluster in an intercalated fashion 
within the dendrogram, above and below the cluster containing E. laevigata and E. purpurea. 
Thus, lipophilic metabolic profiles do not support the broad species combinations proposed by 
Binns et al. [13]. 
In contrast, there is a better correspondence to the species and at least one of the 
varieties recognized by McGregor [9] (Fig. 4).  Of the nine species recognized by McGregor 
[9], accessions from six cluster together into a single branch in the tree: E. laevigata, E. 
purpurea, E. tennesseensis, E. sanguinea, E. atrorubens and E. angustifolia.  The three that do 
not are E. pallida, E. simulata McGregor and E. paradoxa (Norton) Britton.  
For E. pallida, three of five accessions cluster together (Fig. 4), but accessions PI 
631315 and PI 631275 do not.  Interestingly, the three E. pallida accessions that are clustered 
together are adjacent to E. simulata, which McGregor [9] considered to be very close to E. 
pallida and a likely progenitor of this tetraploid species.  He hypothesized that the other species 
involved in the parentage of E. pallida was E. sanguinea; the two “atypical” accessions are 
located on our dendrogram closer to E. sanguinea than to E. simulata.  Support for a close 
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biochemical relationship between E. pallida and E. sanguinea was reported recently by 
Senchina et al. [26], who conducted a phenetic analysis of the immunomodulatory 
characteristics of seven Echinacea taxa.  Binns et al. [13] treated both E. simulata and E. 
sanguinea as varieties of E. pallida.  
For E. paradoxa, the two varieties recognized by McGregor [9] form clean clusters 
adjacent to each other (Fig. 4).  Taken as a single group, the E. paradoxa “cluster” also 
includes two putative hybrid accessions, both of which were collected from populations where 
E. paradoxa was sympatric with other taxa (Table 1), and E. angustifolia var. strigosa 
McGregor PI 631320.  Five of six accessions of E. angustifolia cluster together (Fig. 4), the 
outlier being E. angustifolia var. strigosa PI 631320. We speculate that E. angustifolia var. 
strigosa occupies some “hybrid middle ground” between E. paradoxa var. neglecta McGregor 
and E. angustifolia var. angustifolia (supported geographically); and/or E. angustifolia var. 
strigosa is not well differentiated based on lipophilic compounds. Variety strigosa has been 
recognized as problematic by other researchers as well.  McGregor [9] considered it to be of 
hybrid origin, as did Binns et al. [13], and the conversion table presented by Baum et al. [10] 
does not recognize it as a distinct taxon nor does Flora North America [12]. 
In general, the dendrogram generated on the basis of Canberra distances for lipophilic 
metabolite profiles among our 40 accessions supports the taxonomic treatment presented by 
McGregor [9], with the possible exception of E. angustifolia var. strigosa.  The metabolic 
profiles also indicate that there are diverse chemotypes of E. pallida, consistent with its 
proposed allopolyploid origin. 
Although we sampled a broad geographic distribution of accessions representing each 
taxon, these accessions generally clustered consistently with taxa as identified by 
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morphological, anatomical, and cytological characteristics used by McGregor [9], rather than 
by geographic or environmental variables gleaned from their provenance data.  Thus, our 
analyses imply that the distribution and types of alkamide and ketone metabolites in Echinacea 
do not evolve in a convergent manner in response to particular geo/environmental conditions.    
Finally, the relative concentrations of the 43 lipophilic compounds appear to be 
distinctive enough by taxon to allow us to develop “typical” profiles for Echinacea 
fingerprinting, which could be validated by evaluating additional populations.  Thus, this 
research expands the basis for the evaluation, standardization, and identification of plant 
material of unknown provenance for cultivated Echinacea and for commercial Echinacea 
products.  In addition, these data contribute to the identification of genetic resources for the 
production of specific alkamides and ketones.  In the course of this study, we found over 20 
unidentified metabolites, some of which may be alkamides or ketones.  The bioactivity guided 
fractionation together with compound identification will elucidate these as yet unidentified 
metabolites.  
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Supporting information 
Detailed methods and additional data are available at http://www.thieme-
connect.de/ejournals/toc/plantamedica. 
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Table. 1 Accession information for Echinacea evaluated in this study. 
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Fig. 1 Relative abundance of lipophilic metabolites in roots from 6-month-old plants of 
40 accessions of Echinacea. Error bars indicate standard deviations of means of 
triplicate experiments. 
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Fig. 2 Relationship between the standard deviation (s.d.) and mean across all 
combinations of accessions and metabolites.  Both s.d. and mean are plotted on log 
scales. 
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Fig. 3 Weighted principal component analysis (WPCA) of lipophilic metabolite profiles 
in roots from 6-month-old plants of 40 accessions of Echinacea, illustrating the 
differences among Echinacea accessions. A: The relative importance of each metabolite 
to each of the three WPCs.   B:  The relative abundance of each component in different 
accessions.  
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Fig. 4 Hierarchical dendrogram constructed from profiles generated from 43 lipophilic 
metabolites, using Canberra distance, illustrating the distances between 40 Echinacea 
accessions (3 plants per accession). A is marked only with abbreviations of the 
accessions following McGregor [9] and the final three digits of the accession number.  B 
also includes blocking corresponding to the four species recognized by Binns et al. [13], 
with A = E. atrorubens, L = E. laevigata, Pa = E. pallida, and Pu = E. purpurea.  
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SUPPORTING INFORMATION 
Supporting Information for Materials and Methods  
Plant materials 
Seed samples of the 40 accessions were soaked for 24 hours in a 1 mM solution of 
ethephon to overcome dormancy and promote rapid germination [1].  After soaking, seeds 
were transferred to clear plastic boxes with blotters moistened with distilled water.  
Germination boxes were held at 4 oC for four weeks and then transferred to germination 
chambers maintained at a constant 25 oC with 14 hours of illumination per day.  Three-week-
old seedlings were transferred into 20 cm pots in a growing medium consisting of 50% 
Canadian Peat Moss, 40% Perlite, and 10% mineral soil, and grown under ambient light in a 
greenhouse at 22-25 oC, with daily watering. Pots were arranged on a single greenhouse bench 
in a completely randomized design generated from a random-digits table [2]. Fresh roots were 
harvested from 6-month-old plants.  To standardize plant materials with respect to possible 
diurnal metabolic variation, harvests were between 9 a.m. and 10 a.m..  Harvested roots were 
thoroughly washed and rinsed with distilled water, and were immediately chopped and ground 
to a fine powder in liquid N2 in a mortar and pestle, and stored in liquid N2 until extraction.  
Each accession was analyzed in triplicate on independently extracted plant samples from three 
individual plants. 
Compound quantification 
A mixture of alkamides 8/9 (97% purity) was purchased (Phytolab, Vestenbergsgreuth, 
Germany).  Alkamides 2, 8, 10, 11, 12, 13, 14, Chen alkamide, and ketone 22 were synthesized 
in-house.  Analysis of the 1H NMR and mass spectra of these synthesized compounds reflected 
purity >90%.  In the absence of standards for selected compounds, alkamides 1, 3, 4, 5, 7, 15, 
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16, 17 and ketone 24 were identified by HPLC fractionation coupled with GC-MS analysis.  
Determination of the relative abundance of compounds was carried out by calculating UV 
response relative to the internal standard. 7-Hydroxy-(E)-N-isobutylundeca-2-ene-8,10-
diynamide (C15H21O2) has been found suitable to use as an internal standard for lipophilic 
metabolites because it has not been found in Echinacea plants and did not coelute with any 
other observed metabolites. By adding an internal standard prior to extraction, we were able to 
quantify both known and unknown metabolites by calculating UV response relative to the 
internal standard. Specifically, of the 43 lipophilic metabolites, alkamides 12, 13, 14, 16, and 
17, ketones 22 and 24, unknowns B1-B6, and unknowns 1-9 were determined at A210nm with 
respect to the internal standard.  Alkamides 1, 2, 3, 4, 7, 10 and 11, Chen amide, unknowns A1-
A5 (all with similar UV spectra) and unknown 10 were determined at A260nm with respect to 
the internal standard, by using a relative-response factor derived from reference standard 
alkamide 2, to correct for absorbance differences between these metabolites and the internal 
standard. Alkamides 5, 8, 9, and 15 and unknowns C1-C3 (all with similar UV spectra) were 
also determined at UV260nm with respect to the internal standard, using a relative-response 
factor derived from reference standard alkamide 8/9 to correct for absorbance differences 
between these metabolites and the internal standard. The relative-response factors of alkamide 
2 and alkamides 8/9 were calculated at A260nm. Amounts of authentic alkamide 2 or 
alkamides 8/9 varying between 0.625 and 3.125 μg along with 2.5 μg internal standard were 
injected to give an average relative-response factor of 0.0669 (R2 = 0.99) for amide 2, and 
0.0932 (R2 = 0.99) for amide 8/9 under A260nm.  Because reference standards were not 
available to calculate relative-response factors for each compound in respect to the internal 
standard, and because several of the peaks represent as yet-unidentified metabolites, the values 
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presented for the comparison of profiles herein are relative concentrations rather than absolute 
values, and thus, are presented without units of concentration. 
Statistical analysis 
Metabolite concentrations from three plants per accession were averaged and organized 
into a 40 (accessions) × 43 (relative concentration) matrix.  Because standard deviations among 
replicates increased with mean metabolite values, the average concentrations of more abundant 
(with UV absorbance) metabolites were less precisely measured than were those detected at 
lower levels (Fig. 2). The least precisely measured lipophilic constituents have a standard 
deviation >1000× larger than those most precisely measured. Traditional methods to 
summarize patterns in concentration matrices, e.g. PCA or clustering using Euclidian distance, 
ignore such differences in precision.  The statistical methods used here account for this 
difference, by computing a matrix based on Canberra distances for all pairs of accessions.  
Distances among accessions are illustrated by generating a hierarchical cluster tree (or 
dendrogram), based on average linkage.   
The matrix of metabolite concentrations was decomposed into contributions from 
unique profiles by using the model: 
ijjijijiij eY ++++= K)3()3()2()2()1()1( βαβαβα                   (1) 
where Yij is the observed relative concentration of component j in accession i, β(k) is the 
vector representing the k’th metabolite profile, α(k) is the vector representing the abundance of 
the k’th metabolite profile in each accession, and eij is the random deviation between the 
observed concentration and the summed contributions of k metabolite profiles.  If all 
observations are assumed to have the same precision, the unknown profiles, β(k), and their 
abundances, α(k), can be estimated by PCA without centering or standardization.  This is 
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equivalent to a singular value decomposition of the matrix Y, which can be computed by ‘criss-
cross regression’ [3].  For one profile, the criss-cross regression algorithm starts with an initial 
guess for α(1).  The unknown β(1) values are estimated by linear regression of columns of Y on 
X= α(1).  The estimated β(1) values are used to update the estimate of α(1) by linear regression of 
columns of Y on X= β(1).  These alternating regressions are repeated until the estimates 
converge. 
In our case, however, the precision of an observation is related to the mean, i.e. 
2σijij meVar = ,                             (2) 
where 
( )2)3()3()2()2()1()1( K+++= jijijiijm βαβαβα                      (3) 
When the variance multipliers, mij, are known, the optimal estimator of a multiple 
regression slope is the weighted least squares estimator with a weight proportional to the 
inverse of the variance.  The unknowns, α(k) and β(k), can be estimated by combining criss-cross 
regression with iteratively reweighted least squares.  The weighted Principal Components 
Analysis algorithm to estimate α(k) and β(k)  for a total of K profiles is: 
Assemble the K vectors of profiles into a matrix β with K rows and J columns. 
Assemble the K vectors of abundances into a matrix α with I rows and K columns. 
Use starting values for α and β to calculate a starting mean matrix, m = α β. 
Compute the weight matrix with elements wij = (1/mij)2. 
Given the current profiles, β, estimate abundances, α, by weighted multiple regression 
of columns of Y on β using the matching column of w as weights. 
Given the updated matrix of abundances, α, estimate profiles, β, by weighted multiple 
regression of columns of Y on α using the matching column of w as weights. 
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Recompute the mean and weight matrices by using the updated matrices of profiles and 
abundances. 
Repeat the last three steps until the profile and abundance matrices converge. 
The solutions are illustrated by plotting the K profiles and corresponding abundances. 
Accessions were clustered by computing a distance measure between their chemical 
compositions.  Unequal precision can be incorporated into a distance measure by weighting 
each pairwise contribution.  For example, the weighted version of Manhattan Distance between 
accessions a and b is 
∑ −=
j
bjajabjab YYwMD |             (4) 
where Yaj and Ybj are the concentrations of component j in accessions a and b, and wabj 
is the appropriate weight for that contribution to the overall distance.  When the measurement 
standard deviation is proportional to the mean value, the optimal weight is the reciprocal of the 
mean, wabj = (Yaj + Ybj)/2.  The resulting distance measure is proportional to the distance 
measure known as the Canberra Distance or Lance-Williams distance [4] 
∑
= +
−=
J
j bjaj
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|1                 (5) 
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Table. 1S Lipophilic metabolites found in roots of Echinacea species.  A mixture of 
alkamides 8/9 (97% purity) was purchased (Phytolab, Vestenbergsgreuth, Germany).  
Alkamides 2, 8, 10, 11, 12, 13, 14, Chen alkamide, and ketone 22 were synthesized in-
house.  Analysis of the 1H NMR and mass spectra of these synthesized compounds 
reflected purity >90%.  In the absence of standards for selected compounds, alkamides 
1, 3, 4, 5, 7, 15, 16, 17 and ketone 24 were identified by HPLC fractionation coupled 
with GC-MS analysis.  Metabolites were grouped according to their UV spectra.  Gray 
color: maximum UV absorption at 260 nm; Pink color: maximum UV absorption at 210 
nm; green color: maximum UV absorptions at 235nm and 260nm; yellow color: 
atypical UV spectra. 
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Table. 2S Relative abundance of each metabolite (Mean of 3 independently analyzed 
plants; Standard deviation is shown below each mean) in roots from 6-month-old plants 
of 40 accessions of Echinacea. 
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Table. 2S (Continued) 
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Fig. 1S HPLC chromatograms representing lipophilic metabolite profiles in roots from 
6-month-old and 3-year-old plants of 3 accessions of Echinacea. Blue: HPLC 
chromatograms at UV length of 210nm; Black: HPLC chromatograms at UV length of 
260nm. 
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Fig. 2S Structures of identified lipophilic metabolites in Echinacea species (compound 
numbering as denoted by Bauer et al. [5]). 
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Fig. 3S HPLC chromatograms representing lipophilic metabolite profiles in roots from 
6-month-old plants of 40 accessions of Echinacea. Three plants were analyzed 
independently for each accession with similar results. Blue: HPLC chromatograms at 
UV length of 210nm; Black: HPLC chromatograms at UV length of 260nm. 
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Fig. 3S (Continued) 
  
45
CHAPTER 3.  DIACETYLENIC ISOBUTYLAMIDES OF ECHINACEA: 
SYNTHESIS AND NATURAL DISTRIBUTION 
Modified from a paper published in Phytochemistry 
Lankun Wua, Jaehoon Baeb, George Krausb and Eve Syrkin Wurtelea,∗ 
ABSTRACT 
The syntheses of three diacetylenic isobutylamides of Echinacea angustifolia have been 
achieved by direct synthetic routes by way of a common intermediate. The key step is the 
alkylation of the anion of the silylated diacetylene. We report the presence of all three 
diacetylenic isobutylamides in six of the nine Echinacea species: E. angustifolia, E. sanguinea, 
E. simulata, E. tennesseensis, E. atrorubens and E. laevigata. The accumulation of these 
amides is sensitive to organ type and age. 
Keywords:  Echinacea; Asteraceae; Synthesis; Diacetylenic isobutylamides; 
Alkamides; Alkylamides 
INTRODUCTION 
Polyacetylenes are a class of natural products found mainly in plants. The pioneering 
studies of both Bohlmann (1988) and Bauer (2000) have revealed much useful information 
about the structure, chemistry, and biological activity of this novel class of compounds. 
Acetylenes are found in each of the commonly used species of Echinacea. Amide 1 is a 
significant constituent of E. purpurea (Bauer, 2000), whereas ketone 2 is found mainly in E. 
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pallida (Binns et al., 2002), and diacetylenic amides 3–5 are found in E. angustifolia (Bauer et 
al., 1989) (Fig. 1).  A complex mixture containing at least 12 different acetylenic amides can be 
obtained by supercritical fluid extraction of fresh dried roots of E. angustifolia (Sun et al., 
2002). Crombie and co-workers have reported elegant syntheses of natural amides related to 1–
4 using organometallic coupling reactions (Crombie & Harper, 1949; Crombie & Manzoor-
IKhuda, 1957; Crombie & Fisher, 1985; Crombie et al., 1987). Wailes (1959) has also reported 
the syntheses of natural dienamides. These amides have since been shown to be active against 
Aedes aegyptii larvae and Helicoverpa zea neonates at the microgram per milliliter level 
(Ramsewak et al., 1999). Authentic standards of amides such as 3, 4, and 5 are important for 
both plant metabolomic studies and for structure–activity studies to determine the bioactivities 
of these compounds in heterologous species. 
In conjunction with a broad-based effort in the study of metabolites of Echinacea and 
St. John’s wort (Kraus & Bae, 2003), we report the first syntheses of three naturally occurring 
amides by direct and flexible synthetic routes. The distribution of these diacetylenic 
isobutylamides in accessions of the nine species of Echinacea (E. angustifolia, E. purpurea, E. 
pallida, E. sanguinea, E. simulata, E. tennesseensis, E. atrorubens, E. laevigata and E. 
paradoxa) is described. 
RESULTS AND DISCUSSION 
Synthesis of diacetylenic isobutylamides 
Our route began with the construction of acetal 8 (Scheme 1) from commercially 
available bis-trimethylsilyldiacetylene 6 and aldehyde 7 that was readily available from the 
ozonolysis of cyclopentene by the method of Schreiber (Schreiber et al., 1982). Generation of 
the monoanion from 6 with methyl lithium–lithium bromide complex in THF at 0 °C followed 
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by reaction at −78 °C with aldehyde 7 afforded a propargylic alcohol in 88% isolated yield 
(Holmes and Jones, 1980). Deoxygenation was achieved by reaction of the alcohol with 
thiocarbonyldiimidazole (CH2Cl2, 25 °C) followed by treatment with two equivalents of 
tributyltin hydride and AIBN at 80 °C in toluene to produce acetal 8 in 51% yield over two 
steps (Gunji & Vasella, 2000). The use of larger quantities of tributyltin hydride should be 
avoided since addition to the acetylene occurred. Although alkylation of the anion of the 
diacetylene would have been more direct, several attempts to effect the direct alkylation 
provided only low yields of the desired product. 
Acetal 8 was the key intermediate for the syntheses of amides 3–5 (Scheme 2). 
Hydrolysis of the acetal using pTSA in aqueous acetone at ambient temperature gave almost a 
quantitative yield of aldehyde. The aldehyde reacted with the amide phosphorane to afford E-
isomer 9 in 73% yield (Barrett et al., 1996). Approximately 10% of the Z-isomer 10 was also 
formed and was readily separable from the E-isomer by silica gel flash chromatography. The 
reaction of E-amide 9 with tetrabutylammonium fluoride (TBAF) in THF at 0 °C produced 3 in 
95% yield. The reaction of Z-isomer 10 generated compound 5 in 97% yield. 
The synthesis of 4 from 8 (Scheme 3) began with a desilylation reaction using TBAF 
followed by methylation of the resulting terminal acetylene with n-butyl lithium and methyl 
iodide. The latter reaction was very slow and worked better when an equivalent of 
hexamethylphosphoric triamide was added after generation of the acetylide anion. Hydrolysis 
of the acetal followed by Wittig reaction afforded diacetylene 4 in 46% yield. The proton and 
carbon NMR spectra of the synthesized amides 3–5 were identical to the spectra reported by 
Ramsewack (Ramsewak et al., 1999), and both their HPLC retention volumes and UV spectra 
were identical to those from natural materials (Fig. 2a). The three amides were well separated 
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by the solvent system employed. Their elution sequence on reversed phase C18 column was 
influenced by the chain length and the stereochemistry of the double bond at carbon 2, with 
amides 3, 5 and 4 eluted at 17.6 min, 20.2 min and 21.2 min successively. The three amides 
demonstrated very similar UV spectra, all with an absorption maximum at 210 nm caused by 
the α,βunsaturated amide chromophore, which agrees with that reported by Bauer and Remiger 
(1989). 
The identity of amides 3–5 was further confirmed by comparison of their retention 
times and mass spectra using GC–MS (Fig. 2b). They were well separated by GC, with amide 
5 eluting at 23.1 min followed by amide 3 and 4 at 25.1 min and 28.5 min, respectively. EIMS 
analysis afforded characteristic mass spectrum for each of the amides, i.e. amides 3, 4 and 5 
gave molecular ions at m/z 231, 245 and 231, which were calculated for C15H21ON, C16H23ON 
and C15H21ON, respectively. Molecular ion and many fragment ions of amide 4 were 14 mass 
units greater than those of amide 3 and 5 due to the terminal methyl group. The mass spectra of 
amide 3 and 5 are very similar but can be distinguished by relative abundance of some of the 
fragment ions, eg. fragments m/z = 131 ([M − C5H10NO]+) and m/z = 91 ([C7H7]+).  Both GC 
retention times and mass spectra for the synthetic compounds were identical to those from the 
natural materials. 
Characterization and distribution of the diacetylenic isobutylamides in Echinacea 
Monoene-type isobutylamides 3–5 were first reported in E. angustifolia roots (Bauer et 
al., 1989) and later were identified in roots of E. tennesseensis (Bauer et al., 1990) and E. 
simulata (Bauer & Foster, 1991). They are often used as one of the diagnostic patterns for 
identification of E. angustifolia roots in commercial preparations (Bauer, 1998). Binns et al. 
(2002) have reported that diacetylenic isobutylamides are present to some extent in all 
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Echinacea species, however, in that report HPLC peaks were identified as diacetylenic 
isobutylamides based solely on their UV spectra and their retention times as compared to those 
of non-diacetylenic isobutylamide standards. 
Using the authentic diacetylenic isobutylamides 3–5, we combined GC–MS and HPLC 
to identify and quantify their distribution in plants. The mean levels of amides 3–5 in roots 
from 6-month-old plants from nine Echinacea species are presented in Fig. 3. Our results show 
that of the 9 Echinacea species, compounds 3–5 present in six species: E. angustifolia, E. 
sanguinea, E. simulata, E. tennesseensis, E. atrorubens and E. laevigata. Among these six 
species, the highest concentrations of amide 3 (0.29 ± 0.02 mg g−1 fr. wt) and amide 4 
(0.32 ± 0.03 mg g−1 fr. wt) are found in E. sanguinea, whereas E. tennesseensis contains the 
highest amount of amide 5 (1.2 ± 0.1 mg g−1 fr. wt). Studies of the distributions of the three 
amides in different organs of E. angustifolia indicate they are present mainly in roots, have 
reduced abundance in flowers, and are not detectable (the limit of HPLC detection for all 3 
amides is approximately 0.02 μg ml−1) in leaves (Fig. 4). Moreover, the ratio of amides 3–5 in 
E. angustifolia roots changes with development. In 3-month-old roots, the ratio of amide 3 to 
its isomer amide 5 was 1:9, whereas in 6-month-old roots this ratio was about 2:3, a difference 
significant at p < 0.01. This indicates that isomerisation of the 2-monoene portion of these 
amides may be regulated during root growth and development. 
CONCLUDING REMARKS 
Diacetylenic isobutylamides 3–5 have been synthesized in eight steps from 
cyclopentene by direct and flexible synthetic routes. The presence of these amides in 
Echinacea has been confirmed by comparison of retention times, UV spectra and mass spectra 
using HPLC and GC–MS. They are distributed widely in Echinacea, being present in at least 
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six of the nine species (E. angustifolia, E. sanguinea, E. simulata, E. tennesseensis, E. 
atrorubens and E. laevigata) examined. The abundance of these compounds varies with organ 
type and plant age. Extension of this work to the syntheses of other members of this class of 
amides and their natural distribution will further define the metabolic variation among and 
within Echinacea species. 
EXPERIMENTAL 
General analytical procedures 
Tetrahydrofuran and Et2O were distilled from sodium benzophenone ketyl, whereas 
CH2Cl2, C6H6 and diisopropylamide were distilled over calcium hydride. All experiments were 
performed under argon atmosphere unless otherwise noted. Organic extracts were dried over 
anhydrous MgSO4. Infrared spectra were obtained on a Perkin–Elmer model 1320 
spectrophotometer. Nuclear magnetic resonance experiments were performed with either a 
Varian 300 MHz or Bruker 400 MHz instrument. High resolution mass spectra were recorded 
on a Kratos model MS-50 spectrometer and low resolution mass spectra were performed with a 
Finnegan 4023 mass spectrometer. Sgc is silica gel flash column chromatography. 
Plant material and extraction 
Seedlings of E. angustifolia (Accession 631267), E. purpurea (Accession 631307), E. 
pallida (Accession 631293), E. sanguinea (Accession A23878), E. simulata (Accession 
631249), E. tennesseensis (Accession 631325), E. atrorubens (Accession 631262), E. laevigata 
(Accession 631312) and E. paradoxa (Accession 631301) were provided by Dr. Mark P. 
Widrlechner at the USDA-ARS North Central Regional Plant Introduction Station. Plants were 
grown under ambient light in a greenhouse in 7.5 inch pots in soil (50% Canadian Peat 
Moss + 40% Perlite + 10% mineral soil), at 22–25 °C, with daily watering. Pots were laid out 
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in a completely randomized design generated from random digits table (Clarke and Kempson, 
1997) on a single greenhouse bench. Plant samples were harvested from 3-month-old and 6-
month-old plants between 9 and 10 a.m, to standardize plant material with respect to possible 
diurnal variations in isobutylamide content. Specifically, we used: recently mature leaves 
expanded to over 90% of their final length and located in the mid section of stems; flowers 
with 75–90% of the disc florets open, fully expanded ligulate florets and intensive pollen grain 
release; and entire roots. After harvest, plant material was immediately ground to a fine powder 
in liquid N2 in a mortar and pestle and stored in liquid N2 until extraction. An aliquot of this 
powdered plant material (0.3 g fr. wt per sample) was further ground in liquid N2 in a mortar 
and pestle with addition of 25 μl (1 mg ml−1) 7-hydroxy-(E)-N-isobutylundeca-2-ene-8,10-
diynamide (C15H21O2) as an internal standard, then with 1 ml of 95% ethanol for 2 min, and the 
resultant suspension was transferred to a capped tube. 95% ethanol (2 ml) was used to rinse the 
mortar and this was added to the suspension. The tube was vortexed 30 sec, and centrifuged 1 
min at 12,000g. The supernatant (hence referred to as ethanol extract) was filtered through a 
0.22 μm PTFE filter (Alltech, IL). All experiments were performed in triplicate on 
independently extracted plant samples from three individual plants. 
HPLC analysis 
Ethanol extract (15 μl) was injected into a Beckman Coulter HPLC with a 508 
autosampler, 126 pump control and 168 UV-photodiode array detector (PDA) controlled by 
32karat TM software (Version 5.0), and a YMC-Pack ODS-AM RP C18 (250 × 4.6 mm, 5 μm) 
column (Waters, MA). The solvent system used was CH3CN/H2O at a flow rate of 1.0 ml/min 
following a linear gradient of 40–80% CH3CN in H2O over 45 min. Online UV spectra were 
collected between 200–400 nm. Amides were quantified based on the internal standard because 
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they have the same UV absorption at 210 nm. The limit of HPLC detection for all three amides 
is approximately 0.02 μg ml−1. 
GC–MS analysis 
GC–MS analyses were performed with a GC series 6890 from Agilent (Palo Alto, CA) 
coupled with a 5973 Agilent mass detector operating in the EI mode (70 eV), using a HP- 1 
silica capillary column (30 m × 0.32 mm i.d.; film thickness 0.25 μm), and helium as the 
carrier gas. Extracts were evaporated to dryness under N2 and resuspended in chloroform (2 
ml). The chloroform-dissolved sample (1 μl) was injected using splitless injection mode. The 
temperature of both the injector and detector was at 250 °C. The column temperature was 
programmed to increase after 2 min from 80 to 260 °C at a rate of 5 °C/min, then held for 10 
min, up to 320 °C at a rate of 5 °C/min, then held for 5 min. Resulting chromatograms were 
integrated by Agilent’s HP enhanced ChemStation TM G1701 BA version B.01.00 software. 
Peaks were identified by their mass spectra and retention times. 
Statistical analysis 
Statistical analyses were performed using SAS software version 8.02 (SAS Institute 
Inc., Cary, NC). One-way analysis of variance followed by the Tukey test was used to compare 
means. Significance of difference was defined at p < 0.05. 
Synthesis of amides 
9,9-Dimethoxy-1-trimethylsilyl-1,3-nonadiyne (8) 
To a solution of 1,4-bistrimethylsilylbutadiyne (1.63 g, 8.4 mmol) in 10 ml of THF was 
added 1.5 M MeLi–LiBr (1.5 M solution, 5.58 ml) at 0 °C. The mixture was warmed up to rt. 
After stirring for 3 h at rt the mixture was cooled to −78 °C. To the mixture was added 
aldehyde 7 (0.50 g, 3.4 mmol) in THF. After stirring for 45 min at −78 °C, water (50 ml) was 
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added. The mixture was then extracted with ether (50 ml), washed with brine, and dried 
(MgSO4). The residue was purified by sgc (hexane:ethyl acetate = 4:1) to give the product 
(0.793 g, 88%). 1H NMR (300 MHz, CDCl3): δ 4.43 (1H, q, J = 5.1 Hz), 4.37 (1H, t, J = 5.7 
Hz), 3.32 (6H, s), 1.87 (1H, br s), 1.71–1.78 (2H, m), 1.58–1.68 (2H, m), 1.48–1.56 (4H, m), 
0.19 (9H, s); 13C NMR (75 MHz, CDCl3): δ 104.5, 87.6, 87.5, 78.9, 69.9, 62.6, 52.9, 37.3, 
32.2, 20.4, −0.29. 
To a solution of the compound produced above (0.71 g, 2.65 mmol) in CH2Cl2 (10 ml) 
was added 1,1-thiocarbonyldiimidazole (0.94 g, 5.3 mmol) at rt. After stirring for 12 h, the 
solvent was removed in vacuo. The residue was purified by sgc (hexane:ethyl acetate = 3:1) to 
give the product (0.86 g, 86%). 1H NMR (300 MHz, CDCl3): δ 8.27 (1H, t, J = 0.9 Hz), 7.56 
(1H, t, J = 1.5 Hz), 6.98 (1H, q, J = 0.9 Hz), 5.99 (1H, t, J = 6.6 Hz), 4.33 (1H, t, J = 5.1 Hz), 
3.27 (6H, s), 1.98–2.01 (2H, m), 1.55–1.64 (4H, m), 0.15 (9H, s). 
To a solution of the thioimidazolide produced above (0.91 g, 2.4 mmol) in toluene was 
added AIBN (0.039 g, 0.24 mmol) and Bu3SnH (0.71 ml, 2.64 mmol) at rt. The mixture was 
boiled at 80 °C for 1 h. It was cooled to rt and solvent was removed in vacuo. The residue was 
purified by sgc (hexane:ethyl acetate = 10:1) to give the acetal 8 (0.42 g, 69%). 1H NMR (400 
MHz, CDCl3): δ 4.34 (1H, t, J = 5.6 Hz), 3.30 (6H, s), 2.27 (1H, t, J = 6.8 Hz), 1.46–1.61 (4H, 
m), 1.39–1.45 (2H, m), 0.18 (9H, s); 13C NMR (100 MHz, CDCl3): δ 104.5, 88.6, 83.3, 79.9, 
65.9, 52.9, 32.2, 28.1, 24.1, 19.4, −0.12; HREIMS [M]+ m/z: 252.1549 (Calc. 252.1546) for 
C14H24O2Si. 
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 (E)-N-isobutyl 11-trimethylsilyl-undeca-2-ene-8,10-diynamide (9) and (Z)-N-isobutyl 11-
trimethylsilyl-undeca-2-ene-8,10-diynamide (10) 
To a solution of acetal 8 (0.11 g, 0.44 mmol) in Me2CO/H2O (5 ml/0.5 ml) was added 
pTSA (0.009 g, 0.044 mmol) at rt. After stirring for 12 h at rt, the solvent was removed. Water 
(25 ml) was added and the mixture was extracted with ether (50 ml), washed with sat NaHCO3, 
brine, and dried (MgSO4). The residue was purified by sgc (hexane:ethyl acetate = 4:1) to give 
an aldehyde that was taken on to the next step (0.081 g, 89%). IR νmax (neat) cm−1: 2958, 2359, 
2225, 2108, 1708, 1250, 846; 1H NMR (300 MHz, CDCl3): δ 9.75 (1H, t, J = 1.8 Hz), 2.45 
(2H, td, J = 6.9, 1.8 Hz), 2.30 (2H, t, J = 6.9 Hz), 1.68–1.78 (2H, m), 1.50–1.60 (2H, m), 0.14 
(9H, s); 13C NMR (75 MHz, CDCl3): δ 202.1, 88.5, 83.7, 79.3, 66.2, 43.4, 27.7, 21.4, 19.3, 
−0.1; HREIMS [M]+ m/z: 206.1130 (Calc. 206.1127) for C12H18OSi. 
To a solution of triphenyl-(N-isobutylcarboxamidomethyl)-phosphonium bromide 
(0.415 g, 1.01 mmol) in THF (2 ml) was added 2.5 M n-BuLi (0.404 ml, 1.01 mmol) at 0 °C. 
After stirring for 10 min at 0 °C, aldehyde produced above (0.104 g, 0.51 mmol) in THF (1 ml) 
was added dropwise at 0 °C. After stirring for 30 min at 0 °C, water (25 ml) was added. The 
solution was then extracted with ether (50 ml) and dried over MgSO4. The residue was purified 
by sgc (hexane:ethyl acetate = 10:1) to give (E) isomer 9 (112 mg, 73%) and (Z) isomer 10 (15 
mg, 10%). 
(E) isomer (9): IR νmax (neat) cm−1: 3289,2958, 2359, 2225, 2108, 1669, 1628, 844; 1H 
NMR (300 MHz, CDCl3): δ 6.78 (1H, dt, J = 15.3, 6.9 Hz), 5.78 (1H, d, J = 15.3 Hz), 5.67 
(1H, br), 3.13 (2H, t, J = 6.3 Hz), 2.25–2.29 (2H, m), 2.14–2.20 (2H, m), 1.74–1.83 (1H, m), 
1.52–1.56 (4H, m), 0.91 (6H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3): δ 166.1,143.9, 124.3, 
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88.6, 83.5, 79.8, 66.0, 47.1, 31.5, 28.8, 27.7, 27.5, 20.4, 19.2, −0.2; HREIMS [M]+ m/z: 
303.2023 (Calc. 303.2018) for C18H29NOSi. 
(Z) isomer (10): 1H NMR (300 MHz, CDCl3): δ 5.95 (1H, dt, J = 11.4, 7.5 Hz), 5.69 
(1H, d, J = 11.4 Hz), 5.50 (1H, br), 3.11 (2H, t, J = 6.3 Hz), 2.63–2.70 (2H, m), 2.27–2.31 (2H, 
m), 1.74–1.83 (1H, m), 1.49–1.64 (4H, m), 0.92 (6H, d, J = 6.6 Hz); 13C NMR (75 MHz, 
CDCl3): δ 166.6, 145.0, 122.9, 88.7, 83.3, 80.1, 65.8, 46.8, 28.8, 28.6, 28.2, 27.9, 20.4, 19.2, 
−0.1. 
 (E)-N-isobutyl undeca-2-ene-8,10-diynamide (3) and (Z)-N-isobutyl undeca-2-ene-8,10-
diynamide (5) 
To a solution of amide 9 (0.029 g, 0.096 mmol) in THF (1 ml) was added 1 M TBAF 
(0.144 ml, 0.144 mmol) at 0 °C. After stirring for 30 min, the solvent was removed in vacuo. 
The residue was purified by sgc (hexane:ethyl acetate = 10:1) to give 3 (0.021g, 95%). 
(E)-N-isobutyl undeca-2-ene-8,10-diynamide (3): 1H NMR (300 MHz, CDCl3): δ 6.79 
(1H, dt, J = 15.3, 6.6 Hz), 5.79 (1H, d, J = 15.3 Hz), 5.62 (1H, br), 3.13 (2H, t, J = 6.6 Hz), 
2.23–2.29 (2H, m), 2.16–2.22 (2H, m), 1.97 (1H, t, J = 0.9 Hz) 1.74–1.83 (1H, m), 1.52–1.59 
(4H, m), 0.91 (6H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3): δ 166.1, 143.8, 124.3, 78.1, 
68.6, 65.2, 64.9, 47.1, 31.5, 28.8, 27.6, 27.5, 20.3, 19.0; EIMS 70 eV, m/z (rel. int.): 231 [M]+ 
(6), 216 [M − CH3]+ (8), 202 (27), 188 [M − C3H7]+ (22), 174 [M − C4H9]+ (16), 160 (21), 131 
[M − C5H10NO]+ (43), 116 (56), 103 (40), 91 [C7H7]+ (100), 55 (26), 41 (25); HREIMS [M]+ 
m/z: 231.16260 (Calc. 231.16231) for C15H21 NO. 
(Z)-N-isobutyl undeca-2-ene-8,10-diynamide (5): 1H NMR (300 MHz, CDCl3): δ 5.96 
(1H, dt, J = 11.4, 7.5 Hz), 5.69 (1H, d, J = 11.4 Hz), 5.49 (1H, br), Hz, 1.72–1.86 (1H, m), 
1.50–1.63 (4H, m), 0.92 (6H, d, J = 6.6 Hz); 13C NMR (75 MHz, CDCl3): δ 3.11 (2H, t, J = 6.9 
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Hz), 2.64–2.72 (2H, m), 2.57–2.30 (2H, m), 1.95 (1H, t, J = 1.2 166.6, 145.0, 122.9, 78.5, 68.7, 
65.0, 64.7, 46.8, 28.8, 28.5, 28.2, 27.8, 20.4, 19.1); EIMS 70 eV, m/z (rel. int.): 231 [M]+ (4), 
216 [M − CH3]+ (5), 202 (14), 188 [M − C3H7]+ (11), 174 [M − C4H9]+ (12), 159 (18), 131 
[M − C5H10NO]+ (98), 117 (100), 91 [C7H7]+ (82), 57 (57), 41 (48). 
 (E)-N-isobutyl dodeca-2-ene-8,10-diynamide (4) 
To a solution of acetal 8 (0.09 g, 0.36 mmol) in THF (5 ml) was added TBAF (1 M 
solution, 0.542 ml) at 0 °C. The mixture was warmed to rt and stirred for 30 min. Solvent was 
removed in vacuo. The residue was purified by sgc (hexane:ethyl acetate = 2:1) to give a 
terminal acetylene that was taken immediately to the next step (0.062 g, 96%). 1H NMR (300 
MHz, CDCl3): δ 4.35 (1H, t, J = 5.4 Hz), 3.31 (6H, s), 2.27 (2H, t, J = 6.6 Hz), 1.96 (1H, t, 
J = 1.2 Hz), 1.53–1.65 (4H, m), 1.41–1.49 (2H, m); 13C NMR (75 MHz, CDCl3): δ 104.5, 78.3, 
68.6, 65.1, 64.8, 52.9, 31.8, 28.0, 24.1, 19.2. 
To a solution of the terminal acetylene produced above (0.053 g, 0.29 mmol) in THF (3 
ml) was added n-BuLi (2.5 M solution, 0.119 ml) at −78 °C. After 10 min, MeI (0.063 ml, 1.02 
mmol) was added to the mixture at −78 °C. After adding, the mixture was warmed to rt then 
HMPA (1.5 ml) was added. After stirring 12 h at rt, ice water (10 ml) was added and the 
mixture was then extracted with ether (20 ml × 3). The organic layer was washed with water 
and dried (MgSO4). The residue was purified by sgc (hexane:ethyl acetate = 3:1) to give the 
methylated acetylene that was taken immediately on to the next step (0.045 g, 80%). 1H NMR 
(300 MHz, CDCl3): δ 4.30 (1H, t, J = 5.7 Hz), 3.26 (3H, s), 2.20 (2H, t, J = 6.9 Hz), 1.84 (3H, 
s), 1.49–1.59 (4H, m), 1.33–1.44 (2H, m); 13C NMR (75 MHz, CDCl3): δ 104.9, 77.6, 72.8, 
65.5, 64.0, 51.2, 33.1, 28.6, 23.4, 18.7, 4.2; HREIMS [M]+ m/z: 194.1314 (Calc. 194.1307) for 
C12H18O2. 
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To a solution of the methylated acetylene produced above (0.045 g, 0.23 mmol) in 
Me2CO/H2O (5 ml/0.5 ml) was added pTSA (0.01 g, 0.05 mmol) at rt. After stirring for 12 h at 
rt, the solvent was removed. Water (30 ml) was added and the mixture extracted with ether (50 
ml), washed with sat NaHCO3, brine, and dried (MgSO4). The residue was purified by sgc 
(hexane:ethyl acetate = 4:1) to give an aldehyde that was taken on to the next step (0.030 g, 
87%). 1H NMR (300 MHz, CDCl3): δ 9.75 (1H, t, J = 1.5 Hz), 2.45 (1H, td, J = 7.2, 1.5 Hz), 
2.27 (2H, t, J = 6.9 Hz), 1.84 (3H, s), 1.49–1.59 (4H, m), 1.33–1.44 (2H, m); 13C NMR (75 
MHz, CDCl3): δ 203.1, 77.8, 73.4, 65.3, 63.9, 44.7, 26.3, 21.4, 19.1, 4.3. 
To a solution of triphenyl-(N-isobutylcarboxamidomethyl)-phosphonium bromide 
(0.165 g, 0.4 mmol) in THF (2 ml) was added 2.5 M n-BuLi (2.5 M, 0.16 ml) at 0 °C. After 
stirring for 10 min at 0 °C, the aldehyde produced above (0.03 g, 0.20 mmol) in THF (1 ml) 
was added dropwise at 0 °C. After stirring for 30 min at 0 °C, water (25 ml) was added and the 
mixture was extracted with ether (50 ml), and dried (MgSO4). The residue was purified by sgc 
(hexane: ethyl acetate = 10:1) to give 4 (0.033 g, 68%). 1H NMR (300 MHz, CDCl3): δ 6.68 
(1H, dt, J = 15.3, 6.9 Hz), 5.78 (1H, d, J = 15.5 Hz), 5.56 (1H, br s), 3.14 (2H, t, J = 6.3 Hz), 
2.15–2.27 (4H, m), 1.90 (3H, s), 1.73, 1.83 (1H, m), 1.53–1.59 (4H, m), 0.92 (6H, d, J = 6.6 
Hz); 13C NMR (75 MHz, CDCl3): δ 166.2, 144.1, 124.2, 76.5, 73.5, 65.9, 64.7, 47.1, 31.6, 28.8, 
27.9, 27.4, 20.4, 19.2, 4.4; HREIMS [M]+ m/z: 245.1784 (Calc. 245.1780) for C16H23ON; 
EIMS 70 eV, m/z (rel. int.): 245 [M]+ (13), 230 [M-CH3]+ (12), 216 (47), 202 (32), 188 
[M − C4H9]+ (20), 173 (30), 145 [M − C5H10NO]+ (90), 131 (63), 117 (100), 105 (59), 91 
[C7H7]+ (61), 77 (55), 57 (35), 41 (38). 
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Scheme 1. Synthesis of acetal 8 from bis-trimethylsilyldiacetylene 6 and aldehyde 7. 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of diacetylenic isobutylamides 3 and 5 from acetal 8. 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of diacetylenic isobutylamide 4 from acetal 8. 
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Fig. 1 Typical acetylenes found in Echinacea species: (E,Z,E)-N-isobutyl dodeca-2,4,10-
triene-8-ynamide (1), (Z)-tetradeca-8-ene-11,13-diyn-2-one (2), (E)-N-isobutyl undeca-2-
ene-8,10-diynamide (3), (E)-N-isobutyl dodeca-2-ene-8,10-diynamide (4), (Z)-N-isobutyl 
undeca-2-ene-8,10-diynamide (5). 
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Fig. 2 HPLC chromatogram (a) and GC–MS TIC chromatogram (b) obtained from a 
95% ethanolic extract of 3-month-old E. angustifolia roots, indicating diacetylenic 
isobutylamides 3–5. 
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Fig. 3 Concentration of diacetylenic isobutylamides 3–5 in 6-month-old roots of nine 
species of Echinacea. Error bars indicate standard deviations of means of triplicate 
experiments. For each diacetylenic isobutylamide (3, 4 or 5), different letters indicate a 
significant difference (p < 0.05). 
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Fig. 4 Concentration of diacetylenic isobutylamides 3–5 in E. angustifolia roots from 3 
and 6-month-old plants, and flowers, and leaves of 6-month-old plants. Error bars 
indicate standard deviations of means of triplicate experiments. For each diacetylenic 
isobutylamide (3, 4 or 5), different letters indicate a significant difference (p < 0.05). 
 
  
66
CHAPTER 4.  ECHINACEA-INDUCED INTRACELLULAR CA2+ 
ELEVATION IN HEK293  
A paper to be submitted to Journal of Agricultural and Food Chemistry 
Lankun Wu, Eric W. Rowe, Ksenija Jeftinija, Srdija Jeftinija, Ludmila Rizshsky, Basil J. 
Nikolau, Marian Kohut  and Eve Syrkin Wurtele 
ABSTRACT 
Echinacea was evaluated as a regulator of intracellular Ca2+ levels in HEK293 cells.  
Treatment of HEK293 cells with Echinacea extract resulted in an increase in cytosolic Ca2+, as 
determined by intracellular calcium imaging. Echinacea-evoked responses could not be 
blocked by AM251, a cannabinoid type 1 (CB1) receptor antagonist, indicating that CB1 is not 
involved.   Sustained Ca2+ influx was observed after the Echinacea-induced Ca2+ release from 
intracellular Ca2+ stores.  2-APB, considered as the most potent store operated calcium entry 
(SOCE) inhibitor, abolished this Ca2+ influx evoked by Echinacea, indicating the Ca2+ influx 
was via SOCE.  These stimulatory effects of Echinacea were blocked by U73122, a 
phospholypase C (PLC) inhibitor, and 2-APB, a antagonist of inositol-1,4,5-trisphosphate 
receptor (IP3R) , suggesting involvement of the PLC activation and IP3 receptor.  Interestingly, 
the components thought to be responsible for the major bioactivity of Echinacea (i.e., 
alkamides/ketones, caffeic acid derivatives) cannot explain the observed bioactivity.  Tests of 
28 HPLC fractions from E. purpurea extracts identified 6 active fractions, and GC-MS analysis 
of these fractions indicated that very lipophilic constituents of unknown structure are 
associated with Echinacea bioactivity in HEK293.   
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INTRODUCTION 
Echinacea has been historically used by Native Americans as a universal remedy to 
treat a number of ailments.  Well known for its characteristic fiery and pungent taste, 
Echinacea produces local anesthesia of the mucous membranes; thus, it has been used 
medicinally since ancient times (Foster, 1991).  Perhaps the principal use of Echinacea by 
Native Americans was in relation to alleviation of pain and the promotion of healing, such as in 
cases of snake bites, burns, cough, sore throats, and toothache (Foster, 1991; Greger, 1984). 
Echinacea products are currently promoted as general enhancers of the immune system, and 
are among the best-selling herbal preparations in the U.S.A (Yu, 2004).  
Despite the popularity of Echinacea as an herbal supplement, and many 
pharmacological and clinical studies, understanding of the molecular mechanisms of action of 
Echinacea is still very limited. Among the various groups of phytochemicals reported in 
Echinacea, four major groups of compounds, alkamides/ketones, caffeic acid derivatives, 
glycoproteins and polysaccharides,  exhibit biological activities in vitro and in vivo, including 
anti-inflammatory activity (Speroni et al, 2002; LaLone et al., 2007), anti-fungal activity 
(Binns et al., 2000), anti-viral and immunostimulatory activity (Senchina et al., 2006; Zhai et 
al., 2007; Birt et al., 2008; Woelkart & Bauer, 2007). However, it is still uncertain which 
specific compound(s) are primarily responsible for these bioactivities, or whether they are 
efficacious in humans (Barrett, 2003). 
The potential mechanism of Echinacea as an anti-inflammatory agent is currently an 
active area of investigation (Barrett. 2003; Birt et al., 2008). The growing evidence of the inter-
relationship of pain receptors to inflammatory responses (Veronesi & Oortgiesen, 2006) 
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indicates that Echinacea might mediate inflammatory responses in part via pain receptors.  
Recently a possible mode of action of Echinacea was proposed based on reports that alkamides 
bind to cannabinoid (CB) receptors (Raduner et al. 2006; Woelkart et al., 2008).   The effects 
of whole Echinacea extracts on the CB receptors have not been reported, and neither pure 
alkamides nor whole extracts from Echinacea have been tested for their effect on other cellular 
receptors.    
Calcium ions, one of the most important and universal signaling agents in virtually all 
eukaryotic cells, plays a crucial role as an intracellular second messenger molecule in 
mediating a diverse range of cellular processes (Berridge et al., 1998).  For example, in the 
immune system, Ca2+ signals regulates the activation, function and gene expression of 
lymphocytes, including T and B cells, NK cells and macrophages (Feske, 2007).   In neuronal 
cells, cytoplasmic Ca2+ signals are pivotal in synaptic transmission and plasticity (Friel, 2004).  
In smooth muscle cells,   Ca2+ signals control the contractile process (Leung et al., 2008).  
Because of the critical role for Ca2+ in cell activity, we decided to characterize the mechanism 
of Ca2+ signal regulation in anti-inflammatory actions of Echinacea.   
There are two principal sources that impact cytosolic Ca2+ concentration: internal Ca2+ 
stores, primarily the endoplasmic reticulum (ER), and extracellular Ca2+.  Ca2+ stored in the ER 
is released through Ca2+ channels on ER membrane, usually from the inositol-1,4,5-
trisphosphate receptor ( IP3R) or ryanodine receptor (RyR) families (Park et al., 2008; Norman 
et al., 2008). The ER Ca2+ pumps return the intracellular Ca2+ into the ER, maintaining a Ca2+ 
homeostasis between cytoplasm and ER.  The intracellular Ca2+ stores are refilled from the 
extracellular reservoir mostly through store-operated Ca2+ entry (SOCE).  SOCE is present in 
various cell types, e.g., smooth muscle cells (Pan et al., 2002), epithelial cells (Vanden et al., 
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2003), hippocampal cells (Bouron, 2000), and is an important regulator of physiological 
processes such as anti-inflammation, cardiac contraction and neuro-transmission (Leung et al., 
2008; Bouron, 2000). 
To evaluate the possibility that Echinacea impacts Ca2+ homeostasis, the effect of 
application of  Echinacea was studied in HEK293 (human embryonic kidney) cells using 
intracellular calcium imaging.  The HEK line was chosen because of its wide use as a 
transfection system for receptor studies (Daigle et al., 2008; Kawamata et al., 2008; Kumpost 
et al., 2008), and its well-characterized transcriptome and physiology (Shaw et al., 2002, 
Tatiana et al., 2005). 
Ethanol extracts from Echinacea are capable of inducing transient increases of 
intracellular calcium when applied to HEK293 cells.   HPLC fractionation revealed six 
lipophilic fractions that induced cytosolic calcium elevation.  This activity does not appear to 
be attributable to the known bioactive components of Echinacea.  Based on studies using a 
range of inhibitors and varied conditions, we propose that immunomudulatory and anti-
inflammatory activities of Echinacea might result from interaction with specific membrane 
receptors to induce intracellular Ca2+ release in combination with an ER-depletion-associated 
activation of the SOCE pathway. 
MATERIALS AND METHODS  
Preparation of Echinacea extracts and fractions 
Echinacea extraction and fractionation were performed as in previous published work 
(Lalone et al., 2007; Zhai et al., 2007).  
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GC-MS Analysis.   
All samples were silylated using a protocol based on that of Hannoufa et al. (1993). 
Specifically, nitrogen-dried lipid extract was dissolved in 1 ml of acetonitrile and adjusted to 
6% of bis-trimethylsilyl-trifluoroacetamide and 10% trimethyl-chlorosilane. Samples were 
incubated at 65°C for 20 min, cooled, and filtered through a polytetrafluoroethylene filter. 
Silylated samples were analyzed using a Gas Chromatograph (6890 series; Agilent, Palo Alto, 
CA, USA), equipped with a Mass Detector 5973 (Agilent) operating in the EI mode (70 eV).  
The analyzes were carried out in splitless mode. The fractions were separated on Agilent 
capillary column   (HP 5ms 5% diphenyl 95% dimethyl polysiloxane) with the dimensions (30 
m×0.25 mm, 0.25 µm). Helium was used as the carrier gas at the flow rate of 1.2 ml/min. The 
injector and detector were held at 250°C. The oven was heated initially at 80°C for 2 min and 
then remped at 10°C/min up to 200°C.  This temperature was maintained for 20 min, and then 
remped at 3°C/min to 250°C and held for 5 min. The mass spectra were generally recorded 
over 800 amu. Identification was facilitated by using agilent enhanced ChemStation version 
D.02.00.275.). 
Chemicals 
Fura-2 AM,  pluronic F-127, Dulbecco’s modified Eagle’s Medium, penicillin-
streptomycin, L-glutamine, and trypsin were purchased from Invitrogen (Carlsbad, CA, USA); 
thapsigargin, 2-aminoethoxydiphenyl borate (2-APB),  1-(2,4-Dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251), 1-[6-[((17β)-3-
Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,5-dione (U-73122), linoenic 
acid, linoeic acid, were purchased from Sigma (St. Louis, MO, USA).  Alkamide 8, 10, 11 and 
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ketone 23 were kindly provided by Dr. George Kraus, Department of Chemistry, Iowa State 
University.   
Cell Culture 
HEK293 cells were obtained from ATCC (Manassas, VA, USA) and cultured in 
Dulbecco’s modified Eagle’s Medium supplemented with 10% FBS, 50 U/ml penicillin, 50 
µg/ml streptomycin, and 2 mM glutamine. Cells were grown in an incubator at 37°C with 
humidified 5% CO2 and 95% air. 
Intracellular Calcium Imaging   
 Intracellular calcium concentrations ([Ca2+]i) were measured by ratiometric imaging 
techniques. Cells were plated onto 22-mm coverslips 36 hr before the experiment.  Cells were 
loaded with Fura 2-AM for 60 min at room temperature. The loading solution contained 1 µl of 
25% (w/w) Pluronic F-127 and 4 nM of Fura 2-AM diluted in 1 ml of HEPES buffer. The 
loading solution was removed and the cells were washed twice with HEPES buffer before the 
coverslips were placed onto a perfusion chamber and connected to a micro pump.  The test 
substances were placed in syringes on a five-valve manifold and applied into the perfusion 
chamber by the micro pump with a flow rate of 200 µl per min. As a result of the spatial 
distance between the syringe and the culture in the chamber, there was a time delay between the 
turning on the valve and onset of the response. Initial experimental analysis of calcium imaging 
data was conducted using MetaFluor® soft ware.   
Statistical Analysis 
Statistical analyses were performed using SAS software version 8.02 (SAS Institute 
Inc., Cary, NC). One-way analysis of variance followed by the Tukey test was used to compare 
means. Significance of difference was defined at P < 0.05. 
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RESULTS 
Echinacea purpurea extracts induce cytosolic elevation of Ca2+ in HEK293 cells 
E. purpurea root extracts evoke a transient calcium elevation in HEK293 cells (Fig. 1). 
This Echinacea-evoked current response returns to baseline rapidly after removal of Echinacea 
extract (Fig. 1), indicating that the activation is reversible. Activity can be invoked again by 
about 10 min after application.  Data from this assay and all others described herein is 
compiled from a minimum of 60 independent cell traces obtained during three different 
experiments. To investigate the concentration dependence of this response, seven 
concentrations of extract, from 25 to 300 μg/ml, were tested (Fig. 2). At concentrations as low 
as 50 μg/ml, E. purpurea evokes a transient calcium current, and this response saturates at 
about 200 μg/ml of extract, with an  EC50 of 97.89 ± 6.6 μg/ml (n ≥ 81).  
Evaluation of the Ca2+ response induced by Echinacea fractions and pure compounds.   
To further identify the potential bioactive constituent(s) responsible for inducing this 
Ca2 increase, E. purpurea root ethanol extracts were chromatographed using preparative HPLC.  
Twenty-eight fractions were collected and tested for bioactivity in HEK293. Of these E. 
purpurea fractions tested, six lipophilic E. purpurea fractions are active in evoking Ca2+ 
elevation in HEK.  The other fractions have no detectable bioactivity. These active fractions of 
the Echinacea extract have differential effects on HEK293.  Both the duration and intensity of 
the calcium transient are unique to each fraction (Fig. 3A).  Among the six active fractions, 
fraction 72 has the highest activity (Fig. 4).  
Each fraction was fingerprinted by GC-MS and three of them are shown in Fig. 3B.  In 
addition to numerous non-alkamide compounds, fraction 68 contains alkamides 1, 2, 4 and 6; 
fraction72 contains alkamides 8/9; fraction75 contains alkamides 8/9 and 10; fraction 80 and 
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83 contain alkamides 8/9, 10 and 11.  Synthesized standards of pure alkamides from Echinacea, 
including alkamides 8, 10, 11 and ketone 23 were also tested in HEK293.  Among them, 
alkamide 8 and 11 were reported by Raduner et al. (2006) to bind to the cannabinoid receptor 
CB2.  Neither of these pure compounds from Echinacea displays any activity on HEK293 
(data not shown).  These results indicate that very lipophilic constituents of unknown structure 
are associated with Echinacea bioactivity in HEK293.  LC-MS/MS are currently being used 
for further characterization of these bioactive fractions and identify the novel compound(s) that 
may contribute to this activity.  In parallel, bioactive fractions are being sub-fractionated by 
HPLC and the sub-fractions will be bioassayed to further narrow down the scope in our search 
for bioactive constituents. 
Echinacea-induced intracellular Ca2+ increase in HEK293 cells appears to be release of 
Ca2+ from the IP3-sensitive intracellular store and this process involves PLC activation. 
Our studies showed that the source of the transient calcium increase in Echinacea-
treated HEK293 cells appears to be from intracellular stores, as indicated by the stimulatory 
effect that occurs in calcium-free conditions (Fig. 5A).   
To examine whether or not the Echinacea-induced intracellular Ca2+ release from ER 
stores is via IP3 receptors, 2-APB, an IP3 receptor antagonist, was tested.  As shown in Fig. 5B, 
2-APB completely abolished the intracellular Ca2+ increase evoked by Echinacea.  To test if 
the involvement of IP3 is produced through PLC activation, the effects of U-73122, a PLC 
inhibitor, was evaluated.  Application of U-73122 completely abolished the intracellular Ca2+ 
increase evoked by Echinacea, indicating PLC pathway was involved (Fig. 5C).  In both 
antagonist studies, the culture was treated with Echinacea extract first to show that the culture 
was indeed able to respond to Echinacea. The antagonist was applied afterwards for 10 min 
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before the Echinacea extract was applied again immediately after the antagonist to show if 
there is any blocking effects of the antagonist. 
Echinacea-induced Ca2+ release from intracellular Ca2+ store activates SOCE. 
To demonstrate the action of SOCE experimentally, external Ca2+  was removed and 
internal Ca2+ stores were depleted using the sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase 
(SERCA) pump inhibitor thapsigargin (TG); a subsequent restoration of external Ca2+ indicates 
the action of SOCE which can be observed as an increase of cytosolic [Ca2+]i  (Putney et al., 
2001). Here, intracellular Ca2+ stores were depleted with TG, and this was compared to the 
effect of Echinacea extract.   The pattern of Ca2+ responses evoked by Echinacea and TG were 
similar (Fig. 6).  In the absence of extracellular Ca2+, both agents still evoke a transient 
intracellular Ca2+ elevation, interpreted as being due to Ca2+ release from internal stores.  After 
Ca2+-containing medium was introduced, a sustained cytosolic Ca2+ increase was observed for 
both treatments (Fig. 6A, 6B); this pattern is consistent with SOCE-mediated changes in the 
concentration of cytosolic Ca2+ (Parekh et al., 2005).   
To examine whether TG and Echinacea-induced Ca2+ entry pathway are 
pharmacologically similar, 2-APB, a potent SOCE inhibitor, was applied in the continued 
presence of external Ca2+ after ten minutes of Ca2+ restoration. 100µM 2-APB completely 
blocks SOCE induced by both TG and Echinacea (Fig. 6C, 6D).  This result confirms that the 
Ca2+ influx induced by Echinacea-depletion of Ca2+ from intracellular store is indeed via 
SOCE pathway. 
CB1 is not involved in Echinacea-induced calcium rise in HEK293 cells 
So far CB1 has not been found to present in HEK293 cells (Ross, 2003).  Due to the 
mounting interest in CB as a potential target for Echinacea action (Woelkart et al., 2008), 
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AM251, a specific CB1 receptor antagonist was examined.  Our results showed that AM251 
was not able to abolish the Echinacea response (Fig. 7).  This confirmed that CB1 was indeed 
not responsible for the Echinacea-induced Ca2+ elevation observed in HEK293.  
DISCUSSION 
Echinacea is widely used as an herbal anti-inflammatory agent (Birt et al., 2008).   In 
vitro, animal and human studies indicate that Echinacea extracts enhance the activities of 
various immune cells, particularly associated with cyclooxygenase 2 (COX2)  and cytokine 
signaling (Rininger et al., 2000; Sun et al., 2001; Mishima et al., 2004; Hinz et al., 2007; 
LaLone et al., 2007; Birt el al., 2008).  COX is the key enzyme converting arachidonic acid to 
prostaglandins (PGs), at sites of inflammation (Turini & DuBois, 2002).  Of the two COX 
isoforms, COX2 is more highly inducible and has been shown to suppress pain and 
inflammation (O'Neill, 2006), in part via PGE2, a major product of the COX2 signaling 
pathway, a critical inflammatory mediator (Hu et al., 2008).  Pro-inflammatory cytokines, such 
as tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), Il2, and IL-6, activate the 
inflammatory process, whereas anti-inflammatory cytokines, such as TGF-β, interferon, and 
IL-10, inhibit this process (Opal & DePalo, 2000). As such, cytokine modulators and COX2 
inhibitors provide key targets for anti-inflammatory drugs (Calixto et al., 2004; Guindon & 
Hohmann, 2008). Echinacea extracts inhibit COX-2-dependent PGE2 formation in human 
neuroglioma cells (Hinz et al., 2007) and RAW264.7 mouse macrophage cells (Lalone et al., 
2007).  In addition, Sasagawa et al. (2006) reported that two alkylamides from E. purpurea 
significantly inhibited the ability of activated Jurkat T cells to produce IL-2.  Similar trends 
have been reported in animals: following Echinacea treatment of mice, the anti-inflammatory 
interferon-γ increases, and pro-inflammatory TNF-α and IL-1β decrease (Zhai et al., 2007).   It 
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is generally believed that inflammation and pain are always closely related (Turini and DuBois, 
2002).  In fact, numerous inflammation mediators, such as cytokines, PGs, lipo-oxygenases 
and growth factors, can elicit pain (LeBars and Adam, 2002).   
Despite numerous reports on the physiological consequences of Echinacea, there is 
little understanding of the possible molecular mechanisms whereby Echinacea mediates this 
signal transduction.  One possibility is that Echinacea acts in part via calcium, a central 
intracellular messenger that participates in the regulation and co-regulation of inflammation 
(Feshe, 2007) and pain (Pardo, 2001). Changes in cytosolic calcium, modulated via both Ca2+ 
release from internal stores and Ca2+ influx across the plasma membrane ((Berridge et al., 
1998), regulate numerous cellular processes ((Friel, 2004; Leung et al., 2008).  In the shorter 
term, calcium signals regulate lymphocyte motility and immunological synapse formation; in 
the longer term, Ca2+ controls the transcriptional events that regulate gene expression patterns 
such as cytokine expression (Feshe, 2007).  
To investigate the ability of Echinacea to induce rapid calcium fluctuations, we used 
the HEK293 cell model. We report that E. purpurea ethanol extracts induce an increase in 
cytosolic Ca2+, and that this increase appears to be associated with the release of Ca2+ from IP3-
sensitive intracellular stores via activation of the PLC pathway. We also provide evidence that 
this Echinacea-induced intracellular Ca2+ release from internal Ca2+ stores may be coupled to 
the subsequent activation of the SOCE process.  The participation of IP3 receptor in the 
calcium release from internal store by Echinacea is indicated by treatment with the specific 
membrane-permeable IP3 receptor antagonist (Maruyama et al., 1997) 2-APB, which is able to 
completely abolish the Echinacea–induced calcium release from internal stores.  However, 2-
APB was also reported to enhance leakage of Ca2+ from the ER and inhibition of SERCA 
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activity, resulting in potentiation of Ca2+ signaling (Ma et al., 2002).  This complex action of 2-
APB might explain the small initial intracellular calcium increase we observed in HEK293 
cells after 2-APB application (Fig. 5B).  
In many cell types, depletion of intracellular Ca2+ stores results in the opening of SOCE 
in the plasma membrane.   SOCE, thought to mediate aspects of cell secretion and motility, cell 
proliferation and gene expression by altering cellular Ca2+ influx (Parekh et al., 2005), is 
considered a promising target for therapeutic treatment in inflammatory diseases (Li et al., 
2002).   The nature of SOCE, and the mechanism linking store content to the opening of this 
Ca2+ channel, remains unclear.  Recently, two proteins have been implicated in SOCE function: 
stromal interaction molecule 1 (STIM1), thought to be an ER-based Ca2+ sensor that activates 
SOCE (Zeng et al., 2008), and Orai1, a pore-forming subunit of the SOCE (Lewis, 2007).   The 
molecular mechanism of STIM1 activation of SOCE is not understood.  
So far no selective antagonists have been identified for SOCE. 2-APB was originally 
identified as an IP3 receptor antagonist, and was later found to act as a potent SOCE inhibitor 
independent of its function in IP3 receptor inhibition (DeHaven et al., 2008).   Among the 
SOCE inhibitors, 2-APB is considered as the most potent and consistent in blocking SOCE 
(Bootman et al., 2002); 2-APB has no effect on voltage-operated Ca2+ channels (Maruyama et 
al., 1997), and doesn’t inhibit other non-voltage-activated Ca2+ entry pathways, such as AA-
activated Ca2+ channels in HEK293 cells (Holmes et al., 2007), maitotoxin-evoked Ca2+ entry 
in hepatocytes (Gregore et al., 2001) and diacylglycerol analog induced Ca2+ influx in PC12 
cells (Tesfai et al., 2001).  Therefore, despite its lack of specificity, it provides a critical reagent 
for investigating SOCE activation and for discriminating between different forms of Ca2+ entry. 
Indeed, 100µM 2-APB completely blocks the calcium entry induced by depletion of internal 
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calcium stores by both TG and Echinacea, indicating that this Ca2+ entry is SOCE-activated.   
To further investigate this SOCE activation, tests of the efficacy of other SOCE inhibitors such 
as flufenamic acid, 1-[β-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenethyl]-1H-imidazole 
hydrochloride (SK&F 96365), and 4-methyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-
1,2,3-thiadiazole-5-carboxanilide (BTP2) would provide additional information.  Alternately, 
antibodies against Oria1 and STIM1 could be a useful reagent to block SOCE function. 
Based on the evidence to date, we propose a possible mechanism for Echinacea 
activation of the Ca2+ signaling pathway and further, how this activation might underlie 
possible anti-inflammatory and anti pain effects of Echinacea (Fig. 8).    In this process, cell 
activation begins when bioactive metabolites from Echinacea activate PLC, for example, via 
binding to a surface membrane receptor coupled to PLC, or an intracellular interaction, or both. 
Indeed, the Ca2+ response induced by Echinacea is associated with very lipophilic constituents, 
which are logical candidates for cell membrane permeability. The particular receptor(s) that 
bind to Echinacea and activate the observed calcium modulation have not been identified.  It is 
possible, particularly in light of the results shown in Fig. 3A that the active fractions of the 
Echinacea extract have differential effects (different kinetics and potencies) on HEK293, that 
more than one receptor is stimulated by Echinacea extracts.  The source of Ca2+ that is causing 
the transient increase in intracellular calcium allows classification of the receptor as either 
ionotropic (an ion channel) or metabotropic (a secondary messenger system releasing calcium 
from internal stores).   Our data (Fig. 5A) indicates that the calcium source of the initial 
transient intracellular increase induced by Echinacea is from internal stores, indicative of a 
metabotropic type of receptor.    
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PLC activation would lead to the production of IP3  (Thore et al., 2005) which in turn 
would activate the IP3 receptor causing release of Ca2+ from the compartment of the ER 
(Mikoshiba et al., 2008). The decrease in ER Ca2+ then could activate the plasma membrane 
SOCE through a mechanism that involves STIM1 in the ER (Zeng et al., 2008).  This model 
predicts that the level of cytosolic Ca2+ associated with Echinacea activation increases through 
two mechanisms: release of Ca2+ from ER Ca2+ stores, and Ca2+ influx via SOCE.  This Ca2+ 
concentration increase would regulate various cellular processes.  For example, in T-cells, 
elevated intracellular Ca2+ activate Ca2+-dependent enzymes, such as calcineurin, and thereby 
transcription factors, such as nuclear factor of activated T cells (NFAT) , nuclear factor-κB 
(NF-κB) and cyclic-AMP-responsive-element-binding protein (CREB).  These transcription 
factors modulate the generation of cytokines, a group of multifunctional substances involving 
in various inflammatory responses, which in turn regulate the expression of many target genes 
in inflammation and pain transmission.   
ACKNOWLEDGEMENTS 
This publication was made possible by grant P01 ES012020 from the National Institute 
of Environmental Health Sciences (NIEHS) and the Office of Dietary Supplements (ODS), 
National Institutes of Health (NIH), and grant 9P50AT004155-06 from the National Center for 
Complementary and Alternative Medicine (NCCAM) and ODS, NIH. Its contents are solely 
the responsibility of the authors and do not necessarily represent the official views of the 
NIEHS, NCCAM, or NIH. 
  
80
REFERENCES 
Altamirano-Dimas M, Hudson JB, Cochrane D, Nelson C, Arnason JT. Modulation of immune 
response gene expression by echinacea extracts: results of a gene array analysis. 
Can J Physiol Pharmacol. 2007. 85(11): 1091-8. 
Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia 
(DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a 
review of their chemistry, pharmacology and clinical properties.  J. Pharm. 
Pharmacol.  2005. 57(8): 929-54.  
Barrett B, Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003, 10: 66–
86. 
Berridge MJ, Bootman MD, Lipp P. Calcium--a life and death signal.  Nature. 1998.  
395(6703): 645-8. 
Binns S-E, Purgina B, Bergeron C, Smith M-L, Ball L, Baum B-R, Arnason J-T. Light-
mediated antifungal activity of Echinacea extracts. 2000. Planta Med. 241-4. 
Birt DF, Widrlechner MP, LaLone CA, Wu L, Bae J, Solco AK, Kraus GA, Murphy PA, 
Wurtele ES, Leng Q, Hebert SC, Maury WJ, Price JP. Echinacea in infection. 
American Journal of Clinical Nutrition. 2008. 87(suppl): 488S-92S.  
Bootman MD, Collins TJ, Mackenzie L, Roderick HL, Berridge MJ, Peppiatt CM.  2-
aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ 
entry but an inconsistent inhibitor of InsP3-induced Ca2+ release.  FASEB J. 2002. 
16(10): 1145-50. 
Bouron A. Activation of a capacitative Ca2+ entry pathway by store depletion in cultured 
hippocampal neurones.  FEBS Letters. 2000. 470(3): 269 -72.  
  
81
Brevoort P. The booming U.S. botanical market: A new overview.  Herbal Gram. 1998. 44: 
33-48. 
Calixto JB, Campos MM, Otuki MF, Santos AR. Anti-inflammatory compounds of plant 
origin. Part II. modulation of pro-inflammatory cytokines, chemokines and 
adhesion molecules. Planta Med. 2004. 70(2): 93-103.  
Calixto JB, Otuki MF, Santos AR. Anti-inflammatory compounds of plant origin. Part I. 
Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B (NF-
kappaB). Planta Med. 2003. 69(11): 973-83.  
Clifford LJ, Nair MG, Rana J, Dewitt DL.  Bioactivity of alkamides isolated from Echinacea 
purpurea (L.) Moench. Phytomedicine. 2002. 9: 249-53. 
Daigle TL, Kwok ML, Mackie K.  Regulation of CB1 cannabinoid receptor internalization by a 
promiscuous phosphorylation-dependent mechanism. J Neurochem. 2008. 106(1): 
70-82.  
DeHaven WI, Smyth JT, Boyles RR, Bird GS, Putney JW Jr. Complex actions of 2-
aminoethyldiphenyl borate on store-operated calcium entry. J Biol Chem. 2008. 
283(28): 19265-73.  
Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Internal Review in 
Immunology. 1998. 17: 217-28. 
Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol. 2007. 
7(9): 690-702. 
Foster S. Echinacea: Nature's Immune Enhancer. Healing Arts Press (Rochester, VT). 1991. 
pp. 20-1.  
  
82
Gertsch J, Schopp R, Kuenale U, Degenring FH. Echinacea Alkylamides modulate TNF-α 
gene expression via cannabinoid receptor CB2 and multiple signal transduction 
pathways.  FEBS Lett. 2004.  577: 563-9. 
Greger H. Alkamides: Structural relationship, distribution and biological activity. Planta Med. 
1984. 50: 366-75. 
Gregory RB, Rychkov G, Barritt GJ. Evidence that 2-aminoethoxydiphenyl borate is a novel 
inhibitor of storeoperated Ca2+ channels in liver cells, and acts through a 
mechanism which does not involve inositol trisphosphate receptors. Biochem J 
2001. 354: 285–90. 
Guindon J, Hohmann AG. A physiological role for endocannabinoid-derived products of 
cyclooxygenase-2-mediated oxidative metabolism. Br J Pharmacol. 2008. 
153(7): 1341-3. 
Hu SS, Bradshaw HB, Chen JS, Tan B, Walker JM. Prostaglandin E2 glycerol ester, an 
endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia 
and modulates NFkappaB activity. Br J Pharmacol. 2008. 153(7): 1538-49. 
Kawamata T, Ji W, Yamamoto J, Niiyama Y, Furuse S, Namiki A. Contribution of transient 
receptor potential vanilloid subfamily 1 to endothelin-1-induced thermal 
hyperalgesia. Neuroscience. 2008. 154(3): 1067-76.  
Kumpost J, Syrova Z, Kulihova L, Frankova D et al.  Surface expression of metabotropic 
glutamate receptor variants mGluR1a and mGluR1b in transfected HEK293 cells. 
Neuropharmacology. 2008. 55(4): 409-18.  
  
83
Mikoshiba K, Hisatsune C, Futatsugi A, Mizutani A, Nakamura T, Miyachi K. The role of Ca2+ 
signaling in cell function with special reference to exocrine secretion. Cornea. 
2008. 27 Suppl 1: S3-8. 
Norman JP, Perry SW, Reynolds HM, Kiebala M et al.  HIV-1 Tat Activates Neuronal 
Ryanodine Receptors with Rapid Induction of the Unfolded Protein Response and 
Mitochondrial Hyperpolarization. PLoS ONE. 2008. 3(11) 
Hannoufa A, McNevin J, Lemieux B. Epicuticular waxes of eceriferum mutants of Arabidopsis 
thaliana. Phytochemistry. 1993. 33: 851–5.  
Hinz B, Woelkart K, Bauer R. Alkamides from Echinacea inhibit cyclooxygenase-2 activity in 
human neuroglioma cells. Biochem Biophys Res Commun. 2007. 360(2): 441-6. 
Holmes AM, Roderick HL, McDonald F, Bootman MD. Interaction between store-operated 
and arachidonate-activated calcium entry. Cell Calcium. 2007. 41(1): 1-12. 
LaLone C, Hammer K, Wu L, Bae J, Layva N, Liu Y, Sia-Solco A, Kraus G, Murphy P, Wurtele 
ES, Kim OK, Seo K, Widrlechner MP, Birt DF. Echinacea Species and 
Alkamides Inhibit Prostaglandin E2 Production in RAW264.7 Mouse 
Macrophage Cells. J Agric Food Chem. 2007. 55(18): 7314-22. 
Leung FP, Yung LM, Yao X, Laher I, Huang Y. Store-operated calcium entry in vascular 
smooth muscle.  Br J Pharmacol. 2008. 153(5): 846-57. 
Lewis RS. The molecular choreography of a store-operated calcium channel. Nature. 2007. 
446: 284-7. 
Li SW, Westwick J, Poll CT. Receptor-operated Ca2+ influx channels in leukocytes: a 
therapeutic target?  Trends Pharmacol Sci. 2002. 23: 63–70. 
  
84
Luo D, Broad LM, Bird GJ, Putney JW. Mutual antagonism of calcium entry by capacitative 
and arachidonic acid-mediated calcium entry pathways. J. Biol. Chem. 2001. 276: 
20186–9. 
Ma HT, Venkatachalam K, Li HS, Montell C, Kurosaki T, Patterson RL, Gill DL. Assessment 
of the role of the inositol 1,4,5-trisphosphate receptor in the activation of transient 
receptor potential channels and store-operated Ca2+ entry. J. Biol. Chem. 2001. 
276: 18888–96. 
Maruyama T, Kanaji T, Nakade S, Kanno T, Mikoshiba K. 2APB, 2-aminoethoxydiphenyl 
borate, a membranepenetrable modulator of Ins(1,4,5)P-3-induced Ca2+ release.  
Jpn J Biochem. 1997. 122: 498–505. 
Mishima S, Saito K, Maruyama H, Inoue M, Yamashita T, Ishida T. Gu Y. Antioxidant and 
Immuno-Enhancing Effects of Echinacea purpurea. Biol Pharm Bull. 2004. 
27(7): 1004-9.  
Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest.  2000. 117: 1162-72. 
Parekh AB, Putney  JW. Store-operated calcium channels. Physiol Rev. 2005. 85: 757–810. 
Prado WA. Involvement of calcium in pain and antinociception. Braz J Med Biol Res. 2001. 
34(4): 449-61. 
Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller b, Heinz-Altmann K, Gertsch J 
Alkylamides from Echinacea are a new class of cannabinomimetics. J. Bio. 
Chem. 2006. 281:14192-206. 
O'Neill LA. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev 
Drug Discov. 2006. 5(7): 549-63. 
  
85
Park KM, Yule DI, Bowers WJ. Tumor necrosis factor-alpha potentiates intraneuronal CA2+ 
signaling via regulation of the inositol 1,4,5-trisphosphate receptor. J Biol Chem. 
2008 Oct 6. [Epub ahead of print] 
Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R. In-vivo and in-vitro anti-
inflammatory effect of Echinacea purpurea and Hypericum perforatum.  J Pharm 
Pharmacol. 2002. 54(10): 1379-83.  
Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z.  Immunopharmacological 
activity of Echinacea preparations following simulated digestion on murine 
macrophages and human peripheral blood mononuclear cells. Journal of 
Leukocyte Biology. 2000. 68: 503-10. 
Guo RW, Huang L. New insights into the activation mechanism of store-operated calcium 
channels: roles of STIM and Orai J.  Zhejiang Univ Sci B. 2008. 9(8): 591–601.  
Sasagawa M, Cech NB, Gray DE, Elmer GW, Wenner CA.  Echinacea alkylamides inhibit 
interleukin-2 production by Jurkat T cells. Int Immunopharmacol. 2006. 6(7): 
1214-21. 
Shaw G, Morse S, Ararat M, Graham FL.  Preferential transformation of human neuronal cells 
by human adenoviruses and the origin of HEK 293 cells. FASEB J. 2002. 16(8): 
869-71. 
Singaravelu K, Lohr C, Deitmer JW. Regulation of store-operated calcium entry by calcium-
independent phospholipase A2 in rat cerebellar astrocytes. J Neurosci. 2006. 
26(37): 9579-92. 
  
86
Speroni E, Govoni P, Guizzardi S, Renzulli C, Guerra M-C Anti-inflammatory and cicatrizing 
activity of Echinacea pallida Nutt. root extract. J Ethnopharmacol. 2002. 79: 
265–72. 
Sun LY, Currier NL, Miller SC. The American coneflower: A prophylactic role involving 
nonspecific immunity. The journal of Alternative and Complementary Medicine. 
2001. 5: 427-46. 
Tatiana K. Zagranichnaya, Xiaoyan Wu, Arpad M. Danos and Mitchel L. Villereal. Gene 
expression profiles in HEK-293 cells with low or high store-operated calcium 
entry: can regulatory as well as regulated genes be identified?  Physiol Genomics 
2005. 21: 14-33. 
Tesfai Y, Brereton HM, and Barritt GJ. A diacylglycerol-activated Ca2+channel in PC12 cells 
(an adrenal chromaffin cell line) correlates with expression of the TRP-6 
(transient receptor potential) protein. Biochem J. 2001. 358: 717–26. 
Thore S, Dyachok O, Gylfe E, Tengholm A. Feedback activation of phospholipase C via 
intracellular mobilization and store-operated influx of Ca2+ in insulin-secreting 
beta-cells. J Cell Sci. 2005. 118(Pt 19): 4463-71. 
Tominaga M, Tominaga T. Structure and function of TRPV1. Pflugers Arch. 2005. 451(1): 
143-50.  
Turini ME, DuBois RN. Cyclooxygenase-2: A therapeutic target. Annu Rev Med. 2002. 53: 35-
57. 
Veronesi B, Oortgiesen M. The TRPV1 receptor: target of toxicants and therapeutics. Toxicol 
Sci. 2006. 89(1): 1-3. 
  
87
Woelkart K, Zu W, Ying P, Makriyannis A, Picone RP, Bauer R. The endocannabinoid system 
as a target for alkamides from Echinacea anagustifolia roots.  Planta Med.  2005. 
71: 701-5. 
Woelkart K, Bauer R. The role of alkamides as an active principle of Echinacea.  Planta Med. 
2007. 73(7): 615-23. 
Woelkart K, Salo-Ahen OM, Bauer R. CB receptor ligands from plants. Curr Top Med Chem. 
2008. 8(3): 173-86.  
Yu H, Kaarlas M. Popularity, diversity, and quality of Echinacea. In: Miller SC, editor. 
Echinacea: The genus Echinacea. Boca Raton: CRC Press. 2004. 127-49. 
Zeng W, Yuan JP, Kim MS, Choi YJ, Huang GN, Worley PF, Muallem S. STIM1 gates TRPC 
channels, but not Orai1, by electrostatic interaction. Mol Cell. 2008. 32(3): 439-
48. 
Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES, Murphy PA, Kohut ML, Cunnick JE. 
Enhancement of innate and adaptive immune functions by multiple Echinacea 
species. Journal of Medicinal Food. 2007. 10(3): 423-34.  
  
88
 
 
 
Fig. 1   Echinacea extract causes increase of calcium in HEK293 cells. Left: Time course 
of calcium change in HEK293 cells in response to repeated application of Echinacea 
extract (100 µg/ml).  Right:  Pseudocolor images of calcium transients at rest (Top) and 
when stimulated (Bottom).  In all calcium imaging time course data presented herein, 
each line corresponds to one HEK cell.  The lag between application of extract or 
compound and its effect on the cells is due to the time it takes the extract or compound 
to move through the application tube and reach the cells (i.e., it is a delay associated 
with the experimental setup). 
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Fig. 2 Dose-response curve of Ca2+ elevation in HEK293 cells evoked by E. purpurea 
root ethanol extracts. Results are expressed as percentages of maximum responses.  
Each data point represents mean ± s.e.m., n ≥ 81 (individual HEK293 cell for each 
value, from three experiments repeated on three independent cell cultures ).  EC50 = 
97.89 ± 6.6 µg/ml. This response saturates at about 200 μg/ml of extract. The Hill 
equation was used to fit the response curve. 
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Fig. 3  Left: Different fractions of Echinacea extract, fraction 67 (A), fraction 80 (B) and 
fraction 83 (C), produce different effects on calcium transients in HEK293 cells. Data 
are representative traces from cells in three independent experiments.  Right:  GC-MS 
chromatograms of metabolite contents in these three fractions. For experiments with 
the inactive fraction (fraction 67), Echinacea was always applied later to confirm that 
the particular culture used was indeed responsive to Echinacea extract.  
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Fig. 4  Different fractions from ethanol extract of E. purpurea root showed significantly 
different levels of Ca2+  response. Bar graphs show the mean values of the evoked Ca2+ 
increase by different fractions (mean ± s.e.m., n ≥ 60 of cells analyzed in three 
independent experiments).  For each application, different letters indicate a significant 
difference (p < 0.05). 
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Fig. 5  Intracellular Ca2+ increase in HEK293 cells induced by Echinacea is Ca2+ release 
from the IP3-sensitive intracellular store and PLC pathway is involved. (A) Kinetic 
changes of [Ca2+]i in HEK cells in response to repeated application of Echinacea extract 
(100 μg/ml) in normal (2 mM) and Ca2+ free solution.  (B) Calcium transients evoked by 
Echinacea can be abolished by 10min treatment of 100 µM 2-APB, an IP3 receptor 
antagonist.  (C) Calcium transients evoked by Echinacea can be abolished by 10min 
treatment of 2 µM U73122, a PLC inhibitor.  Data are representative traces from cells 
in three independent experiments. 
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Fig. 6   Echinacea-depletion of Ca2+ from intracellular store induced Ca2+ influx via 
SOCE in HEK293 cells, which was pharmacologically similar to the Ca2+ influx evoked 
by thapsigargin. A and B:  After depletion of Ca2+ stores by treating  2µM thapsigargin 
(A) or 100µg/ml Echinacea (B) in Ca2+ free conditions for 10min, 2 mM Ca2+ was then 
added to assess SOCE.  C and D:  After 10 min of restoration of external Ca2+, 100µM 
2-APB was applied while maintaining extracellular Ca2+.  Data are representative 
traces from cells in three independent experiments.  
 
  
94
 
 
Fig. 7  Calcium transients evoked by Echinacea extracts are not mediated by CB1 
receptor activation.  Echinacea extract (100 µg/ml)-evoked calcium transients in 
HEK293 cells were not abolished by the CB1 receptor antagonist AM251 (50 µM).  Data 
are representative traces from cells in three independent experiments.  
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Fig. 8   Proposed mechanism for Ca2+ signaling underlying the anti-inflammatory 
activities of Echinacea.   Metabolites in Echinacea bind to unidentified surface 
membrane receptor(s), resulting in the activation of PLC.  PLC activation catalyses the 
production of IP3 from PIP2.    IP3 binds to and opens IP3R in the membrane of the ER, 
resulting in the release of Ca2+ from ER Ca2+ store.   The fall in the Ca2+ content of the 
ER is sensed by STIM1, which in turn activates SOCE in the plasma membrane.  The 
level of intracellular Ca2+ is increased through release of Ca2+ from ER Ca2+ store as 
well as Ca2+ influx via SOCE and this increase regulates various cellular processes.  For 
example, in T-cells, elevated intracellular Ca2+ activate Ca2+-dependent enzymes, such 
as calcineurin, and thereby transcription factors, such as NFAT , NF-κB and CREB.  
These transcription factors in turn modulate the expressions of cytokines, such as IL-2, 
IL-10, TNF-α, etc., as well as COX-2, which are all involved in many steps of the 
inflammatory responses and mediate pain transmission.  Potential targets for the 
unknown receptor(s) that interact with Echinacea are: Chemokine R, Muscarinic 
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acetylcholine R, Glutamate R, B2-bradykinin  R, P2X, P2Y purinergic R, which have 
been reported to be endogenous to HEK293 cells (Shaw et al., 2002).  
 
ER:  endoplasmic reticulum    
SOCE: store-operated calcium entry 
SERCA: sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase  
PLC:  phospholipase C  
PIP2:  phosphatidylinositol-4,5-bisphosphate  
IP3:  inositol-1,4,5-trisphosphate (InsP3)  
IP3R : IP3 receptor 
DAG:  diacylglycerol 
STIM1:  stromal interaction molecule 1  
NFAT: nuclear factor of activated T cells  
NF-κB (nuclear factor-κB) 
CaMK:  calmodulin-dependent kinase  
CREB:  cyclic-AMP-responsive-element-binding protein 
IKK:   inhibitor of NF-κB kinase 
TG: thapsigargin 
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 CHAPTER 5.  ECHINACEA EXTRACTS ACTIVATE RAT 
ASTROCYTES VIA CANNABINOID TYPE 1 RECEPTOR   
A paper to be submitted to Journal of Pharmacy and Pharmacology 
Eric W. Rowe, Lankun Wu, Ksenija Jeftinija, Srdija Jeftinija and Eve Syrkin Wurtele 
ABSTRACT 
Cannabinoid receptors (CB) in the central nervous system (CNS) are molecular targets 
for endocannabinoids and a wide range of exogenously taken compounds such as marijuana.  
Echinacea species are studied extensively as herbal immunomodulators. Effects on CB2 
receptors of several of the alkamides found in Echinacea extracts have been described but 
interaction with the CB1 receptor has not been reported.  Here we report for the first time 
evidence from primary cell cultures that extracts from Echinacea contain a new class of CB1 
cannabinomimetics. In cultured astrocytes, Echinacea extract produced calcium transients. The 
CB1 receptor antagonist AM251 blocked the effect of the extract in a reversible manner.  
These stimulatory effects of extracts were independent of extracellular calcium.  When 
Echinacea was applied to mixed astrocyte-neuron cultures, calcium transients were primarily 
confined to astrocytes. Our results reveal a new potential target of Echinacea extract and a 
cannabinomimetic effect in the CNS.  
INTRODUCTION 
Cannabinoid receptors are members of a superfamily of seven-transmembrane-
spanning G coupled receptors. Endogenously, these receptors are known to bind to anandamide 
(arachidonylethanolamide) and have endocrine/metabolic functions and modulate the immune 
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response.  These characteristics have promoted research of the cannabinoid system because of 
its involvement in various conditions, including pain, immune regulation, appetite control, 
peripheral vascular disease, and motor disorders (Goutopoulos & Makriyannis, 2002).   CB 
receptors consist of at least two main groups, type 1 (CB1) and type 2 (CB2) (Goutopoulos & 
Makriyannis, 2002).  The CB1 receptors are found in many tissues throughout the body and are 
widely distributed in CNS and are thought to modulate brain physiology (Goutopoulos & 
Makriyannis, 2002; Chevaleyre et al., 2006).  The second receptor type, CB2, is expressed 
primarily, but not limited to cells of the immune system (Goutopoulos & Makriyannis, 2002; 
Pazos et al., 2005).  
Echinacea species contain a variety of specialized compounds, many of which are 
thought to have biological activities in heterogenous species.  For Echinacea, putatively 
bioactive compounds include phenolics, alkamides and ketones, and others (Barnes et al., 
2005).  These compounds may act individually or in concert to confer bioactivity.   The 
alkamides of Echinacea have a structural similarity to anandamide (the natural ligand for 
cannabinoid receptors) and also are very lipophilic (Woelkart et al., 2005). Recently, specific 
alkamides that are found in Echinacea have been shown to modulate expression of TNF-α in 
human macrophages and monocytes, and this modulation appears to be occurring via the CB2 
receptor (Gretsch et al., 2004; Woelkart et al., 2005).  Affinity studies conducted using 12 
different alkamides that are present in E. angustifolia has shown that some of these compounds 
have high affinities for both CB1 and CB2 receptors (Woelkart et al., 2005).  This concept was 
further supported by Raduner et al. (2006), who found certain alkamides (alkamide 8 and 11) 
bound to human CB2-receptor more strongly than did endogenous cannabinoids.  This work 
also demonstrated that the interaction between the CB2 receptor and specific alkamides present 
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in Echinacea may play some role in mediating the immunomodulatory effects that are 
described associated with this plant.  However, none of this previous work has demonstrated or 
investigated an effect of Echinacea constituents on CB1. 
Within the CNS there are two categories of cells, neurons and glia, with glia 
constituting 90% of the cells in the adult.  The astrocyte is the most common type of glial cell, 
and also the most common cell type in the adult CNS, accounting for roughly 50% of the total 
cell population (Song et al., 2002). Astrocytes traditionally have been considered as having 
only a supportive and maintenance role, including modulation of the perineural environment, 
providing both structural and metabolic support to the neuron, and axonal guidance during 
development (Haydon, 2001; Svendsen, 2002).  However, more recently astrocytes have been 
shown to have a much more extensive function. Astrocytes have been shown to be important in 
synapse formation (Mauch et al., 2001; Slezak & Pfrieger, 2003), capable of releasing 
neurotransmitters (Purpura et al., 1994; Jeftinija et al., 1996; Newman, 2003), and modulate 
synaptic activity (Araque et al., 1999; Haydon, 2001; Newman, 2003; Perea & Araque, 2005).  
Furthermore, astrocytes appear to play a role in the immune response and cytokine production 
(Dong et al., 2001; Milkovic et al., 2007).  Specifically, the astrocyte CB1 receptor has been 
implicated as one potential mechanism for the modulation of synaptic activity (Navarrete & 
Araque, 2008). Hence, the astrocyte is being unveiled as a central player in many events 
critical to the function of the nervous system.   
Our central hypothesis in this study is that endogenous compounds present in 
Echinacea activate specific receptors in cells of the CNS.  Furthermore, we hypothesize that 
Echinacea contains compounds that have a cannabinomimetic effect, and that these 
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compounds are likely alkamides.  Finally, we hypothesize that the compounds from Echinacea 
other than alkamides have bioactivity on CNS receptors. 
MATERIALS AND METHODS 
Preparation of Echinacea extracts and fractions 
Echinacea extraction and fractionation were performed as in previous published work 
(Lalone et al., 2007).  
Cell cultures 
Mixed neuron-glia cultures from neonatal rat cerebral cortex were established as 
described.  Cortex from newborn pups (1-3 days old) were  freshly dissected and tissue was 
treated in 2 ml of papain solution (1.54 mg/ml of EBSS; 40 min at 37oC), than washed with 
EBSS; incubated 5 min in trypsin inhibitor, and mechanically dissociated in DMEM high 
glucose+ 10% FBS, + pen/strep (1 ml/100 ml DMEM) using pipettes.  Cells were plated in 
DMEM medium in culture flasks and maintained at 37oC in a humidified 5% CO2/95% air 
atmosphere. After mixed cultures reach confluence (9-12 days), the flasks were "preshaken" 
(260 rpm) for 90 min to remove microglia and dividing type I astroglia. The cultures were then 
shaken overnight (12-18 hours) at 260 rpm at 37°C. Cultures enriched in type I astroglia were 
obtained by trypsinizing (0.25%) the attached cells for 3 min. Trypsin was inactivated by 
adding 3 ml DMEM (the same media as above) supplemented with 10% heat-inactivated FBS 
(serum contains protease inhibitors). Astrocytes were plated on poly-L-lysine (100 mg/ml; 
MW 100,000)-coated glass coverslips. All experiments were performed on cells that have been 
in culture for 1-3 days after re-seeding.   
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Chemicals 
Fura-2 AM and pluronic F-127 were purchased from Invitrogen (Carlsbad, CA, USA); 
1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-
carboxamide (AM251) was purchased from Sigma (St. Louis, MO, USA).   
Intracellular Calcium Imaging   
 Intracellular calcium concentrations ([Ca2+]i) were measured by ratiometric imaging 
techniques. Cells were plated onto 22-mm coverslips 36 hr before the experiment.  Cells were 
loaded with Fura 2-AM for 60 min at room temperature. The loading solution contained 1 µl of 
25% (w/w) Pluronic F-127 and 4 nM of Fura 2-AM diluted in 1 ml of HEPES buffer. The 
loading solution was removed and the cells were washed twice with HEPES buffer before the 
coverslips were placed onto a perfusion chamber and connected to a micro pump.  The test 
substances were placed in syringes on a five-valve manifold and applied into the perfusion 
chamber by the micro pump with a flow rate of 200 µl per min. As a result of the spatial 
distance between the syringe and the culture in the chamber, there was a time delay between the 
turning on the valve and onset of the response.  All image processing and analysis were 
performed using MetaFluor® soft ware with a Nikon microscope. Background subtracted, 
rationed images (340/380 nm) were used to calculate the [Ca2+]i according to Equation 5 of 
Grynkiewicz et al. (1985). Using wavelengths of 340 and 380 nm, Fura 2-AM was excited, and 
the emitted light was collected at 510 nm.  
RESULTS AND DISCUSSION 
Our results indicate that ethanol extracts of E. purpurea selectively increase 
intracellular calcium concentrations in post-natal hippocampal astrocytes, and not neurons (Fig. 
1).  Furthermore, the source of this calcium appears to be from intracellular stores, as indicated 
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by the stimulatory effect that occurs in calcium free conditions (Fig. 2). This is consistent with 
the CB receptors being mediators of the Echinacea-induced intracellular calcium increase in 
these cells.  This indication was further supported by the ability of a CB1 receptor antagonist 
(AM251) to block the effect of the extract in a reversible manner (after wash out, the cells 
remained capable of response) (Fig. 3).  All of this suggests a potential new target for 
Echinacea that has a centrally-mediated cannabinomimetic effect. 
Additional experiments indicate that different HPLC-separated fractions of the E. 
purpurea extract have differential effects on astrocytes.  Of the three bioactive fractions thus 
far identified (two are shown), both the duration and intensity of the calcium transient is unique 
(Fig. 4).  GC-MS analysis indicates a complex mixture of components in all fractions tested, 
with the predominate constituents of bioactive fractions being alkamide 4 (fraction 67), and 
alkamides 8, 9 and 11 (fraction 80).  It is hoped that by testing different fractions we will 
enable us to determine the specific bioactive constituents and fractions. 
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Fig. 1  Echinacea extracts induce calcium increases in cultured astrocytes and have no 
or little effect on neurons in hippocampal mixed cell cultures.  (A) Panels on the left 
illustrate pseudocolor images of calcium transient in cells stimulated with 50 mM K+ 
and Echinacea extract (200 μg/ml). (B) Kinetic changes of [Ca2+]i in 5 cells  that 
responded  to perfusion application of 50 mM K+ , and failed to respond significantly to 
200 μg/ml Echinacea extract. This type of response to 50 mM K+ is characteristic of 
neurons. (C) Kinetic tracings of five cells (cells in the lower half of the cluster) that 
failed to respond to 50mM K+ and responded to Echinacea extract. In primary cultures, 
astrocytes can be distinguished from neurons because of their failure to respond to 
depolarization induced by high potassium, with increase in intracellular calcium. 
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Fig. 2  Echinacea extract causes increase of calcium in cultured astrocytes that is 
independent of extracellular calcium. (A) Pseudocolor images of calcium transients at 
rest and (B) when stimulated.  Time course of calcium change in astrocytes in response 
to repeated application of Echinacea extract (200 µg/ml) in normal (C) and low Ca2+(D).  
In all calcium imaging time course data presented herein, each line corresponds to one 
region of interest (i.e., one astrocyte or neuron).   
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Ech 100 μg/ml Ech 100 μg/ml Ech 100 μg/ml
AM251 50 μM
 
 
Fig. 3  Astrocytic calcium transients evoked by Echinacea extracts may be mediated by 
CB1 receptor activation.  Echinacea extract (100 µg/ml)-evoked calcium transients in 
cultured astrocytes were greatly diminished by the CB1 receptor antagonist AM251 (50 
µM).  The antagonistic effect was reversed after 15 minutes of washing with HEPEs 
buffer.  
 
 
 
 
 
 
  
109
 
 
 
Fig. 4  Different fractions of Echinacea extract produce different effects on calcium 
transients in cultured astrocytes (A) Fraction 67 (1.26 µg/ml) and (B) Fraction 80 (0.48 
µg/ml). 
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CHAPTER 6.  EFFECTS OF ECHINACEA EXTRACTS ON TRPV1 
TRANSIENT PAIN RECEPTOR EXPRESSED IN XENOPUS LAEVIS 
OOCYTES 
A paper to be submitted to Proceedings of the National Academy of Sciences USA 
Lankun Wu, Qiang Leng, Steven Hebert, Eve Syrkin Wurtele 
ABSTRACT  
With a long history of traditional medical uses for various ailments such as pain relief, 
Echinacea extracts are currently widely used mainly as herbal immunomodulators.  However, 
their efficacy and underlying molecular mechanisms of action remain unclear. Three 
medicinally used species of Echinacea (E. angustifolia, E. pallida and E. purpurea) were 
investigated for their stimulating effects on transient receptor potential vanilloid 1 (TRPV1) 
expressed in Xenopus laevis oocytes. Echinacea ethanol extracts had potent activity in opening 
TRPV1 channel, evoking currents up to 10 times of that evoked by a saturating dose of 
capsaicin, the ligand used to clone TRPV1. Among the 3 species tested, E. angustifolia is the 
most active. Ethanol extract of E. purpurea root was fractionated by HPLC; only the most 
lipophilic fraction evoked a current, a current was induced by a 7 µg dry weight/ml of this 
fraction.  Echinacea-evoked responses could not be blocked by capsazepine, a competitive 
TRPV1 receptor antagonist not only for capsaicin but also for many known endogenous 
TRPV1 agonists.  TRPV1 mutants lacking either PKC phosphorylation sites (TRPV1-S502A, 
TRPV1-S800A and TRPV1-S502A/S800A) or critical capsaicin binding sites (TRPV1-S512Y 
and TRPV1-Y511A) that reduce capsaicin-dependent TRPV1 activity, do not affect 
Echinacea-induced TRPV1 activity.  In addition, Echinacea extracts induce a much more rapid 
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desensitization of TRPV1, compared to the calcium-dependent desensitization of TRPV1 by 
capsaicin. Furthermore, unlike capsaicin, Echinacea extracts rapidly desensitize TRPV1 in the 
presence of only minimum concentration of calcium. These results indicate the activation of 
TRPV1 by Echinacea involves a distinct mechanism from that of capsaicin and most likely this 
activation is via an indirect signaling pathway instead of direct binding. 
INTRODUCTION   
Well known for its characteristic fiery and pungent taste, Echinacea produces local 
anesthesia of the mucous membranes; thus, it has been used medicinally by Native Americans 
since ancient times (1).  Perhaps its principal use was in relation to pain alleviation and the 
promotion of healing, such as in cases of snake bites, burns, cough, sore throats, and toothache 
(1, 2). Echinacea extracts are currently promoted in pure forms and as additives to vitamins 
and medicines as general enhancers of the immune system, and are among the best-selling 
herbal preparations in the U.S.A (3).  
Despite the popularity of Echinacea as an herbal supplement, and many 
pharmacological and clinical studies, understanding of the efficacy and the molecular 
mechanisms of action of Echinacea is still very limited. The potential mechanism of Echinacea 
as an anti-inflammatory agent is currently an active area of investigation (4). The growing 
evidence of the inter-relationship of pain receptors to inflammatory responses (5, 6) indicates 
that Echinacea might mediate inflammatory responses in part via pain receptors.  Two of the 
alkamides (alkamides 8 and 11 in Fig. 6s, supporting information) found in Echinacea have 
been shown to activate the cannabinoid receptor (CB) (7). The effects of whole extracts on this 
receptor have not been reported, and neither pure alkamides nor whole extracts from Echinacea 
have been tested with other pain receptors.  
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TRPV1 is a ligand-gated cation channel that is considered as a molecular integrator of 
multiple stimuli in pain signaling (8). Under resting conditions, the channel pore of TRPV1 is 
closed.  When activated, TRPV1 allows the influx of monovalent and divalent cations, 
predominantly Ca2+, through the cell membrane; this influx leads to a rise in cytosolic Ca2+, a 
subsequent depolarization of nociceptive neurons, and a release of inflammatory peptides from 
primary afferent nerve terminals (9).  Mounting evidence indicates that TRPV1 acts as an 
integrator of inflammatory pain, making this ion channel an excellent potential target for 
analgesic or anti-inflammatory therapies (10-12).  TRPV1 is easily desensitized by its ligands. 
Desensitization of TRPV1 following its activation in the sensory neurons is crucial in blocking 
pain transmission (13). Therefore compounds that serve as agonists have potential for use as 
analgesics or anti-inflammatory agents.  
Anandamide (arachidonylethanolamide), originally isolated from brain as an 
endogenous CB agonist (14), also activates TRPV1 (15), the first mammalian pain receptor to 
be cloned using capsaicin (the “hot” component in “hot” peppers) as a probe (16).  The dual 
effect of anandamide in activating both CB and TRPV1 has intrigued many researchers about 
the complex interactions between CB and TRPV1 signaling systems (15, 17-18).   
In this study, we investigate the effects of Echinacea extracts on TRPV1-dependent 
inward ion current.  Transient expression of TRPV1 in an efficient non-mammalian model, 
Xenopus oocytes (16, 19), is used to test the effect of extracts of Echinacea and constituents on 
TRPV1. Using this model system, we find that Echinacea extracts have potent effects in 
activating TRPV1 through a different mechanism from that of capsaicin and can strongly 
desensitize this channel. The activation of TRPV1 is not induced by major alkamides in 
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Echinacea. We propose that immunomudulatory and anti-inflammatory activities of Echinacea 
might result from interacting with both CB and TRPV1 molecular signal transducers. 
RESULTS 
Echinacea activates TRPV1 expressed in Xenopus laevis oocytes.    
Our initial studies show E. angustifolia root extracts evoke an inward current in 
TRPV1-expressing Xenopus oocytes. To investigate the concentration dependence of this 
response, seven concentrations from 10 to 250 μg/ml of extracts were tested. The dose 
response curve is shown in Fig. 1A. At concentrations as low as 20 μg /ml, E. angustifolia 
evokes a TRPV1-dependent current, and this response saturates at about 200 μg/ml of extract. 
EC50 is 105.3 ± 4.1 μg/ml (n = 7).  
Ethanol extracts from roots of all three major medicinally-used species of Echinacea 
have potent TRPV1 stimulating activity (Fig. 1B), opening the channel within 10 s, and 
evoking an inward current significantly higher than that evoked by a saturating dose of 
capsaicin (10 µM). This Echinacea-evoked current response returns to baseline rapidly after 
removal of Echinacea extract (Fig. 1B), indicating that the TRPV1 activation is reversible. The 
relative potencies of extracts are shown in Fig. 1C. Of the three species tested, E. angustifolia 
is the most active; at a dose of 250 µg/ml, it evokes a current up to 10-fold of that evoked by 
saturating dose of capsaicin. None of the three root extracts evoke a response in the absence of 
TRPV1 (water-injected oocytes) (data shown for E. angustifolia root ethanol extract), 
indicating the response is TRPV1-dependent. Furthermore, a spinach ethanol extract didn’t 
evoke any currents in TRPV1-expressing oocytes (Fig. 1C), indicating the response is not 
general to any plant extract. 
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Although ethanol extracts of Echinacea activate TRPV1, it is possible that aqueous 
extracts also elicit TRPV1-channel-dependent inward current.  Aqueous extracts of Echinacea 
contain unusual polysaccharides that have been reported to have anti-inflammatory activity 
(20-21). However, polysaccharides are absent when Echinacea is extracted with solvent 
containing less than 90% water (7). To test whether polysaccharides from Echinacea activate 
the TVPR1 channel, we evaluated the effects of water extracts of E. purpurea, E. angustifolia 
and E. pallida on the TRPV1 channel in the frog-oocyte model. Echinacea aqueous extracts do 
not induce a TRPV1-dependent inward current, excluding the Echinacea polysaccharides from 
being promising candidates as potential TRPV1 ligands.  
The HPLC-PDA fingerprints of the Echinacea and spinach extracts are shown in Fig. 2. 
The phytochemical compositions of the Echinacea extracts used in this study (Fig. 6 and Table 
1, supporting information) are similar to those reported (22).  None of the UV-absorbing 
alkamides, ketones, and only traces of putative caffeic acid derivatives were detected in 
spinach, which was used as a negative control.  
Evaluation of the activation of TRPV1 by Echinacea fractions and pure compounds.   
To further identify the potential bioactive constituents responsible for activating 
TRPV1, E. purpurea root ethanol extracts were chromatographed using semi-preparative 
HPLC. Four fractions were collected and tested for bioactivity in TRPV1-injected frog oocytes 
(Fig. 3A). The least polar of these fractions, Fraction 4, induces a high and specific influx of 
cations.  The other fractions have no detectable bioactivity. Furthermore, if these fractions are 
added back to Fraction 4, the activity of Fraction 4 is not affected.  These results indicate that 
the Echinacea-dependent stimulation of TRPV1 is induced by bioactive metabolites in Fraction 
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4, and furthermore that this response is not influenced by compounds in the other fractions of 
the extract. 
Each fraction was fingerprinted by HPLC-PDA (Fig. 3B). Fraction 4 contains alkamide 
10, alkamide 11 and several unknown metabolites (indicated by red arrows), presumably 
ketones by their UV spectra. There would be other non-UV absorbing metabolites that are 
unique to Fraction 4 undetected in this HPLC-PDA analysis.  LC-MS/MS are currently being 
used for further characterization of bioactive fractions and identify the novel compound(s) that 
may contribute to TRPV1-stimulating activity.  In parallel, Fraction 4 is being sub-fractionated 
by HPLC and the sub-fractions will be bioassayed to further narrow down the scope in our 
search for bioactive constituents. 
Synthesized standards of pure alkamides from Echinacea, including alkamides 8, 10, 
11, 13 and 14 were also tested in the TRPV1-expressing Xenopus oocytes.  Among them, 
alkamide 8 and 11 were reported by Raduner et al. (7) to bind to the cannabinoid receptor CB2.  
Standards of five caffeic acid derivatives, caftaric acid, cynarin, echinacoside, cichoric acid and 
chlorogenic acid, were also tested.  None of these pure compounds from Echinacea displays 
any activity on TRPV1 (Fig. 7s, supporting information). The activation of the TRPV1 channel 
by Fraction 4 could be caused by synergistic effects contributed by multiple compounds, or 
effects by novel bioactive compound(s) that have not been identified.   
Echinacea activation of TRPV1 is via a different mechanism from that of capsaicin.  
 The mechanism of action of Echinacea on TRPV1 appears to differ from that of 
capsaicin.  Our results to date indicate the Echinacea constituents that activate TRPV1 are 
lipophilic metabolites and thus might interact with TRPV1 at the same locus.   
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To investigate whether Echinacea activates TRPV1 through a capsaicin-like mechanism, we 
studied the effects of Echinacea on TRPV1-S512Y and TRPV1-Y511A, two TRPV1 mutants 
lacking critical capsaicin binding sites and reduced in their ability to be activated by 
capsaicin in both Xenopus oocyte and human HEK293t cell systems (23).  Interestingly, there 
is no significant difference between the currents evoked by Echinacea extract in Xenopus 
oocytes injected with mutants compared to those injected with wild type TRPV1 (Fig. 4A).   
Protein kinase Cepsilon (PKC), known to sensitize TRPV1 to agonists (24-26), has been 
demonstrated to directly phosphorylate TRPV1 at Ser502 and Ser800 (25).  In order to 
elucidate whether the Echinacea activation of TRPV1 requires phosphorylation and whether 
PKC is involved in regulating this process, we constructed TRPV1-S502A, TRPV1-S800A 
and TRPV1-S502A/S800A mutants, lacking critical PKC phosphorylation sites Ser 502 and 
Ser 800. TRPV1 activation was assessed in Xenopus oocytes expressing either wild-type or 
mutant TRPV1 channels.  Our results show that either single mutant (TRPV1-S502A and 
TRPV1-S800A) (data not shown), or the double AA mutant (TRPV1- S502A/S800A), has 
significantly reduced capsaicin sensitivity compared to wild type.  However, there is no 
significant difference between the currents evoked by Echinacea extract in oocytes injected 
with mutant TRPV1 channels compared to those injected with wild type TRPV1 (Fig. 4B).   
These results indicate that Echinacea might activate TRPV1 by a different mechanism from 
that of capsaicin. To test this hypothesis, we evaluated the activation of TRPV1 in the 
presence of capsazepine, a close derivative of capsaicin and a competitive TRPV1 antagonist 
that can abolish the capsaicin activation of TRPV1.  The Echinacea extract response to 
TRPV1 is not blocked by capsazepine (Fig. 4C), further supports the concept that Echinacea 
activation of TRPV1 is via a mechanism distinct from that of capsaicin. It is therefore 
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possible that Echinacea extracts interact with TRPV1 via a indirect pathway different from 
that of capsaicin. 
Echinacea strongly desensitizes TRPV1.   
Capsaicin desensitizes TRPV1 after repeated application at short intervals (27).  
Calcium plays a key role in this capsaicin-evoked desensitization, supported by the findings 
that capsaicin desensitization was greatly diminished with decrease of external calcium 
concentration, or with chelation of intracellular calcium by adding EGTA (28).   
Here, we compare the desensitization process of Echinacea extracts vs. that of 
capsaicin in response to extracellular calcium (Fig. 5). In the presence of calcium (2 mM), 
Echinacea induces rapid desensitization, usually resulting in total desensitization after the very 
first application. In contrast, capsaicin-dependent desensitization is more gradual, with 
complete desensitization at the fourth successive application or later. With no addition of 
external calcium (< 20 μM calcium is present in the medium, from the Milli-Q water), 
Echinacea still displays fast desensitization, although slower than that in calcium plus solution 
(Fig. 5B). However, capsaicin does not induce TRPV1 desensitization under this condition (Fig. 
5A). Thus these results indicate that Echinacea rapidly desensitizes TRPV1. 
DISCUSSION 
Echinacea has been traditionally used for pain relief by Native Americans. For example, 
the Crow, Omaha-Ponca, and other native groups chewed fresh root to alleviate pain from 
toothaches (29); juice from roots was used to relieve the pain resulting from burns (1); the 
Cheyenne chewed on roots for sore throats and applied an infusion of powdered leaves and 
roots to reduce sore neck pains (30).  However, the underlying molecular mechanisms are still 
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poorly understood. Here we report that Echinacea extracts have potent activity as agonists of 
the TRPV1 pain receptor, which might underlie pain alleviating effects of Echinacea.   
Our results indicate that the mechanism of action of Echinacea on TRPV1 differs from that 
of capsaicin (15) and many other TRPV1 agonists (13, 31-33).   Most TRPV1 activators 
reported to date (7, 31-33) appear to act at the capsaicin binding site and can be abolished by 
the competitive TRPV1 receptor antagonist capsazepine. The only known ligand that 
activates TRPV1 in the presence of capsazepine is camphor (34).  In contrast to capsaicin, 
Echinacea activation of TRPV1 can not be abolished by capsazepine (Fig. 4B), indicating 
that it might work through different a mechanism from that of the reported endogenous 
activation. In addition, TRPV1 mutants that lack either PKC phosphorylation regulatory sites 
or capsaicin-binding sites, both important for capsaicin-dependent activation of TVPR1 (26, 
28), respond differently to Echinacea extract/fraction than to capsaicin.  From these findings 
we propose that Echinacea extracts contain metabolites that activate TRPV1 via an indirect 
pathway instead of direct binding.  
Different TRPV1 agonists cause calcium-dependent desensitization of TRPV1 (21).  
The mechanisms underlying the calcium-dependent desensitization of TRPV1 are not well 
understood. One explanation for capsaicin is that TRPV1 activity is decreased as a result of 
calcium-dependent dephosphorylation (35). The characterization of this desensitization process 
may reveal how sensory neurons adapt their responses to repetitive stimuli, thus this 
information could be of great help to develop new therapeutic approach for pain mitigation. In 
contrast to other agonists (15, 34), Echinacea extracts induce desensitization rapidly even in 
the near absence of calcium.  The “tingling”, rather than “painful” sensation when ingesting 
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Echinacea (described in 1, 2) may in part to reflect a rapid desensitization of the TRPV1 pain 
receptor in response to Echinacea.  
TRPV1 is a molecular integrator of multiple stimuli in pain signaling, and is considered 
to play an integrative role in inflammatory pain (10-11, 30, 36-37).  Other members of the TRP 
channel family proteins and other receptors including CB and ASIC (acid-sensing ion channel), 
and more recently Trek-1, are thought to interacts with TRPV1 to sense, transmit, and integrate 
pain responses and associated inflammatory responses (18, 38-39).  In particular, there appears 
to be an intimate relationship between CB and TRP receptors. Firstly, a high degree of co-
expression of CB and TRPV1 receptors has been reported, such as in nociceptive primary 
sensory neurons (40) and in cerebromicrovascular endothelial cells (41).  Secondly, CB and 
TRPV1 receptors appear to functionally interact with each other; for instance, CB1 stimulation 
modulates the activities of TRPV1 in cultured rat dorsal root ganglion cells (42), and CB1, 
CB2 and TRPV1 receptors cooperate in controlling cerebral blood flow and blood-brain barrier 
permeability (41). Furthermore, TRPV1 and CB have overlapping ligand recognition 
properties, thus several CB-activating ligands, such as anandamide, olvanil, can also activate 
TRPV1 (14, 16, 43). This may have important therapeutic implications; for example, arvanil 
(N-vanillylarachidonamide), a synthesized capsaicin analog, is an agonist of both TRPV1 and 
CB1 and has already proved to be a powerful analgesic drug in mouse (44), although the 
mechanism of action is not yet understood (45-46, 17). 
Due to the high structural similarity shared between anandamide and alkamides, 
Gertsch et al. (47) postulated that alkamides play a role in Echinacea-induced 
imunomodulation, demonstrated that alkamides stimulate transcription of tumor necrosis factor 
α (TNF-α) in human monocytes, and suggested the stimulation was via the CB receptor.  
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Twelve alkamides were reported to bind in vitro to CB2 from mouse spleen membranes (48), 
and alkamides 8 and 11 were shown to bind human CB2 more strongly than did the 
endogenous CB agonist anandamide (49).  These data suggest that Echinacea may act on CB 
via its alkamide constituents (47-49).  In this report we demonstrate that Echinacea extracts 
(but not Echinacea alkamides including alkamides 8 and 11) have potent activities in opening 
the TRPV1 channel and can strongly desensitize this channel in the oocyte model.  We propose 
that Echinacea may modulate both TRPV1 and CB receptors through different chemical 
mediators, and that a complex interaction among signaling pathways may regulate the 
immunomodulatory and anti-inflammatory activities of Echinacea.  
MATERIALS AND METHODS  
Preparation of Plant Extracts.   
Dried roots of 2-year-old Echinacea plants were provided by the USDA North Central 
Regional Plant Introduction Station (Ames, IA), accession numbers PI 631285 (E. 
angustifolia), PI 631293 (E. pallida), and PI 631307 (E. purpurea). Spinach was purchased 
from a super market.  Six g ground dry root powder was added to 50 ml 95% ethanol, 
sonicated for 10 mins and then extracted under shaking at room temperature for 1 hr.  The 
supernatant was filtered through a 0.22 µm PTFE filter (Alltech, IL), evaporated to dryness 
under N2 gas, vacuum desiccated at 30°C, and stored at -20°C.  The dry residue was re-
dissolved in dimethyl sulfoxide (DMSO), diluted 1,000-fold in recording solution for 
electrophysiological assays.  
HPLC Analysis.   
The phytochemical composition of each extracts was evaluated by HPLC-PDA using 
the same method as that in our previously published work (50-52). Briefly, extracts were 
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dissolved in DMSO to adjust the concentration to 10mg/ml. Into 320 µl of each extract, 40 µl 
(1 mg/ml) N-isobutylundeca-2-ene-8,10-diynamide (C15H21O2) and 40 µl (1 mg/ml) 3,5-
dimethoxy-4-hydroxy-cinnamic acid (C11H12O5) was added as internal standards for 
quantification of alkamides/ketones, and caffeic acid derivatives, respectively.  Specific HPLC 
instrumentation and solvent conditions are the same as that previously published (55).  For 
compound identification, alkamides 8/9, cichoric acid, echinacoside, caftaric acid and cynarin 
were purchased from Phytolab (Vestenbergsgreuth, Germany); chlorogenic acid was purchased 
from Sigma Aldrich (St. Louis, MO, USA); and alkamides 2,10-14 and ketone 20-22 were 
synthesized (50-51).  Peaks were identified according to retention time and mass spectra 
obtained from LC-MS and/or GC-MS.  In the absence of standards, alkamides 1-5, 7, 15-17 
and ketone 24 were identified by HPLC fractionation coupled with GC-MS analysis. 
Compounds were quantified based on the internal standards, with the limit of HPLC detection 
at approximately 0.02 μg/ml.  
Molecular Biology.   
cDNA encoding rat TRPV1 sequence was subcloned into pCDNA3 vector. All 
plasmids containing TRPV1 transcripts were verified by sequencing, linearized with Not-1 
restriction endonuclease, and used to generate full-length cRNA transcripts using mMESSAGE 
mMACHINE T7 High Yield Transcription Kit (Ambion, Austin, TX).  
Preparation and Injection of Oocytes.   
Standard methods (56) were used to express TRPV1 cRNA in stage 5 and 6 Xenopus 
laevis oocytes. Frogs were anesthetized in 0.02% 3-aminobenzoic acid ethyl ester (tricane; 
titrated to pH 7.4 with 5 mM HEPES using NaOH) for 3-7 min. Oocytes were removed by 
partial ovarectomy and the frog allowed to recover. Oocytes were separated into clumps of 
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around ten using forceps and chemically defolliculated with 2 mg/ml type 1A collagenase 
dissolved in a minus-Ca2+ solution (in mM: 82 NaCl, 2 KCl, 20 MgCl2, 5 HEPES, adjusted to 
pH 7.4 with NaOH) while being gently agitated on a level-plane shaker for ~ 1 hr. Oocytes 
were washed 12 times in ND-96 solution (in mM: 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 
HEPES, pH 7.4) and placed in incubation medium consisting of ND-96 solution containing 
500 Units/ml penicillin and 500 μg/ml streptomycin (Invitrogen, Carlsbad, CA). Within 12 hrs 
defolliculation, healthy oocytes were injected with 50 nl water containing 5 ng cRNA using an 
Inject+Matic injector (Genève, Switzerland). Oocytes were incubated at 18 ºC. Incubation 
medium was changed daily, and dead or unhealthy oocytes were removed.  Due to rapid 
desensitization of TRPV1 by Echinacea extracts, different oocytes were used to acquire each 
value. To account for the variation between different oocytes, each oocyte was first tested with 
capsaicin (10 µM) and then with Echinacea extracts. Current responses elicited from each 
extract were normalized to responses obtained with capsaicin. Capsaicin and capsazepine were 
purchased from Sigma Aldrich (St. Louis, MO, USA). 
Two-electrode Voltage Clamp (TEVC).  
Microelectrodes were formed from boroscillicate glass tubing (Kimble Products, NJ) 
by pulling to a tip resistance of 0.9 - 1.5 MΩ using a pipette-puller (PP830, Narishigie 
Scientific Equipment Laboratories, Japan), and backfilled with 3 M KCl. Currents were 
measured using a Warner Oocyte Clamp OC-725C (Hamden, USA) and passed through a low-
pass 8 pole Bessel filter (1000 Hz, 902LPF, Frequency Devices, MA). Data were acquired via 
a Digidata 1200 Series Interface digital-to-analogue converter (Axon Instruments, CA) driven 
by commercial software Clampex 8.20 (Axon Instruments, CA). Steady-state currents were 
analyzed off-line with Clampfit 9.2 (demonstration version, Axon Instruments, CA) and Prism 
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4 (GraphPad, USA), holding potential – 60 mV. Bath solution containing (in mM) 90 NaCl, 
1.0 KCl, 2.4 NaHCO3, 0.1 BaCl2, 1 MgCl2, 10 HEPES, titrated to pH 7.6 with NaOH, with 2 
CaCl2 or without CaCl2, was perfused at 2 ml/min rate (15). 
Data Analysis of Dose–Response Curve.   
The solid lines on the dose–response curves are least-squares fits to mean data using 
Eq. 1 where I is raw current, Imin is minimum currents, Imax is maximum currents, EC50 is 
half-maximum concentration of Echinacea extract, X is logarithm of concentration, n is Hill 
coefficient.. All data are presented as means ± SEM and were fit by using PRISM 4.02 for 
Windows (GraphPad). 
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Statistical Analysis.  
Statistical analyses were performed using SAS software version 8.02 (SAS Institute 
Inc., Cary, NC). One-way analysis of variance followed by the Tukey test was used to compare 
means. Significance of difference was defined at P < 0.05. 
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Fig. 1 Activation of TRPV1 by Echinacea ethanol extracts. (A) Dose-response curve of E. 
angustifolia root ethanol extract on TRPV1 (each point represents mean ± s.e.m., n = 7 
independent oocytes for each value), with EC50 value of 105.3 ± 4.1 µg/ml. The Hill 
equation was used to fit the response curve. (B) Responses to saturating doses of 
capsaicin (10 µM) and extracts from 3 Echinacea species (250 µg /ml) in Xenopus laevis 
oocyte expressing TRPV1. The treatment (capsaicin or Echinacea is applied for 10s), 
membrane currents were recorded in the whole-cell voltage clamp configuration. (C) 
Relative potencies of each Echinacea extract (mean ± s.e.m., n ≥ 4 independent oocytes 
for each value).  Current responses were normalized in each cell to responses obtained 
with capsaicin (10 µM). Spinach extract (250 µg /ml) was used as negative control. 
Extracts evoked no responses in water-injected cells.  
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Fig. 2 HPLC chromatograms of the lipophilic and hydrophilic phytochemicals in 95% 
ethanol extracts of E. angustifolia, E. purpurea, E. pallida and spinach. HPLC 
conditions see Materials and Methods.  UV absorbance at 210 nm (blue) and 260 nm 
(black) for lipophilic chromatography, UV absorbance at 330 nm for hydrophilic 
chromatography. Lipophilic compounds numbering as denoted in Figure 1. Red arrows 
indicate internal standards. 
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Fig. 3  (A)  Whole cell currents evoked on TRPV1 by 4 fractions collected from ethanol 
extract of E. purpurea root by semi-preparative HPLC.  (B) HPLC chromatograms of 
the lipophilic and hydrophilic phytochemicals in each fractions.  UV absorbance at 210 
nm (blue) and 260 nm (black) for lipophilic chromatography, UV absorbance at 330 nm 
for hydrophilic chromatography. Lipophilic compounds numbering as denoted in 
Figure 1.   
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Fig. 4 (A) Whole-cell current responses evoked by E. angustifolica root ethanol extract 
(250 µg /ml) show that TRPV1-S512Y and TRPV1-Y511A, mutants lacking critical 
capsaicin binding sites, have significantly reduced capsaicin sensitivity compared to 
wild type, whereas there is no significant difference between the currents evoked by 
Echinacea extract on the mutant and wild type (mean ± s.e.m., n ≥ 3 independent 
oocytes for each value). Within each treatment (Echinacea or capsaicin), different 
letters indicate a significant difference (p < 0.05).  (B) Whole-cell current responses 
evoked by E. angustifolica root ethanol extract (250 µg /ml) show that TRPV1- 
S502A/S800A, TRPV1 mutant lacking critical PKC phosphorylation sites, has 
significantly reduced capsaicin sensitivity compared to wild type, whereas there is no 
significant difference between the currents evoked by Echinacea extract on TRPV1-AA 
mutant and wild type (mean ± s.e.m., n ≥ 3 independent oocytes for each value).  Within 
each treatment (Echinacea or capsaicin), different letters indicate a significant 
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difference (p < 0.05).  (C) Echinacea evoked response can not be blocked by the 
competitive TRPV1 receptor antagonist capsazepine. Traces at top show that currents 
evoked by E. angustifolia root ethanol extract (250 µg /ml) can not be abolished by 
capsazepine (5 µM); traces at bottom show block of a capsaicin (10 µM) -evoked 
response by capsazepine (5 µM). Traces represent one of 3 replicate experiments. 
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Fig.5 Desensitization of TRPV1 by capsaicin vs. by Echinacea extract.  (A)  Whole-cell 
current responses evoked by successive capsaicin (10 µM) applications show 
desensitization in calcium-containing standard bath solution, but minimum 
desensitization in minus-calcium solution. (B) Whole-cell current responses evoked by 
successive E. angustifolia root ethanol extract (250 µg /ml) applications show very rapid 
desensitization in calcium-containing standard bath solution, and much faster 
desensitization in minus-calcium solution compared with that of capsaicin. Capsaicin 
and Echinacea extract were applied every 2 min. Traces represent one of 3 replicate 
experiments. Bar graphs show the values of the evoked ion currents (mean ± s.e.m., n ≥ 
3 independent oocytes for each value).  For each application, different letters indicate a 
significant difference (p < 0.05). 
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SUPPORTING INFORMATION 
Table 1. Phytochemical compositions of Echinacea extracts determined by HPLC-PDA. 
The levels of phytochemicals were adjusted to μg/mg of dry extract. a Each value 
represents the average of three HPLC measurements, the variation between three 
HPLC runs is less than 3%. (ND: non-detectable). 
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Fig. 6 Structures of identified phytochemicals in Echinacea. (A) Lipophilic 
phytochemicals (compounds numbering as denoted by Bauer et al., 1988).  (B) 
Hydrophilic phytochemicals. 
 
 
 
Fig. 7 Whole cell currents evoked on TRPV1 by capsaicin (10 µM) and pure compounds 
(100 µM) from Echinacea. Traces represent one of 3 replicate experiments. 
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CHAPTER 7.  GENERAL CONCLUSIONS 
This dissertation describes the constituents of Echinacea genotypes (Chapters 2 and 3; 
Appendices A, B, D and E).   A high throughput metabolite profiling method with a 
combination of HPLC-PDA, GC–MS and HPLC-ESI-MS/MS has been developed.  During 
this process standard MS library spectra were established for future identifications of 
alkamides and ketones in Echinacea.  Semi-preparative HPLC fractionation methods for larger 
scale preparations of Echinacea fractions were established. Natural distribution of metabolites 
in forty accessions of Echinacea representing different species of defined geographical origins 
has been evaluated.   These results not only have critical biological significance in that they 
contribute knowledge to the current understanding of evolution and of taxonomy of Echinacea, 
but also provide the basis for the evaluation, standardization, and identification of plant 
material of unknown provenance for cultivated Echinacea and for commercial Echinacea 
products.   
This dissertation also provides the first examination of the Echinacea-activated 
calcium-signaling pathway.   Three models, frog oocytes, HEK293 cells and rat hippocampal 
cells, have been established.  Electrophysiological techniques and calcium imaging have been 
used to study the intracellular Ca2+ regulation by Echinacea (Chapters 4, 5, and 6).    
In the frog oocyte model, I demonstrated that Echinacea extracts activated TRPV1 
expressed in frog oocytes and evoked a TRPV1-dependent inward ion current.  However, this 
interaction appeared to be indirect, as indicated by the observations that TRPV1 antagonist 
capsazepine did not block this activation, and that TRPV1 mutants lacking critical capsaicin 
binding sites were still able to respond to Echinacea (Chapter 6). The complex actions of 
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Echinacea on TRPV1 remain to be further investigated using additional model systems.  Due 
to the limitation of the frog oocyte system, in that the oocytes are subjected to considerable 
variation associated with the source of the frogs, and the additional consideration that this is a 
non-mammalian model, we decided to focus on a mammalian model with better technical 
repeatability.  
I then established the HEK293 model as a reliable high throughput system for rapid 
evaluation of fractions and extracts.  Using this model, I evaluated the intracellular Ca2+ 
regulation by Echinacea extracts (Chapter 4).   Six active fractions were identified and 
metabolite analysis of these fractions pointed to the association of very lipophilic unknown 
constituents with the Echinacea bioactivity in HEK293.   Investigation of the mechanisms of 
this Ca2+ signaling indicated the involvement of PLC activation, IP3 receptor and SOCE.  
Interestingly, the constituents thought to be responsible for the major bioactivity of Echinacea 
(i.e., alkamides/ketones, caffeic acid derivatives) cannot explain the observed bioactivity.  So 
far the identity of the receptor(s) that bind(s) to Echinacea and activate(s) the observed calcium 
elevation in HEK293 remains unknown.  CB1 and TRPV1 are not involved as neither is 
present in HEK293 cells (Ross, 2003).  
Another more physiological model system we set up is hippocampal cells dissected 
from rat brain for endogenous TRPV1 and CB receptors studies.  The hippocampus is one of 
the most studied brain regions. It is critical to memory formation and also plays important role 
in spatial learning, navigation and much more.  Interestingly both TRPV1 and CB have been 
reported to express in hippocampus (Drysdale et al., 2006).  Astrocyte, neuron as well as 
hippocampal mixed cell cultures from rat have been tested with Echinacea (Chapter 5). 
Echinacea extracts induced intracellular calcium elevation in cultured astrocytes but had no or 
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little effect on neurons. Multiple active Echinacea fractions were identified.  This activation of 
astrocytes by Echinacea appeared to be mediated by CB1 receptor.  Interestingly, one of the 
active fraction in astrocytes, fraction 67, was inactive in the HEK293 model, indicating that 
different receptor(s) were involved in these two model systems. 
In addition, the effects of Echinacea extracts on cell viability will be studied on 
HEK293 cells and astrocytes, and the possibility that calcium studies might be associated with 
toxicity will be explored.  Cytotoxicity and cell viability studies will be conducted using 
Promega Cytotox-Glo kit assays of media and lysed cells with luminescence detection (Cho et 
al., 2008).  If a particular extract or fraction proves to be highly toxic at concentrations similar 
to those that elicit calcium responses, we will proceed to evaluate whether we can separate the 
toxicity from the bioactivity.  If we cannot, we will discontinue studies with that 
extract/fraction. 
Based on my findings (Chapters 4, 5 and 6) and the current literature, I propose that 
receptor-mediated calcium signaling may be a central link in different bioactivities of 
Echinacea, particularly anti-inflammatory and anti-pain activities.  Various receptors interact 
with bioactive metabolites in Echinacea and regulate intracellular calcium homeostasis, 
Intracellular calcium, in turn, controls crucial cellular processes involved in inflammation and 
pain transmission (Feske, 2007; Pardo, 2001).  CB1 and TRPV1 are two potential receptors 
that are involved but apparently they don’t act alone.  To evaluate the breadth of action of 
Echinacea extracts, I have generated a list of constructs for various pain receptors and 
established an efficient HEK293 transfection system (Appendix C).  These receptor genes will 
be expressed in HEK293 and tested for responses to Echinacea.  Future work will also test for 
selective antagonists of various receptors endogenous to HEK293 cells.  Microarray 
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experiments on both HEK293 cells and rat astrocytes treated with Echinacea extracts and 
active fractions will be carried out to understand the mechanism of action on gene 
transcriptional level and help to search for the potential target receptor(s) interacting with 
Echinacea.  Human and rat microarray databases are currently being constructed for our future 
microarray data analysis. 
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APPENDIX A.  COMPARISON OF METABOLIC PROFILES OF 
ECHINACEA PURPUREA FLOWERS DURING DEVELOPMENT  
INTRODUCTION 
Echinacea purpurea (L.) Moench is one of the most frequently utilized Echinacea 
species for medicinal purpose (Barnes et al., 2005).  Preparations are either from the roots or 
flowers, or both.  There are many problems with these commercial products in that very little 
or no quality control has been exerted on the plant source materials used in these preparations 
and the quantities or types of bioactive compounds contained are not standardized.  Plant 
phytochemicals have been reported to be greatly affected by the plant development (i.e., the 
type of organ and morphogenetic stage of that organ) (Honee et al, 1998).  Gene expression 
and phytochemical accumulation are also anticipated to be very different in different regions of 
the same organ, as has been found for other plant species (Wang et al., 1995; Held et al., 1997).  
Existing studies, though very few, do indicate that there is wide fluctuation in the accumulation 
of secondary phytochemicals in association with developmental cues in Echinacea (Schulthess 
et al., 1991).  However, the changes in metabolite contents of E. purpurea flowers during 
development have not been reported.   In this study, different stages of flowers, from buds, 
young flowers, mature flowers and old flowers, were sampled and the developmental 
distribution of alkamides and phenolics were determined. The information resulting from this 
study will provide important information for botanical and chemical standardization of the 
Echinacea preparations so that reproducible pharmacological and therapeutic results could be 
obtained.  
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MATERIALS AND METHODS 
Plant materials  
Plants from one accession (PI 631307) of E. purpurea was used.   Growth conditions 
and sample harvesting procedure were the same as in previous work (Chaper 2, Chapter 3).  
Flowers were classified into five stages (Fig. 1). Specifically, Stage 1 (early bud): the bracts 
developed, the disc florets just started to appear, but no appearance of ray florets (petals); Stage 
2 (bud): the disc florets made full appearance but were not open, the ray florets started to 
appear without expansion; Stage 3 (young flowers): the first two to three lines of the disc 
florets opened while the ray florets just started to expand and showed their typical purple color; 
Stage 4 (mature flowers): most of the disc florets opened, the ray florets fully expanded and 
pollen grains formed;  and Stage 5 (old flowers): the ray florets started to turn into to brown 
color, with seed development and decline in pollen grain production.  
Metabolic profiling 
Metabolic profiling was carried out using HPLC-PDA analysis as in previous published 
work (Chapter 2; Appendix F). 
RESULTS AND DISCUSSION 
Major metabolites of E. purpurea flowers were quantitatively but not qualitatively 
altered during development (Fig. 2 & Fig. 3).  In all stages of E. purpurea flowers, alkamides 8 
and 9 were the predominant lipophilic compounds (0.028-0.112mg/g fresh weight and 0.067-
0.233mg/g fresh weight, respectively), while cichoric acid was the predominant hydrophilic 
compound (1.341-4.032mg/g fresh weight).  The levels of alkamides 8 and 9 were significantly 
higher in stage 4 and 5 than the other three earlier stages;  alkamide 1 and unknown alkamide 
at RT 14.4 also demonstrated significant differences between stages with the peaks at stage 1 
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and stage 4 respectively; alkamide 11 changed only very slightly.  The levels of phenolic 
compounds showed different trends of changes from that of alkamides: cichoric acid, 
chlorogenic acid, and unknown phenolics at RT 21.4 and 24.5 min all had highest levels at 
stage 2 and declined somehow as flowers developed to older stages; among the five selected 
phenolic compounds, cichoric showed biggest changes in content while caftaric acid changed 
very little during flower development.   
In conclusion, we have found that metabolic profile in Echinacea flowers is strongly 
influenced by development, therefore it is important that floral developmental stages be 
considered during standardization of Echinacea preparations.   Our data also indicate that 
specific branches of the biosynthesis of alkamides and phenolics are independently regulated 
during organ formation.  
REFERENCES 
Barnes J, Anderson LA, Gibbons S, Phillipson JD.  Echinacea species (Echinacea angustifolia 
(DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a 
review of their chemistry, pharmacology and clinical properties.  J Pharm 
Pharmacol. 2005. 57(8): 929-54. 
Held BM, John I, Wang HQ, Wurtele ES, Colbert JT. zrp2: a novel maize gene whose mRNA 
accumulates in the root cortex and mature stems. Plant Mol Biol. 1997. 94: 957-
67. 
Honee G, Buitink J, Jabs T, De Kloe J, Sijbolts F, Apotheker M, Weide R, Sijen T, Stuiver M, 
De Wit PJ. Induction of defense-related responses in Cf9 tomato cells by the 
AVR9 elicitor peptide of Cladosprorium fulvum is developmentally regulated. 
Plant Physiol. 1998. 117: 809-20. 
  
143
Schulthess BH, Giger E, Baumann TW. Echinacea: anatomy, phytochemical pattern, and 
germination of the achene. Planta Med. 1991. 57(4): 384-8. 
Wang HQ, Colbert JT, Wurtele ES. A molecular marker of the root cortical ground meristem is 
present in both root and coleorhiza of the maize embryo. Amer J Bot. 1995. 82: 
1083-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
144
 
 
Fig. 1 Flowers of Echinacea purpurea (accession PI 631307) at five different stages.
  
145
 
 
 
 
Fig. 2 HPLC chromatograms representing metabolic profiles of E.purpurea flowers.  A: 
lipophilc profiles; B: hydrophilic profiles. 
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Fig. 3 Variations in content of selected alkamides (A) and phenolic compounds (B) of E 
.purpurea flowers at five different developmental stages.  
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APPENDIX B.  MASS SPECTRA FOR IDENTIFIED ALKAMIDES AND 
KETONES IN ECHINACEA 
SUMMARY 
The mass spectra for all of the alkamides and ketones identified from this work are 
attached in this appendix.  This information has been compiled into an Echinacea mass spectra 
library and are currently used by the Core C group in NIH Dietary Botanical Supplement 
Center at Iowa State University for phytochemical analysis of Echinacea extracts. 
Among the seventeen alkamides and ketones listed below, alkamides 8, 10, 11, 12, 13, 
14 and ketone 22 were synthesized in our group, alkamides 1, 2, 3, 4, 5, 7, 15, 16, 17 and 
ketone 24 were identified by HPLC fractionation coupled with GC-MS analysis.  Eluted 
fractions from HPLC were collected and subsequently subjected to GC-MS analysis; six 
replicate runs were carried out to increase the compound amount in each fraction. Compounds 
contained in each fraction were identified by comparing their recorded mass spectra and online 
UV spectra with those from published literature (Bauer et al., 1988, 1989; Bauer & Remiger, 
1989).  HPLC and GC-MS analysis analyses were performed as in our previous published 
work (Chapter 2; Appendix F). 
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APPENDIX C. ESTABLISHMENT OF EFFICIENT HEK293 
TRANSFECTION SYSTEM AND MOLECULAR CONSTRUCTS OF 
RECEPTOR GENES FOR TRANSFECTION 
SUMMARY 
To evaluate the breadth of action of Echinacea extracts, an efficient HEK293 
transfection system has been set up for probing responses to fractions and subfractions of 
extracts in a high throughput manner.   Transfection protocol optimization in HEK293 was 
carried out by testing three different transfection reagents: Effectene (QIAGEN, CA, USA), 
Lipofectamine and Lipofectamine 2000 (Invitrogen, CA, USA).  The starting cell density and 
DNA: transfection reagent ratios, two most important factors impacting transfection efficiency 
were optimized.  The transfection efficiency was evaluated by Immunocytochemistry (ICC).  
Best transfection efficiency (≥ 85%) was achieved by using Lipofectamine 2000 (Fig. 1).  The 
optimized protocols for HEK293 plasmid DNA transfection and ICC were described below.  
Molecular constructs for various receptor genes, including TRPV1, CB1, CB2, TRPV2, 
TRPA1, TRPM8 and ASIC1 (Fig. 2) have been completed.  These constructs will be used in 
transient transfection-assays of HEK cells.  HEK cells transiently transfected with these 
constructs or control vectors will be used to test the ability of Echinacea to stimulate these 
receptors. The results of these studies will dictate the generation of stable transgenic HEK lines 
using the same established transfection protocol. 
Plasmid DNA Transfection with HEK293  
24 hr before transfection, about 75,000 cells were plated on 18 mm circular coverslips 
in a 12-well plate, with 1 ml of DMEM medium without antibiotics (Invitrogen).  For each 
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transfection samples, plasmid DNA and Lipofectamine 2000 were diluted separately in 100 µl 
of Opti-MEM I Reduced Serum Medium (Invitrogen), with  DNA: Lipofectamine 2000  ratios 
= 1: 5 (µg: µl).   The diluted DNA and Lipofectamine 2000 were incubated for 5 min at room 
temperature and then mixed gently and incubated for 20 min at room temperature. The 200 µl 
resulting complexes were added into each well containing cells and medium and were mixed 
gently. Cells were incubated at 37°C in CO2 inculator for 24 hr prior to ICC testing for 
transgene expression.  Medium must be replaced with complete DMEM medium with 
antibiotics 5 hr after transfection.  For stable cell line selection, cells were passed at 1:10 into 
fresh growth medium 24 hr after transfection and selective buffer G418 was added the 
following day and medium was changed daily. This selection process took about 3 weeks and 
selected stable lines were confirmed by ICC for expression of target gene. 
Immunocytochemistry 
HEK293 cells were fixed with 4% formaldehyde in phosphate-buffered saline (PBS) at 
room temperature for 30 min. Cells were permeabilized with 0.2% Triton X-100 on ice for 5 
min and treated with 50 mM NH4Cl in PBS for 15 min for two times at room temperature. 
Nonspecific binding was blocked using 1% fat-free milk in PBS for 15 min for 3 times, 
followed by primary antibody for 1 hr and secondary antibody for 1 hr at room temperature. 
Coverslips were mounted with VECTASHIELD, and images were captured with a using a 
Zeiss Axioplan II compound microscope equipped with a Zeiss AxioCamHRc digital camera 
(Carl Zeiss, Inc., Thornwood, NY, USA),  and the appropriate filter sets for fluorescein 
isothiocyanate (FITC) and Tetramethyl Rhodamine Isothiocyanate (TRITC) imaging. 
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Fig. 1   Immunocytochemistry images of HEK293 cells transfected with TRPV1.   At 24 
h after transfection, cells were fixed and stained with goat polyclonal TRPV1 lgG  and  
donkey anti-goat lgG-FITC (Santa Cruz Biotechnology, CA, USA), and  phalloidin-
TRITC (Invitrogen, CA, USA).   Red: phalloidin, binds to actin (control);  Green: 
TRPV1 antibody, binds to TRPV1. 
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Fig. 2  Molecular constructs for TRPV1 (transient receptor potential cation channel, 
subfamily V, member 1), TRPV1-GFP, TRPV2 (transient receptor potential cation 
channel, subfamily V, member 2), TRPA1 (transient receptor potential cation channel, 
subfamily A, member 1), TRPM8 (transient receptor potential cation channel, 
subfamily M, member 8), CB1 (cannabinoid  receptor subtype 1), CB2 (cannabinoid  
receptor subtype 2),  and ASIC1( acid sensing ion channel 1) receptors.  GFP (green 
fluorescent protein). All constructs are in the pCDNA3.1 vector (Invitrogen, CA, USA).   
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APPENDIX D. SYNTHESIS AND NATURAL DISTRIBUTION OF ANTI-
INFLAMMATORY ALKAMIDES FROM ECHINACEA 
Modified from a paper published in Molecules 
George A. Kraus, Jaehoon Bae, Lankun Wu, and Eve Syrkin Wurtele 
ABSTRACT 
The synthesis of the alkamides 2Z,4E-undeca-2,4-dien-8,10-diynoic acid isobutyl 
amide (1) and 2Z,4E-undeca-2,4-dien-8,10-diynoic acid isobutyl amide (5) was accomplished 
by organometallic coupling followed by introduction of the doubly unsaturated amide moiety. 
The distribution of these two amides in accessions of the nine species of Echinacea was 
determined. 
Keywords: Echinacea, alkamides, synthesis 
 
INTRODUCTION 
Echinacea angustifolia, Echinacea pallida and Echinacea purpurea are the main 
medicinal Echinacea species and have long been used to treat infections, to aid in wound 
healing and to enhance the immune system [1]. In 2005, Echinacea products ranked among the 
top botanical supplements sold in the United States. In recent years, treatment of rhinoviruses 
has been the focus of several studies, a number of which have failed to show the efficacy of 
Echinacea [2]. Commercial Echinacea products often are mixtures of the three main medicinal 
species and there is no regulation of the concentrations of the chemical constituents. Among 
the chemical constituents of Echinacea species, the alkamides, caffeic acid derivatives such as 
chicoric acid and the polyphenols are considered important for biological activity [3]. 
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Alkamide levels differ significantly among roots, stems, and flowers of E. purpurea. 
The roots had higher levels of the dodeca-2,4-diene-8,10-diyne alkamides, whereas levels of 
the dodecatetraene alkamides and nonadeca-2,4-diene-8,10-diynes were highest in stems [4]. 
Accessions from different geographical regions often show different chemical fingerprints. 
Additionally, preliminary studies on the stability of alkamide compounds in E. angustifolia 
revealed a 13% loss of alkamide levels over two months [5]. The effects of storage time and 
temperature on alkamide levels in E. purpurea roots showed that levels of all alkamides fell by 
over 80% during storage at 24° C for 64 weeks [6]. The ready availability of authentic 
standards of select alkamides would not only facilitate standardization for the purposes of 
medical studies, but would also permit biological evaluation of individual components. 
The recent discovery that dodecadiendiynoic amide 1 from E. purpurea and E. pallida 
inhibited LPS-mediated activation of a murine macrophage line, RAW264.7, suggests that this 
alkamide may have anti-inflammatory activity [7]. 
 
Using male rats, an in vivo study examined the immunomodulatory effects of alkamides 
purified from Echinacea purpurea. These results suggest that the alkamides are among the 
active constituents of E. purpurea plants. At a dose level of approximately 12 μg/kg body 
weight/day they effectively stimulated alveolar macrophage function in healthy rats [8]. 
Alkamides isolated from Echinacea angustifolia had inhibitory activity in in vitro 
cyclooxygenase (sheep microsomes) and 5-lipoxygenase (porcine leukocytes) assays [9]. 
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Hexane extracts of Echinacea variably inhibit growth of yeast strains of Saccharomyces 
cerevisiae, Candida shehata, C. albicans, and C. tropicalis under near UV irradiation and to a 
lesser extent without irradiation [10]. Synergistic antioxidant effects were found when cichoric 
acid was combined with a natural mixture of alkamides [11]. 
RESULTS AND DISCUSSION 
Synthesis of alkamides 
Despite the potential importance of the alkamides, few reports of synthesis of authentic 
standards have been reported. Crombie and co-workers have reported elegant syntheses of 
natural amides using organometallic coupling reactions [12]. Bohlmann synthesized 1 and 5 in 
low overall yields, in part because the Wittig reactions that installed the cis-amide moiety 
produced the cis-isomers in only 13–14% yields [13]. Kraus and Bae have reported syntheses 
of amides 2 and 3 and ketone 4 [14, 15]. We report herein the preparation of diacetylenic 
amides 1 and 5. The improved overall yields in our syntheses are the result of recent advances 
in synthetic methodology and the ready availability of larger quantities of these bioactive 
amides should accelerate the study of the scope of activity of these novel compounds. 
 
The general procedure for synthesis of amides 1 and 5 is shown in Scheme 1 below. 
Copper chloride-mediated coupling of 6 [16] followed by oxidation and a Wittig reaction 
provide 7a or 7b. Reduction of the ester to an aldehyde with DIBAL followed by Swern 
oxidation and a cis-selective Wittig reaction [17] generated 1 in 38 % overall yield from 7b. 
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Removal of the silyl group with tetra-n-butylammonium fluoride afforded 5 in 45 % overall 
yield from 7a. 
 
Scheme 1 
Characterization and distribution of the diacetylenic isobutylamides in Echinacea 
The distribution of these two amides in accessions of the nine species of Echinacea (E. 
angustifolia, E. purpurea, E. pallida, E. sanguinea, E. simulata, E. tennesseensis, E. 
atrorubens, E. laevigata and E. paradoxa) was determined by HPLC. Amides 1 and 5 elute at 
19.55 min and 23.28 min respectively (Fig. 1). These two amides display very similar UV 
spectra, all with an absorption maximum at 260 nm, which agrees with that reported [3]. 
The mean levels of amides 1 and 5 in roots, flowers and leaves from 6-month-old plants 
from nine Echinacea species are presented in Fig. 2. These two amides are distributed widely 
in Echinacea. Our results show that of the nine Echinacea species examined, amide 1 is 
present in at least six species (E. purpurea, E. pallida, E. sanguinea, E. simulate, E. laevigata 
and E. paradoxa), while amide 5 is present in at least eight species (E. angustifolia, E. 
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purpurea, E. pallida, E. sanguinea, E. simulata, E. tennesseensis, E. laevigata and E. 
paradoxa). The highest concentrations of both amide 1 (0.818 ± 0.06 mg g−1 fr. wt) and amide 
5 (0.826 ± 0.1mg g−1 fr. wt) were found in E. purpurea roots, which have significantly higher 
amount of these two amides compared with all other species that contain these compounds. 
The species that is deficient in both amide 1 and amide 5 is E. atrorubens. Although not 
typically used for commercial medicinal preparations, some Echinacea species (e.g. E. 
paradoxa, E. laevigata and E. simulata) have fairly high contents of these amides. 
We also found that the abundance of these two amides varied considerably with organ 
type. Generally speaking, they are present mainly in roots, displaying reduced abundance or 
even being not detectable in flowers and they are not detectable (the limit of HPLC detection 
for both amides is approximately 0.02 μg mL−1) in leaves. Interestingly, there is one exception, 
the E. paradoxa species, whose leaves have the highest quantity of amide 5 (0.303 ± 0.052 mg 
g−1 fr. wt), whereas flowers have less (0.147 ± 0.052 mg g−1 fr. wt ) and roots have the least 
(0.145 ± 0.019 mg g−1 fr. wt). This indicates that the biosyntheses of these amides may be 
regulated differently in different organs and species. 
CONCLUSIONS 
We have presented an improved synthesis of diacetylenic amides 1 and 5 which should 
pove useful for the preparation of appropriate standards. Investigation of their distribution in 
different Echinacea species revealed that both genetic source and organ type of the plant 
materials used in Echinacea preparations need to be considered for product standardization. 
The information reported in this work will be very useful for the standardization of Echinacea 
products. 
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EXPERIMENTAL 
General 
Unless stated otherwise, all reactions were magnetically stirred and monitored by thin-
layer chromatography (TLC) using 0.25 mm precoated silica gel F254 plates (Sigma-Aldrich). 
Column or flash chromatography were performed with the indicated solvents using silica gel 
(230–400 mesh) purchased from Dynamic Adsorbents, LLC. All melting points were obtained 
on a Laboratory Devices capillary melting point apparatus and are uncorrected. 1H- and 13C-
NMR spectra were recorded on a Bruker VXR-300 (300 MHz) or a Bruker VXR-400 (400 
MHz) spectrometer. Chemical shifts are reported relative to internal chloroform (1H, 7.26 ppm; 
13C, 77.23 ppm). High resolution mass spectra were performed at the Iowa State University 
Mass Spectrometry Laboratory. 
Plant material and extraction 
Nine species of Echinacea, E. angustifolia (Accession 631267), E. purpurea 
(Accession 631307), E. pallida (Accession 631293), E. sanguinea (Accession A23878), E. 
simulata (Accession 631249), E. tennesseensis (Accession 631325), E. atrorubens (Accession 
631262), E. laevigata (Accession 631312) and E. paradoxa (Accession 631301), provided by 
Dr. Mark P. Widrlechner at the USDA-ARS North Central Regional Plant Introduction Station, 
were studied to evaluate the natural distribution of amides 1 and 5 in Echinacea species. Six-
month-old roots, flowers and leaves from each species/accessions were used. Specific plant 
growth conditions, plant material harvest and extraction method are the same as those in our 
previously published work [15]. 7-Hydroxy-(E)-N-isobutylundeca-2-ene-8,10-diynamide 
(C15H21O2) was added as an internal standard prior to extraction for quantification purposes. 
  
168
All experiments were performed in triplicate on independently extracted plant samples from 
three individual plants. 
HPLC analysis 
Ethanol extract (15 μL) was injected into a YMC-Pack ODS-AM RP C18 (250 × 4.6 
mm, 5 μm) column (Waters, MA) on a Beckman Coulter HPLC equipped with a 508 
autosampler, 126 pump control and 168 UV-photodiode array detector (PDA) controlled by 
32karat ™ software (Version 5.0). The solvent system used was CH3CN/H2O at a flow rate of 
1.0 mL/min following a linear gradient of 40→80% CH3CN in H2O over 45 min. Online UV 
spectra were collected between 200–400 nm. Compound quantification was carried out by 
calculating the UV response relative to the internal standard 7-hydroxy-(E)-N-isobutylundeca-
2-ene-8,10-diynamide (C15H21O2), which has been found suitable for use as an internal 
standard for these two amides because it was not found in Echinacea plants and does not 
overlap with any other metabolites found in Echinacea. Amides 1 and 5 were quantified at UV 
260 nm with respect to the internal standard, using relative response factors to correct for 
absorbance differences between these two amides and the standard. These relative response 
factors for amides 1 and 5 were calculated at UV 260 nm. Various amount of authentic amide 1 
or amide 5 (0.625 – 3.125 μg) with internal standard (2.5 μg) were injected to give average 
relative response factors of 0.0677 (R2 = 0.99) for amide 1, and 0.0669 (R2 = 0.99) for amide 5, 
respectively. The internal quantification method used here can account for variations in 
extraction efficiencies in different extracts. The HPLC detection limit for both of the amides 
was approximately 0.02 μg mL−1. 
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Statistical analysis 
Statistical analyses were performed using SAS software version 8.02 (SAS Institute 
Inc., Cary, NC). One-way analysis of variance followed by the Tukey test was used to compare 
means. Significance of difference was defined at p < 0.05. 
Ethyl 9-trimethylsilylnona-2-ene-6,8-diynoate (7a) 
To a solution of trimethylsilylacetylene (0.5 mL, 3.51 mmol) and 5-iodo-4-pentynol 6 
(0.281 g, 1.34 mmol) in degassed piperidine (2 mL) was added CuCl (0.014 g, 0.14 mmol) at 
0 °C. The mixture was stirred at rt for 0.5 h and then quenched with sat. NH4Cl (aq) (6 mL) 
and extracted with Et2O (3 × 10 mL). The combined organic layers were washed with brine (2 
× 20 mL), dried (MgSO4), filtered and concentrated. The crude residue was purified via flash 
chromatography to give the alcohol (0.188 g, 78 % yield). 
Dimethylsulfoxide (0.766 mL, 10.8 mmol) was added dropwise at −78 °C to a solution 
of oxalyl chloride (0.471 mL, 5.4 mmol) in CH2Cl2 (10 mL). The mixture was stirred at same 
temp. for 20 min and triethylamine (2.25 mL, 16.2 mmol) was added dropwise and stirred at 
same temp. for 20 min. To the mixture was added the alcohol synthesized above (0.487 mg, 2.7 
mmol) at −78 °C and stirred for 80 min while slowly warmed to room temperature. The 
reaction was quenched with sat NH4Cl (aq) and the aqueous layer was extracted with CH2Cl2 
(2 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The crude residue was purified via flash column 
chromatography to give the aldehyde (0.409 g, 85 % yield). 
To a solution of carbethoxymethyl(triphenyl)phosphonium bromide (3.94 g, 9.19 mmol) 
in THF (30 mL) was added n-BuLi (3.67 mL, 2.5 M soln in hexane) at 0 °C under Ar. The 
mixture was stirred for 20 min at 0 °C and added the above aldehyde (0.409 g, 2.29 mmol) at 
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the same temperature. After 1 h of stirring at room temperature, reaction was quenched with sat. 
NH4Cl (aq) and extracted with Et2O (3 × 30 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude residue was purified via flash column chromatography to give compound 7a 
(0.465 g, 82% yield). 1H-NMR (300 MHz, CDCl3) δ 6.94-6.89(m, 1H), 5.86 (d, J= 15.2 Hz, 
1H), 4.17 (q, J= 7.2 Hz, 2H), 2.43 (m, 4H), 1.28 (t, J= 7.2 Hz, 3H), 0.18 (s, 9H). 
2Z,4E-undeca-2,4-dien-8,10-diynoic acid isobutyl amide (5) 
To a solution of compound 7a (0.341 g, 1.37 mmol) in 10 mL of THF was added 
DIBAL (4.12 mL, 1 M soln) at −78 °C in Ar. After stirring for 2 h at −78 °C, the reaction was 
quenched with EtOAc (30 mL) at −78 °C and the reaction wixture was warmed to rt, washed 
with 10% HCl(aq), brine, dried (MgSO4), filtered and concentrated in vacuo. The crude residue 
was purified via flash chromatography to give allyl alcohol (0.260 g, 92 % yield) 
Dimethylsulfoxide (0.178 mL, 2.46 mmol) was added dropwise at −78 °C to a solution 
of oxalyl chloride (0.110 mL, 1.23 mmol) in CH2Cl2 (5 mL). The mixture was stirred at the 
same temperature for 20 min and triethylamine (0.526 mL, 3.69 mmol) was added dropwise 
and stirred at same temperature for 20 min. To the mixture was added the above alcohol (0.127 
mg, 0.616 mmol) at −78 °C and stirred for 80 min while slowly warming to rt. The reaction 
was quenched with sat NH4Cl (aq) and aqueous layer was extracted with CH2Cl2 (2 × 10 mL). 
The combined organic layers were washed with water (2 × 10 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified via flash column chromatography to 
give aldehyde (0.106 g, 81% yield.) 
To a solution of diphenylphosphonoacetamide (0.187 g, 0.539 mmol) in 10 mL of THF 
was added NaHMDS (0.735 mL, 1M soln in THF) at −78 °C and stirred at same temperature 
for 20 min. To the mixture was added above aldehyde (0.1 g, 0.49 mmol) in THF (2 mL) by 
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cannula and the resulting mixture was warmed to 10 °C over 2 h. The reaction was quenched 
with NH4Cl (aq), washed with water, brine, dried (MgSO4), filtered and concentrated in vacuo. 
The crude residue was purified via flash column chromatography to give (2Z, 4E) amide (0.090 
g, 62 % yield). 1H-NMR (300 MHz, CDCl3) δ 7.49 (dd, J= 15.3, 11.4 Hz, 1H), 6.37 (t, J= 11.4 
Hz, 1H), 6.05-5.90 (m, 1H), 5.58 (brs, 1H), 5.52 (d, J= 12.9 Hz, 1H), 3.12 (t, J= 6.9 Hz, 2H), 
2.39-2.38 (m, 4H), 1.84-1.75 (m, 1H), 0.92 (d, J= 6.9 Hz, 6H), 0.18 (s, 9H); 13C-NMR (75 
MHz, CDCl3) δ 166.5, 140.9, 140.0, 128.5, 119.9, 88.5, 82.3, 79.1, 66.2, 46.9, 31.6, 28.8, 20.4, 
19.4, −0.13; HRMS m/e (EI) for C18H27NOSi (M)+ calcd 301.1862, measured 301.1843 
To a solution of the above (2Z, 4E) amide (0.032 g, 0.106 mmol) in THF (2 mL) was 
added TBAF (0.159 mL, 1.159 mmol) at 0 °C. The mixture was stirred for 1h at rt and the 
solvent was removed. The crude residue was purified via flash column chromatography to give 
compound 5 (0.024 g, 99 % yield) 1H-NMR (300 MHz, CDCl3) δ 7.51 (dd, J= 14.7, 11.4 Hz, 
1H), 6.37(t, J= 11.4 Hz, 1H), 6.02-5.89 (m, 1H), 5.63 (brs, 1H), 5.53 (d, J= 11.4 Hz, 1H), 3.12 
(t, J= 6.6 Hz, 2H), 2.49-2.31 (m, 4H), 1.97 (s, 1H), 1.84-1.74 (m, 1H), 0.91 (d, J= 6.6 Hz, 
6H);13C-NMR (75 MHz, CDCl3) δ 166.5, 140.9, 139.8, 128.5, 119.9, 82.3, 77.5, 65.2, 65.1, 
46.9, 31.4, 28.8, 20.4, 19.1; HRMS m/e (EI) for C15H19NO (M)+ calcd 229.1467, measured 
229.1579. 
Ethyl deca-2-ene-6,8-diynoate (7b) 
Degassed piperidine (5.5 mL), 5-iodo-4-pentynol (1.74 g, 8.49 mmol) and CuCl (0.086 
g, 0.85 mmol) were mixed in a sealed tube. The mixture was cooled to −78 °C and excess 
propyne gas (condensed to liquid, 2 mL) was added by blowing along the wall of the tube. The 
mixture was slowly warmed to room temperature. After stirring for 2 h at rt, the mixture was 
cooled to −78 °C and the sealed tube was opened then slowly warmed to rt to evaporate excess 
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propyne. NH4Cl (aq) (20 mL) was added to the mixture then extracted with Et2O (3 × 20 mL). 
The organic layer was washed with water, brine, dried (MgSO4), filtered and concentrated in 
vacuo. The crude residue was purified via flash column chromatography to give alcohol (0.847 
g, 82 % yield) 
Dimethylsulfoxide (1.63 mL, 22.9 mmol) was added dropwise at −78 °C to a solution 
of oxalyl chloride (1 mL, 11.5 mmol) in 60 mL of CH2Cl2. The mixture was stirred at the same 
temperature for 20 min and triethylamine (4.78mL, 34.4mmol) was added dropwise and stirred 
at same temperature for 20 min. To the mixture was added above alcohol (0.70 g, 5.73 mmol) 
at −78 °C and stirred for 80 min while slowly warmed to rt. The reaction was quenched with 
sat NH4Cl (aq) (10 mL) and aqueous layer was extracted with CH2Cl2 (2 × 30 mL). The 
combined organic layers were washed with water (2 × 20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified via flash column chromatography to 
give aldehyde (0.55 g, 80 % yield). 1H-NMR (300 MHz, CDCl3) δ 9.76 (s, 1H), 2.68 (t, J= 6.6 
Hz, 2H), 2.54 (t, J=6.6 Hz, 2H), 1.89 (s, 3H); 13C-NMR (75 MHz, CDCl3) δ 199.9, 74.4, 74.2, 
66.5, 64.4, 42.4, 12.6, 4.3. 
To a solution of carbethoxymethyl(triphenyl)phosphonium bromide (5.26 g, 12.37 
mmol) in THF (40 mL) was added n-BuLi (4.95 mL, 2.5 M soln in hexane) at 0 °C under Ar. 
The mixture was stirred for 20 min at 0 °C and the aldehyde (0.59 g, 4.95 mmol) was added at 
same temperature. After 1 h of stirring at rt, the reaction was quenched with sat NH4Cl (aq) and 
extracted with ethyl ether (3 × 30 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
crude residue was purified via flash column chromatography to give compound 7b (0.73 g, 
78 % yield). 1H-NMR (300 MHz, CDCl3) δ 7.01-6.85 (m, 1H), 5.86 (d, J= 15.6Hz, 1H), 4.18 
(q, J= 7.2 Hz, 2H), 2.43-2.40 (m, 4H), 1.90 (s, 3H), 1.26 (t, J= 7.2 Hz, 3H). 
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2Z, 4E-undeca-2,4-dien-8,10-diynoic acid isobutyl amide (1) 
To a solution of compound 7b (0.437 g, 2.3 mmol) in 20 mL of THF was added 
DIBAL (4.6 mL,1.0M soln in THF) at −78 °C in Ar. After stirring for 2 h at −78°C, the 
reaction was quenched with ethyl acetate (30 mL) at −78 °C and warmed to rt. The mixture 
was washed with 10% HCl (aq) (10 mL), brine, dried (MgSO4), filtered and concentrated in 
vacuo. The crude residue was purified via flash column chromatography to give the allylic 
alcohol (0.28 g, 81 % yield). 
Dimethylsulfoxide (0.530 mL, 7.48 mmol) was added dropwise at −78 °C to a solution 
of oxalyl chloride (0.326 mL, 3.74 mmol) in 20 mL of CH2Cl2. The mixture was stirred at the 
same temp for 20 min and triethylamine (1.56 mL, 11.2 mmol) was added dropwise and stirred 
at same temperature for 20 min. The above alcohol (0.277 g, 1.87 mmol) was added to the 
mixture at −78 °C and stirred for 80 min while slowly warming to rt. The reaction was 
quenched with sat NH4Cl (aq) and aqueous layer was extracted with CH2Cl2 (2 × 10 mL). 
Combined organic layer was washed with water (2 × 10 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified via flash column chromatography to 
give aldehyde (0.229 g, 84 % yield). 1H-NMR (300 MHz, CDCl3) δ 9.49 (d, J= 7.8 Hz, 1H), 
6.83 (dt, J= 15.6, 6.0 Hz, 1H), 6.14 (dd, J= 15.6, 7.8 Hz, 1H), 2.58-2.40 (m, 4H), 1.86 (s, 3H); 
13C-NMR (75 MHz, CDCl3) δ 193.9, 155.4, 134.0, 74.3, 74.3, 67.0, 60.6, 31.4, 18.2, 4.3. 
To a solution of diphenylphosphonoacetamide (0.370 g, 1.06 mmol) in THF (10 mL) 
was added NaHMDS (1.06 mL, 1 M soln in THF) at −78 °C and stirred at same temp for 20 
min. To the mixture was added the above aldehyde (0.140 g, 0.97 mmol) in THF (2 mL) via 
cannula and the resulting mixture was warmed to 10 °C over 2h. The reaction was quenched 
with NH4Cl (aq), washed with water, brine, dried (MgSO4), filtered and concentrated in vacuo. 
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The crude residue was purified via flash column chromatography to give amide 1 (0.131g, 56% 
yield). 1H-NMR (300 MHz, CDCl3) δ 7.47 (dd, J= 15.3, 11.4 Hz, 1H), 6.34 (t, J= 11.4 Hz, 1H), 
5.99-5.87 (m, 1H), 5.78 (brs, 1H), 5.52 (d, J= 11.4 Hz, 1H), 3.09 (t, J= 6.6 Hz, 2H), 2.37-2.32 
(m, 4H), 1.87 (s, 3H), 1.82-1.73 (m, 1H), 0.89 (d, J= 6.6 Hz, 6H); 13C-NMR (75 MHz, CDCl3) 
δ 166.7,140.9, 140.3, 128.4, 119.9, 75,8, 73,7, 66.2, 64.7, 46.9, 31.8, 28.8, 20.4, 19.3, 4.4. 
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Fig. 1 Representative HPLC chromatogram obtained from a 95% ethanolic extract of 
6-month-old E. purpurea roots, indicating amides 1 and 5. 
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Fig. 2 Concentration of amides 1 and 5 in roots (A), flowers (B), and leaves (C) from 6-
month-old plants of nine species of Echinacea. Error bars indicate standard deviations 
of means of triplicate experiments. For each amide, different letters (a – g) indicate a 
significant difference (p < 0.05). 
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APPENDIX E. THE SYNTHESIS AND NATURAL DISTRIBUTION OF 
THE MAJOR KETONE CONSTITUENTS IN ECHINACEA PALLIDA 
Modified from a paper published in Molecules 
George A. Kraus, Jaehoon Bae, Lankun Wu, and Eve Syrkin Wurtele 
ABSTRACT 
The first synthesis of a series of ketones naturally occurring in E. pallida is described. 
The natural distribution of these ketones among different Echinacea species is also reported. 
Keywords: Echinacea, synthesis, diaetylenic ketones 
INTRODUCTION 
Echinacea angustifolia, Echinacea pallida and Echinacea purpurea are the main 
medicinal Echinacea species and have long been used to treat infections, aid in wound healing, 
and enhance the immune system [1]. In 2005, Echinacea products ranked among the top 
botanical supplements sold in the United States. In recent years, treatment of rhinoviruses has 
been the focus of several studies, a number of which have failed to show the efficacy of 
Echinacea [2]. Commercial Echinacea products often are mixtures of the three main medicinal 
species and there is no regulation of the concentrations of the chemical constituents. Among 
the chemical constituents of Echinacea species, the alkamides, the ketones, caffeic acid 
derivatives such as chicoric acid and the polyphenols are considered important for biological 
activity [3]. 
The ketones from E. pallida exhibit a range of biological activities. An amphotericin-B-
resistant strain (D10) of C. albicans and Tricophyton mentagrophytes were susceptible to E. 
pallida var pallida root extract in the presence of UV light [4]. Bauer reported the use of a 
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mixture of ketones and alkamides was useful as an immunostimulant [5]. Binns has reported 
that the ketones from E. pallida are potent antifungal agents [6]. Related polyacetylenic 
ketones have been reported by Bohlmann in Centaurea ferox roots [7]. 
Despite the potential importance of the ketones from E. pallida, few reports of 
synthesis of authentic standards or analogs have been reported. Recently, Shi Shun and 
Tykwinski have reviewed natural polyacetylenes [8]. Crombie and co-workers have reported 
elegant syntheses of natural amides using organometallic coupling reactions [9–11]. Wailes has 
also reported the synthesis of natural dienamides [12]. Kraus and Bae recently reported the first 
synthesis of ketone 1 [13]. We report herein the direct preparation of ketones 2, 3 and 4, shown 
in Scheme 1. 
 
Scheme 1 
RESULTS AND DISCUSSION 
Syntheses 
The synthesis route to ketones 3 and 4, found in E. pallida, is illustrated in Scheme 2. 
The known aldehyde 5 is treated with the anion derived from bis-trimethylsilyl diacetylene to 
generate an alcohol that can readily and selectively be converted into the olefinic acetylene 6 
[14]. 
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Scheme 2 
The selective reduction is the result of an intramolecular hydroalumination reaction 
which is directed by the hydroxyl group [15]. Compound 6 can be brominated by the 
conditions of Yun and Danishefsky [16], and then coupled [17] with either propyne or 
trimethylsilylacetylene. The ketal protecting group of the resulting diacetylene can be removed 
using mild aqueous acid (PPTS, H2O) to afford 4 in 27 % yield from 6. The silyl protecting 
group can be removed with tetrabutylammonium fluoride at ambient temperature to provide 3 
in 30% overall yield from 6. 
Although we reported the first synthesis of 1, the number of steps and low overall yield 
limit the amounts of this ketone that can be made available for biological testing. Therefore, a 
new synthetic route to ketones such as 1 and 2 was explored. We could shorten the synthesis 
significantly if the phosphonium salt 9 shown in Scheme 3 reacted efficiently with 5, an 
intermediate of our syntheses of compounds 3 and 4. Since a copper-catalyzed acetylene 
coupling reaction was likely to be successful with 4-iodo-3-butyn-1-ol (7) we introduced the 
acetylene coupling step at an early stage [18]. Thus, 4-iodo-3-butyn-1-ol was coupled with 
propyne in 81% yield. Diynol 8 was then converted into phosphonium salt 9 in two steps. 
Compound 9 underwent a cis-selective Wittig reaction with aldehyde 5 to generate an ene 
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diyne in 54 % yield. This reaction gave the cis-alkene exclusively. Removal of the ketal 
protection group (PPTS, water) provided ketone 2 in 15% overall yield from 7. 
 
Scheme 3 
Natural distribution of ketones 3 and 4 
The distribution of these two ketones in accessions of six species of Echinacea (E. 
angustifolia, E. purpurea, E. pallida, E. sanguinea, E. simulata and E. tennesseensis) was 
determined by HPLC. Ketones 3 and 4 elute at 13.65 and 16.28 minutes, respectively (Fig. 1). 
These two ketones demonstrate very similar UV spectra, both with λmax at 210 nm, which 
agrees with previously reported results [19]. 
The mean levels of ketones 3 and 4 in two-year-old roots from six Echinacea species 
are presented in Fig. 2. Our results show that of the six Echinacea species examined, ketones 3 
and 4 present in at least two species: E. pallida and E. simulata. 
Of these two species, significantly (p < 0.01) higher concentrations of both ketone 3 
(0.32 ± 0.05 mg g−1 fr. wt) and ketone 4 (0.89 ± 0.12 mg g−1 fr. wt) were found in E. simulata, 
a species not typically used for commercial preparations. This information will be very useful 
for the standardization of Echinacea products. 
CONCLUSIONS 
The route described above for ketone 2 represents a significant improvement over our 
previous synthetic strategy. Our synthetic route to hydroxy ketones 3 and 4 is direct and quite 
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flexible with regards to the preparation of analogous compounds. The observation that levels of 
ketones 3 and 4 are higher in E. simulata, a species of Echinacea not used commercially, 
demonstrates the value of studying the natural distribution of plant constituents using authentic 
standards. 
EXPERIMENTAL 
General 
Unless stated otherwise, all reactions were magnetically stirred and monitored by thin-
layer chromatography (TLC) using 0.25 mm precoated silica gel F254 plates (Sigma-Aldrich). 
Column or flash chromatography were performed with the indicated solvents using silica gel 
(230–400 mesh) purchased from Dynamic Adsorbents, LLC. All melting points were obtained 
on a Laboratory Devices capillary melting point apparatus and are uncorrected. ¹H- and 13C-
NMR spectra were recorded on a Bruker VXR-300 (300 MHz) or a Bruker VXR-400 (400 
MHz) spectrometer. Chemical shifts are reported relative to internal chloroform (¹H, 7.26 ppm; 
13C, 77.23 ppm). High resolution mass spectra were performed at the Iowa State University 
Mass Spectrometry Laboratory. 
Plant material and extraction 
Two-year-old fresh roots of 6 species of Echinacea, E. angustifolia (Accession PI 
631285), E. purpurea (Accession PI 631307), E. pallida (Accession PI 631279), E. sanguinea 
(Accession PI 633672), E. simulata (Accession PI 631251) and E. tennesseensis (Accession PI 
631350), provided by Dr. Mark P. Widrlechner at the USDA-ARS North Central Regional 
Plant Introduction Station, were studied to evaluate the natural distribution of ketones 3 and 4 
in Echinacea species. The plant extraction method is the same as that in our previously 
published work [16]. Similarly, 7-hydroxy-(E)-N-isobutylundeca-2-ene-8,10-diynamide 
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(C15H21O2) was added as an internal standard prior to extraction for quantification purposes. 
All experiments were performed in triplicate on independently extracted plant samples from 
three individual plants. 
HPLC analysis 
HPLC procedures were as previously described [20]. Ketones 3 and 4 were quantified 
at UV 210 nm based on the internal standard because they have the same UV absorption at 210 
nm. The internal quantification method used here can account for variations in extraction 
efficiencies in different extracts. The limit of HPLC detection for each of the ketones is 
approximately 0.04 µg mL−1. 
1-Trimethylsilyl-11-oxodocec-3-en-1-yn-5-ol ethylene ketal (6) 
MeLi-LiBr complex (5 mL, 1.5 M soln in ether) was added to a solution of 1,4-
bis(trimethylsilyl)-1,3-butadiyne (1.46 g, 7.5 mmol) in THF (10 mL) at 0 °C under Ar. The 
mixture was warmed to room temperature and stirred for 4 h. The mixture was then cooled 
down to −78 °C and aldehyde 5 (0.700 g, 3.76 mmol) in THF (4 mL) was added via cannula. 
The mixture was stirred for 1 h while warmed to rt. The reaction was quenched with sat NH4Cl 
(aq) and the aqueous layer was extracted with ethyl ether. The combined organic layer was 
washed with water, brine, dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified via flash column chromatography to give the diynol (0.890 g, 77 % yield); 
¹H-NMR (400 MHz, CDCl3) δ: 4.45–4.38 (m, 1H), 3.97–3.89 (m, 4H), 1.89–1.80 (brs, 1H), 
1.74–1.60 (m, 4H), 1.48–1.32 (m, 6H), 1.31 (s, 3H), 0.19 (s, 9H). 
To a solution of above diynol (0.600 g, 1.94 mmol) in diethyl ether (20 mL) was added 
LAH (0.088 g, 2.33 mmol) at 0 °C and the mixture was stirred for 2 h while warming to rt. The 
mixture was poured into ice cold water (5 mL) then extracted with diethyl ether. The organic 
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layer was washed with water, brine, dried (MgSO4), filtered and concentrated in vacuo. The 
crude residue was purified via flash column chromatography to give compound 6 (0.590 g, 
98 % yield). ¹H-NMR (300 MHz, CDCl3) δ: 6.19 (dd, J= 15.9, 6.0 Hz, 1H), 5.72 (d, J= 15.9 Hz, 
1H), 4.28–4.10 (m, 1H), 3.96–3.87 (m, 4H), 1.68–1.47 (m, 6H), 1.42–1.32 (m, 5H), 1.30 (s, 
3H), 0.19 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 147.0, 110.3, 110.0, 72.4, 66.1, 64.8, 39.3, 
36.9, 29.8, 25.4, 24.2, 23.9, 15.5, 0.1; HRMS m/e (EI) for C17H30O3Si (M)+ calcd 310.1964, 
measured 310.1921. 
8-Hydroxytetradeca-(9E)-ene-11, 13-diyn-2-one (3) 
To a solution of compound 6 (0.125 g, 0.40 mmol) in acetone (10 mL) was added N-
bromosuccinimide (0.086 g, 0.48 mmol) and AgNO3 (0.004 g, 0.02 mmol) at rt. After stirring 
for 1 h at this temperature, the mixture was cooled to 0 °C and cold water (5 mL) was added. 
The aqueous layer was extracted with Et2O, dried (MgSO4), filtered and concentrated in vacuo. 
The crude residue was purified by flash column chromatography (hexanes-EtOAc) to give the 
corresponding bromoacetylene (0.055 g, 43% yield). 
To a solution of trimethylsilylacetylene (0.052 mL, 0.37 mmol) and bromoacetylene 
(0.040 g, 0.126 mmol) in degassed piperidine (1 mL) was added CuCl (0.002 g, 0.013 mmol) 
at 0 °C. The mixture was stirred at rt for 0.5 h. The reaction was quenched with sat. NH4Cl(aq) 
(1 mL) and extracted with ethyl ether (3 × 10 mL). The organic phase was washed with brine 
(2 × 10 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude residue was 
purified via flash chromatography to give the corresponding alcohol (0.035g, 83% yield). 
To a solution of the above alcohol (0.030 g, 0.08 mmol) in water/acetone (1 mL/1 mL) 
was added PPTS (0.002 g, 0.008 mmol) at rt. The mixture was heated at 40 °C for 3 h and 
extracted with diethyl ether. The organic layer was washed with brine (2 × 20 mL), dried 
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(MgSO4), filtered and concentrated in vacuo. The crude residue was purified via flash column 
chromatography to give the expected hydroxyketone (0.022 g, 95% yield). 
To a solution of hydroxyketone (0.022 g, 0.076 mmol) in THF (5 mL) was added 
TBAF (0.114 mL, 1M soln in THF) at 0 °C. The mixture was stirred for 1h at rt and solvent 
was removed. The crude residue was purified via flash column chromatography (hexanes/ethyl 
acetate, 2:1) to give compound 3 (0.015 g, 89 % yield). ¹H-NMR (400 MHz, CDCl3) δ: 6.34 
(dd, J= 16.5, 5.6 Hz, 1H), 5.73 (d, J= 16Hz, 1H), 4.22–4.17 (m, 1H), 2.42 (t, J= 7.6 Hz, 2H), 
2.41 (s, 1H), 1.60 (brs, 1H), 1.62–1.50 (m, 6H), 1.40–1.30 (m, 2H); 13C-NMR (100 MHz, 
CDCl3) δ: 209.4, 150.6, 108.0, 74.3, 73.9, 72.1, 71.3, 68.3, 43.8, 36.8, 30.2, 29.2, 25.2, 23.8; 
HRMS m/e (EI) for C14H18O2 (M)+ calcd. 218.1307, measured 218.1229. 
8-Hydroxy-pentadeca-(9E)-ene-11, 13-diyn-2-one (4) 
To a solution of compound 6 (0.125 g, 0.40 mmol) in acetone (10 mL) was added N-
bromosuccinimide (0.086 g, 0.48 mmol) and AgNO3 (0.004 g, 0.02 mmol) at rt. After stirring 
for 1 hr at rt, the mixture was cooled to 0 °C and cold water (5 mL) was added. The aqueous 
layer was extracted with Et2O, dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified by flash column chromatography (hexane-EtOAc) to give the 
bromoacetylene (0.055 g, 43% yield). 
Degassed piperidine (2 mL), bromoacetylene (0.060 g, 0.189 mmol) and CuCl (0.003 g, 
0.019 mmol) were mixed in a sealed tube. The mixture was cooled to −78 °C and excess 
propyne gas (condensed to liquid, 2 mL) was added by blowing along the wall of the tube. The 
mixture was slowly warmed to rt. After stirring for 2h at rt, the mixture was cooled to −78 °C 
and the sealed tube was opened then slowly warmed to room temperature while excess propyne 
was evaporated. Sat. NH4Cl (aq) was added to the mixture then extracted with ethyl ether. The 
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organic layer was washed with 10% HCl (aq), brine, dried (MgSO4), filtered and concentrated 
in vacuo. The crude residue was dissolved in 1:1 water/acetone (2 mL) and treated with PPTS 
(0.003 g, 0.012 mmol) at rt. The mixture was heated at 40 °C for 3 h and extracted with diethyl 
ether. The organic layer was washed with brine (2 × 20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified via flash column chromatography 
(hexanes/ethyl acetate, 2:1) to give compound 4 (0.027 g, 63 % yield). ¹H-NMR (300 MHz, 
CDCl3) δ: 6.26 (dd, J= 15.9, 6.0 Hz, 1H), 5.71 (d, J= 15.9 Hz, 1H), 4.20–4.12 (m, 1H), 2.42 (t, 
J= 7.5 Hz, 2H), 2.13 (s, 3H), 1.98 (s, 3H), 1.62–1.49 (m, 4H), 1.39–1.24 (m, 4H); 13C-NMR 
(75 MHz, CDCl3) δ 209.4, 148.7, 109.1, 81.8, 80.4, 76.8, 72.2, 64.5, 43.8, 36.8, 30.1, 29.2, 
25.2, 23.8, 4.8; HRMS m/e (EI) for C15H20O2 (M)+ calcd 232.1463, measured 232.1497. 
3, 5-Heptadiyn-1-ol (8) 
Degassed piperidine (5.5 mL), 4-iodo-3-butynol (1.22 g, 6.2 mmol) and CuCl (0.061 g, 
0.62 mmol) were mixedIn a tube. The mixture was cooled to −78 °C and excess propyne gas 
was added by blowing along the wall of the tube. The propyne was condensed to liquid (2 mL) 
in tube and the tube was sealed. The mixture was slowly warmed to rt. After stirring for 2 h at 
rt, the mixture was cooled to −78 °C and the sealed tube was opened. The mixture was warmed 
to rt slowly to evaporate excess propyne. NH4Cl (aq) (20 mL) was added to the mixture then 
extracted with Et2O (3 × 20 mL). Organic layer was washed with water, brine, dried (MgSO4), 
filtered and concentrated in vacuo. The crude residue was purified via flash column 
chromatography (hexanes/ethyl acetate= 2:1) to give compound 8 (538 mg, 81 % yield). ¹H-
NMR (300 MHz, CDCl3) δ: 3.74–3.71 (m, 2H), 2.51 (t, J = 6.8 Hz, 2H), 1.91 (s, 3H). 
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Triphenyl(hepta-3, 5-diynyl)phosphonium Iodide (9) 
To a solution of imidazole (374 mg, 5.5 mmol) and Ph3P (1.44 g, 5.5 mmol) in Et2O–
MeCN (12 mL/4 mL) was slowly added iodine (1.40 g, 5.5 mmol) at 0 °C. The resulting slurry 
was warmed to room temperature and then stirred for 20 min. The slurry was cooled to 0 °C 
and the alcohol 8 (538 mg, 4.9 mmol) was added in Et2O (10 mL) at 0 °C. The solution was 
slowly warmed to room temperature and then stirred for 1 h. The reaction was quenched by 
adding hexane (30 mL). The organic layer was washed with aq NaHCO3, brine, dried (MgSO4), 
filtered and concentrated in vacuo. The crude residue was purified via flash column 
chromatography (hexanes–EtOAc, 2:1) to give the iodide (1.04 g, 98 % yield). ¹H-NMR (300 
MHz, CDCl3) δ: 3.13 (t, J = 7.2 Hz, 2H), 2.77 (t, J = 7.2 Hz, 2H), 1.83 (s, 3H). To a solution of 
PPh3 (0.793 g, 3.03 mmol) in acetonitrile was added the above iodide (0.60 g, 2.75 mmol) and 
the mixture was boiled for 24 h, then cooled to rt and the solvent was removed to give 9 as a 
yellowish oil. (1.02 g, 78% yield). ¹H-NMR (400 MHz, CDCl3) δ: 7.76–7.53 (m, 15H), 3.86–
3.80 (m, 2H), 2.79 (dt, J = 20.8, 6.4 Hz, 2H), 1.87 (s, 3H). 
Pentadec-8Z-ene-11, 13-diyn-2-one (2) 
To a solution of compound 9 (612 mg, 1.19 mmol) in THF (10 mL) was added 
NaHMDS (1.19 mL, 1M in THF) at −78 °C. The mixture was stirred for 20 min at −78 °C, 
then aldehyde 5 (201 mg, 1.08 mmol) in THF (3 mL) was added by cannula. The mixture was 
slowly warmed to rt then stirred for 12 h. The reaction was quenched with NH4Cl (5 mL) and 
extracted with Et2O (20 mL). The organic layer was washed with water, brine, dried (MgSO4) 
and concentrated. The residue was purified via column chromatography (hexanes/ethyl 
acetate= 2:1) to give an enediyne (173 mg, 54 % yield). ¹H-NMR (400 MHz, CDCl3) δ: 5.46 
(dt, J = 10.4, 7.2 Hz, 1H), 5.36 (dt, J = 10.4, 7.2 Hz, 1H), 3.96–3.88 (m, 4H), 2.98 (d, J = 7.2 
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Hz, 2H), 2.01 (td, J = 7.2, 6.0 Hz, 2H), 1.89 (s, 3H), 1.63–1.59 (m, 2H), 1.41–1.29 (m, 6H), 
1.30 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ: 132.7, 122.9, 110.4, 75.0, 73.6, 65.3, 64.8, 64.7, 
39.4, 29.7, 29.5, 27.3, 24.2, 24.0, 17.8, 4.4. 
To a solution of the above compound (56 mg, 0.22 mmol) in 1:1 acetone/water (2 mL) 
was added PPTS (4.6 mg, 0.022 mmol) at rt. The mixture was heated at 40 °C for 3 h and 
extracted with ether. The organic layer was washed with brine (2 × 20 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The crude residue was purified via flash column 
chromatography (hexanes/ethyl acetate, 2:1) to give compound 2 (43 mg, 93% yield). ¹H-NMR 
(400 MHz, CDCl3) δ: 5.48–5.34 (m, 2H), 2.96 (d, J = 7.2 Hz, 2H), 2.41 (t, J = 7.2 Hz, 2H), 
2.12 (s, 3H), 2.01 (td, J = 7.2, 6.0 Hz, 2H), 1.88 (s, 3H), 1.60–1.51 (m, 2H), 1.42–1.22 (m, 6H); 
13C-NMR (100 MHz, CDCl3) δ: 209.4, 132.5, 123.1, 74.9, 73.6, 65.3, 64.8, 43.9, 30.1, 29.2, 
28.9, 27.2, 23.9, 17.8, 4.4; HRMS (EI): m/z calcd. for C15H20O : 216.1514; found: 216.1510. 
Statistical analysis 
Statistical analyses were performed using SAS software version 8.02 (SAS Institute 
Inc., Cary, NC). One-way analysis of variance followed by the Tukey test was used to compare 
means. Significance of difference was defined at p < 0.01. 
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Footnotes 
Sample availability: Milligram quantities of 3 and 4 are available from the authors. 
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Fig. 1 HPLC chromatograms obtained from a 95% ethanolic extracts of two-year-old 
roots from Echinacea pallida and Echinacea simulata, indicating ketones 3 and 4. 
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Fig. 2 Concentrations of ketones 3 and 4 in two-year-old roots from six species of 
Echinacea. Error bars indicate standard deviations of means of triplicate experiments. 
For each ketone, different letters indicate a significant difference (p < 0.01). 
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APPENDIX F.  YEAR-AND-A-HALF OLD, DRIED ECHINACEA ROOTS 
RETAIN CYTOKINE-MODULATING CAPABILITIES IN AN IN VITRO 
HUMAN OLDER ADULT MODEL OF INFLUENZA VACCINATION 
Modified from a paper published in Planta Medica 
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ABSTRACT 
Alcohol tinctures prepared from aged Echinacea roots are typically taken for 
preventing or treating upper respiratory infections, as they are purported to stimulate immunity 
in this context. The effects of long-term (> 1 year) dry storage on the capabilities of Echinacea 
spp. roots from mature individuals to modulate cytokine production are unknown. Using an 
older human adult model of influenza vaccination, we collected peripheral blood mononuclear 
cells from subjects 6 months post-vaccination and stimulated them in vitro with the two Type 
A influenza viruses contained in the trivalent 2004–2005 vaccine with a 50% alcohol tincture 
prepared from the roots of one of seven Echinacea species: E. angustifolia, E. pallida, E. 
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paradoxa, E. purpurea, E. sanguinea, E. simulata, and E. tennesseensis. Before being 
processed into extracts, all roots had been stored under dry conditions for sixteen months. Cells 
were cultured for 48 hours; following incubation, supernatants were collected and assayed for 
interleukin-2, interleukin-10, and interferon-γ production, cytokines important in the immune 
response to viral infection. Four species (E. angustifolia, E. purpurea, E. simulata, E. 
tennesseensis) augmented IL-10 production, diminished IL-2 production, and had no effect on 
IFN-γ production. Echinacea pallida suppressed production of all cytokines; E. paradoxa and 
E. sanguinea behaved similarly, although to a lesser extent. The results from these in vitro 
bioactivity assays indicate that dried Echinacea roots stored for sixteen months maintain 
cytokine-modulating capacities. Our data support and extend previous research and indicate 
that tinctures from different Echinacea species have different patterns of immune modulation; 
further, they indicate that certain species may be efficacious in the immune response to viral 
infection. 
Keywords:  Echinacea angustifolia, Echinacea pallida, Echinacea paradoxa, 
Echinacea purpurea, Echinacea sanguinea, Echinacea simulata, Echinacea tennesseensis, 
interleukin-2, interleukin-10, interferon-gamma, influenza, tincture 
INTRODUCTION 
The use of Echinacea phytomedicinal preparations has grown in the past few decades 
[1], [2]. Echinacea has documented immunomodulatory properties and is most frequently 
consumed to prevent or minimize symptoms from upper respiratory infections, although 
scientific studies regarding its efficacy in this capacity report dissimilar findings [3]. Echinacea 
can alter patterns of cytokine production in vitro as shown previously [4], [5], and this may 
increase resistance to infection. Some cytokines important in response to viral infection include 
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interleukin-2 (IL-2; enhances T-helper cell function, important in adaptive immunity against 
many viruses), IL-10 (regulator of cytokine synthesis with anti-inflammatory actions), and 
interferon-γ(IFN-γ, an antiviral cytokine). Although a well-controlled clinical trial recently 
demonstrated that Echinacea angustifolia did not minimize viral load in response to rhinovirus 
challenge [6], it is possible that various Echinacea species may alter cytokine expression in 
such a way as to reduce inflammation and associated symptoms. 
Recently, progress has been made to better understand the effects of drying on 
bioactive constituents of Echinacea roots. Both commercial manufacturers and lay herbalists 
commonly employ drying processes. The effects of commercial drying regimens (i.e., high 
temperatures and short drying times, sometimes involving techniques such as convection 
drying, freeze drying, or vacuum drying) on bioactive constituents of Echinacea have been 
studied [7], [8], [9], [10], [11], [12], [13]; however, various teams report conflicting findings. It 
is even less clear how drying conditions such as those a lay herbalist would employ may affect 
bioactivity of Echinacea roots; however, Perry et al. [14] have reported that alkamide levels 
dropped 80 % when E. purpurea roots were stored at 24 °C for 64 weeks, a method similar to 
that employed by lay herbalists. Data on the effects of longer-term storage (> 1 year) are 
lacking. Medicinal plants may be capable of retaining their medicinal properties long after 
harvest, as has been recently demonstrated with an 85-year-old specimen of black cohosh 
(Actaea racemosa L.) [15]. 
The effects of plant age on root bioactive constituent concentrations have also been 
investigated. However, the results of these studies are conflicting. The roots from older plants 
may have increased, decreased, or similar levels of constituents compared to younger 
counterparts per the specific constituent [16], [17]. 
  
196
While numerous phytomedicinal studies of Echinacea spp. roots have been reported, 
only a handful of these reports state specifically that dried roots were employed. In vitro 
cytokine production from mouse splenocyte cultures stimulated with water and ethanol/water 
extracts of dried E. purpurea roots and leaves has been investigated. Various extracts increased 
production of IL-6, IL-10, MIP-1α, and TNF-α, but not IL-2, IL-12, or IFN-γ [4]. In other 
studies, E. purpurea dried root powder has shown cyclooxygenase-inhibiting properties in both 
in vitro [18] and ex vivo [19] models. Granulocytes from mice fed Echinacea (several spp.) 
demonstrated higher levels of stimulation both during and immediately after the feeding period 
as compared to granulocytes from control mice [20]. Splenic lymphocytes from mice treated 
with E. purpurea dried root powder showed greater apoptosis resistance compared to non-
treated controls, suggested by down-regulation of Fas-Ag expression and up-regulating Bcl-2 
expression at the cell surface [21]. In combination with roots of wild indigo (Baptisia tinctoria 
L. [Vent], Fabaceae) and shoots of white cedar (Thuja occidentalis L, Cupressaceae), extracts 
of dried E. pallida and E. purpurea roots lowered mortality, increased mean survival time, 
reduced lung consolidation, and reduced lung viral titer in mice infected with influenza Type A 
[22]. 
Despite these data, it is difficult to compare the results from different researchers 
because several important variables were not reported, including: (a) age of plant at time of 
harvest; (b) length of drying time; (c) drying and storage conditions; (d) accession and origin of 
plant materials used; and (e) plant handling conditions (i.e., was the plant kept intact, 
portioned, chopped, etc.?). 
The aim of the present study was to investigate the effects of sixteen months of dry 
storage on the immunomodulatory properties of roots from defined accessions of seven 
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Echinacea species by using an older human adult model of influenza vaccination. Our 
hypothesis was that Echinacea roots stored under dry conditions for sixteen months and then 
processed into alcohol tinctures would retain cytokine-modulating capabilities, although these 
effects would vary by species. To test this hypothesis, we isolated peripheral blood 
mononuclear cells from older humans (> 64 years of age) who had been vaccinated with the 
trivalent influenza vaccine 6 months prior to this study. Cells were incubated in vitro for 48 
hours with Echinacea tinctures or control, along with influenza antigen. We tested supernatants 
for the synthesis of IL-2, IL-10, and IFN-γ, cytokines known to be important in the immune 
response to upper respiratory infections such as influenza [23]. 
MATERIALS AND METHODS 
Plant collection, drying, and storage 
All plant material used in this study was harvested in December 2003 from the North 
Central Regional Plant Introduction Station in Ames, Iowa. Every attempt was made to keep 
root bundles intact upon excavation; further, all aerial parts were left attached. The following 
species were collected and are given with their respective accession identifiers as well as the 
abbreviations by which they and the corresponding tinctures will be referred to in this 
publication: E. angustifolia var. strigosa (ANG; PI631302A), E. pallida (PAL; PI631275), E. 
paradoxa var. neglecta (PAR; PI631263), E. purpurea (PUR; unknown parentage), E. 
sanguinea (SAN; PI631257C), E. simulata (SIM; PI631304A), and E. tennesseensis (TEN; 
PI631250C). Voucher specimens for PUR, SAN, and TEN were deposited at Ada Hayden 
Herbarium, Ames, IA (ISC 435975,434027, and 435980, respectively). Vouchers for ANG, 
PAL, and SIM were prepared by K. McKeown (McKeown #97004,97007,97002, 
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respectively). All collections are available through the Station; images and respective data may 
be found at http://www.ars-grin.gov/npgs. 
Whole plants were taken to the laboratory for temporary storage before being moved to 
a climate-controlled facility for sixteen months of storage. This room was held at 25.5 – 26.5 
°C and 38 % relative humidity during the study as determined by a separate temperature 
hygrometer. Plants were hung upside down during this time. No special plant preparatory or 
drying procedures were used. 
Extract preparation 
Following storage, plants were removed to the laboratory where ethanol tinctures 
consisting of 50% ethanol and 50% sterile water were prepared from roots. In all cases, plant 
cross-sections and/or shavings were produced using a surgical scalpel and combined with 
solvent as 1 part plant, 9 parts solvent. Preparations were steeped at room temperature for 20 
minutes on a horizontal agitator before being filtered through sterilized tulle and stored at −20 
°C until use. 
High-performance liquid chromatography 
Phytochemical analysis was performed to detect alkamides and caffeic acid derivatives 
in the Echinacea extracts with the use of high-performance liquid chromatography (HPLC). 
Before analysis, into 160 μL of Echinacea extracts, 15 μL (1 mg mL−1) N-isobutylundeca-2-
ene-8,10-diynamide (C15H21O2) and 15 μL (1 mg m L−1) 3,5-dimethoxy-4-hydroxycinnamic 
acid (C11H12O5) were added as internal standards for quantification of lipophilic metabolites 
and hydrophilic metabolites, respectively. Fifteen microliters of each sample were injected into 
a Beckman Coulter HPLC with a 508 autosampler, 126 pump control and 168 UV-photodiode 
array detector controlled by 32karat™ software (Version 5.0), and a YMC-Pack ODS-AM RP 
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C18 (250 × 4.6 mm, 5 μm) analytical column (Waters; Bedford, MA, USA). The solvent 
system for lipophilic constituents was acetonitrile/H2O at a flow rate of 1.0 mL/min following a 
linear gradient of 40–80% acetonitrile over 45 min. The solvent system for hydrophilic 
constituents consisted of acetonitrile/H2O and 0.01 % formic acid, at a flow rate of 1.0 mL/min 
following a linear gradient of 10–35% acetonitrile over 25 min. Online UV spectra were 
collected between 190 and 400 nm. 
For compound identification, alkamides 8/9, cichoric acid, echinacoside, caftaric acid 
and cynarin were purchased from Phytolab (Vestenbergsgreuth, Germany); chlorogenic acid 
was purchased from Sigma Aldrich (St. Louis, MO, USA); alkamides 8, 10, 11, 12, 13, and 14 
and ketone 22 were synthesized by Dr. George Kraus, Department of Chemistry, Iowa State 
University [24], [25]. In the absence of standards, alkamides 1, 2, 3, 4, 5, 7 and ketone 24 were 
identified by HPLC fractionation coupled with GC-MS analysis. Phytochemicals were 
quantified based on the internal standard with the limit of HPLC detection at approximately 
0.02 μg/mL 
Human subjects and PBMC isolation 
All procedures involving human subjects were approved by the Institutional Review 
Board (ethics commission) at Iowa State University and Des Moines University of Osteopathic 
Medicine. Forty subjects were recruited. Exclusion/inclusion criteria were dependent on age, 
health status, and medication and supplement use. The minimal age of subjects was 64. 
Subjects reporting cancer within the last 5 years, or autoimmune disorders or other disorders 
likely to impact on immune variables, were excluded. Individuals treated with medications that 
might significantly alter immune variables (i.e., oral corticosteroids) or medications for treating 
anxiety/depression were excluded. In addition, subjects taking dietary supplements thought to 
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alter immune responses were excluded. In October 2004, participants received the trivalent 
influenza vaccine containing A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2), 
and B/Jiangsu/10/2003 (Aventis Pasteur; Swiftwater, PA, USA). Six months post-vaccination 
(April 2005), subjects returned to the laboratory for a blood draw to be used for testing the 
Echinacea extracts. Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-
Paque plus (Amersham Pharmacopia Biotech; Piscataway, NJ, UAS) gradient centrifugation, 
counted manually using a hemacytometer, and adjusted to a concentration of 1.0 × 106 
cells/mL in AIM-V media (GIBCO/Invitrogen; Carlsbad, CA, USA). 
Vaccine efficacy 
To determine whether the vaccine elicited an immunological response in subjects, 
hemagluttination inhibition (HI) assays as described elsewhere by Kohut et al. [26] were 
performed. Sera were collected pre- and four weeks post-vaccination, and HI titer (antibody 
response) was measured for the Influenza A/New Caledonia/20/99 (H1N1) and Influenza 
A/Wyoming/03/2003 (H3N2) viruses contained in the vaccine. 
Influenza-specific activation of PBMCs 
1.0× 106 cells were plated per well in 24-well Costar plates. Each well received either 
50 μL of one of the Echinacea preparations diluted 1:12.5 or a solvent vehicle control 
containing an equal volume of ethanol as the extract. The ethanol for the solvent vehicle 
control was diluted in AIM-V media. This extract concentration was selected based on 
preliminary studies of cell ethanol tolerance (data not shown). Wells received 10 HA units/mL 
of either the Influenza A/New Caledonia/20/99 (H1M1) virus or the Influenza 
A/Wyoming/03/2003 (H3N2) virus identical to that contained in the vaccine to stimulate virus-
specific cytokine production. Based on several previous studies, the wells that do not contain 
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virus typically have cytokine levels ranging from undetectable up to 10–30 pg/mL at peak time 
points of in vitro culture. The cytokine levels in wells containing virus are typically 10- to 100-
fold greater than the cytokine level in wells containing media or vehicle alone, suggesting that 
the response detected is antigen-specific. The Echinacea preparations were added to culture 
wells at the same time that virus was added. Control wells received virus identical to 
Echinacea-treated wells, but received the solvent vehicle control instead of an Echinacea 
preparation. 
Cytokine assays 
Cells were incubated for 48 hours at 37 °C, 5.0% carbon dioxide in humidified 
conditions for the cytokine assay. Following incubation, the supernatants were harvested and 
stored at −20 °C until used in cytokine quantification assays. Cytokines [interleukin-2 (IL-2), 
IL-10, and interferon-γ (IFN-γ)] were quantified by ELISA (BD Biosciences Pharmingen; San 
Diego, CA, USA). 
Endotoxin determination 
Measures were taken to minimize endotoxin contamination. All glassware was baked at 
180 °C for 24 hours prior to use. Sterile water was obtained from the manufacturer labeled for 
human medical use. Endotoxin levels were determined from both the sterile water (0 endotoxin 
units [EU]/mL) and from all final extracts by using Bio-Whitaker QCL 1000 kits (Cambridge, 
MA, USA). Levels (in EU/mL) from the extract stocks were as follows: ANG 8.925, PAL 
8.553, PAR 9.817, PUR 8.999, SAN 9.222, SIM 8.255, TEN 9.743. 
To experimentally determine whether the endotoxin levels seen in the extracts 
influenced our immune outcomes, we isolated PBMC from four healthy, young adults 
according to the methods described above. Cells were cultured for 24 hours in AIM-V media 
  
202
with 50 μL of stock concentrations of Escherichia coli endotoxin at 10 EU/mL or 100 EU/mL 
or sterile water (0 EU/mL). The 10 EU/mL stock represented an endotoxin level > 12.5 × 
higher than our Echinacea diluted extract with the highest endotoxin level (PAR), and the 100 
EU/mL stock represented an endotoxin level known to be immunostimulatory. For the 
endotoxin assay, supernatants were collected and cytokines [IL-2, IL-10, interleukin-1β (IL-
1β), and tumor necrosis factor-α (TNF-α)] quantified by ELISA (BD Biosciences Pharmingen). 
Statistical analyses 
A two-way ANOVA [species × virus type] was used to compare differences in 
cytokine production by using SPSS (Chicago, IL, USA) software. One-way ANOVA was used 
to determine the effects of different endotoxin doses on cytokine production. Statistical 
significance was defined as α = 0.05. 
RESULTS 
Extracts prepared by using methods resembling those of lay herbalists may harbor 
endotoxin from contaminating bacterial populations growing on the plant, and endotoxin is a 
known mitogen in vitro. To determine experimentally if endotoxin levels in our extracts may 
be influencing immune outcomes, we tested stock concentrations of E. coli endotoxin against 
human PBMC. Results are shown in Fig. 1. Cytokine production from cells receiving the 
diluted stock of 10 EU/mL was not significantly different from control (0 EU/mL) for IL-1β (p 
= 0.995), IL-10 (p = 0.973), and TNF-α (p = 0.98); however, cells receiving the diluted stock of 
100 EU/mL produced higher levels of cytokine as compared to control for IL-1β (p = 0.068), 
IL-10 (p = 0.044), and TNF-α (p = 0.005). No differences were observed for IL-2, which is 
expected, as this is primarily a T-cell-produced cytokine with little responsiveness to endotoxin 
[27]. 
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The phytochemical analysis of our extracts for alkamides, ketones, and caffeic acid 
derivatives is presented in Table 1 and Fig. 1S in the Supporting Information. Extracts from 
ANG, PUR, and SAN had the highest concentrations of alkamides. PAL, PAR, and SIM had 
the highest concentrations of ketones. Contents of caffeic acid derivatives differed by specific 
molecule. Overall, PUR had the highest total concentration of caffeic acid derivatives, and 
PAL had the greatest diversity of molecules. 
Hemagluttination inhibition assays for vaccine efficacy indicated that subjects 
responded to the vaccination. Antibody titers for Influenza A/Wyoming/03/2003 (H3N2) were 
6.9 ± 1.5 pre-vaccination compared to 8.0 ± 1.8 post-vaccination (p < 0.001). Antibody titers 
for Influenza A/New Caledonia/20/99 (H1N1) increased, but were not significantly different 
(6.38 ±1.0 pre-vaccination, 6.43 ± 1.2 post-vaccination), likely due to the presence of this same 
H1N1 antigen in several previous years’ influenza vaccines, as other researchers have also 
shown in this age group [28]. 
Results for interleukin-10 production are given in Fig. 2. A significant main effect of 
plant species was observed (p < 0.001) as well as a plant species by virus interaction (p = 
0.038). Follow-up analyses were conducted separating results from the two viruses. For 
Influenza A/New Caledonia/20/99 (H1N1) alone, a significant effect of plant species remained 
(p = 0.001). Four extracts stimulated significant increases in cell production of IL-10 compared 
to the control condition containing no Echinacea (Fig. 2A): ANG (p < 0.001), PUR (p < 
0.001), SIM (p = 0.001), and TEN (p = 0.002). PAL significantly decreased IL-10 production 
(Fig. 2A; p = 0.005). A similar pattern of results was found for the H3N2 virus. For Influenza 
A/Wyoming/03/2003 (H3N2) alone, a significant effect of plant species remained (p < 0.001). 
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Extracts from the same four species stimulated increases in IL-10 production (Fig. 2B): 
ANG (p < 0.001), PUR (p = 0.002), SIM (p = 0.001), and TEN (p = 0.010). PAL again 
significantly decreased IL-10 production (p < 0.001). 
Results for interleukin-2 production are shown in Fig. 3. A significant main effect of 
plant species was found (p < 0.001). All seven extracts induced statistically significant (all p < 
0.001) reductions in IL-2 production compared to control condition containing no Echinacea. 
Results for interferon-γ production are displayed in Fig. 4. A significant main effect of 
plant species was observed (p < 0.001). No extracts significantly augmented IFN-γ production. 
However, three extracts significantly diminished IFN-γ synthesis: PAL (p < 0.001), PAR (p < 
0.001), and SAN (p = 0.003). 
DISCUSSION 
In this study, we employed an in vitro human older adult model of influenza 
vaccination to assess the bioactivity of Echinacea roots stored dry for sixteen months, 
specifically focusing on their ability to modulate patterns of cytokine expression in response to 
antigen challenge. This model had several virtues that made it readily amenable to the 
questions being addressed in this investigation. Echinacea extracts are typically taken for the 
prevention or treatment of upper respiratory infections, such as influenza [29]. The model 
chosen here allowed us to test the potential efficacy of Echinacea extracts in an in vitro context 
of viral infection using human PBMC. The elderly are one segment of the population that 
typically consumes Echinacea preparations in an attempt to “boost” their immunity [30]. 
Influenza vaccine efficacy rates in geriatric populations are typically poorer than those of 
young adult controls, and influenza infection is a major cause of morbidity and mortality in this 
group [31]. Thus, results from this study may provide information on the potential feasibility of 
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using Echinacea preparations to improve influenza vaccine efficacy rates in older adults. In 
addition, a better understanding of how Echinacea may modulate cytokines in response to 
influenza virus challenge in vitro may be a first step in understanding the potential role of 
Echinacea during an influenza infection in vivo. 
The effects of endotoxin in our extracts were explored experimentally (Fig. 1). Cells 
stimulated with endotoxin levels somewhat higher than levels in the extracts behaved no 
differently than controls that contained no endotoxin. These findings suggest that endotoxin 
levels in our Echinacea extracts did not influence the immune outcomes reported here. 
Results for our cytokine assays (Figs. 2–4) are summarized in Table 2. As is clear from 
these figures, even after sixteen months of dry storage, Echinacea roots maintained cytokine-
modulating capabilities. 
We saw contrasting effects of preparations made from different Echinacea species on 
the production of interleukins. In general, Echinacea preparations tended to have no effect or 
increased production of IL-10 (Fig. 2; Table 2). In contrast, all tinctures decreased production 
of IL-2 (Fig. 3; Table 2). Table 1 does not suggest any single molecule or class of molecules 
that may be responsible for the IL-10 activities seen in Table 2. According to Table 1, amides 
and caffeic acid derivatives (but not ketones) were present in all species to varying extents. 
Chlorogenic acid was the only molecule detectable in extracts from all seven species. It is 
possible that multiple alkamides or multiple caffeic acid derivatives may be responsible for this 
activity. One possible explanation for these results is that compounds in Echinacea may 
promote a down-regulation of the immune response following viral infection (e.g., by 
producing more IL-10 and less IL-2). This explanation may also support those studies finding a 
beneficial effect of Echinacea during viral infection [32]. 
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With respect to our findings, Echinacea did not appear to enhance IFN-γ (Fig. 4; Table 
2). Some species inhibited IFN-γ, suggesting that these species may not be efficacious in 
stimulating antibody production if consumed at the time of vaccination. No single molecule or 
group of molecules from Table 1 was unique to these three species, making it unclear which 
constituent s) are responsible for these activities. Our results suggest that Echinacea 
preparations made in the manner employed here may not have a large effect on the production 
of IFN-γ. Though IFN-γ response following influenza vaccination is reduced in older adults 
compared to younger counterparts [33], researchers have shown that increases in IFN-γ 
correlate with increases in antibody titer in vaccinated elderly [34]; similarly, a poor Th1 (IFN-
γ) response to influenza vaccine is correlated with reduced antibody response to the vaccine 
[35]. Therefore, our findings based on the IFN-γ response may suggest that Echinacea 
administered at the time of immunization is not likely to increase antibody response to the 
vaccine, but direct evidence regarding this possibility is not available from our study. In older 
adults, the vaccine does not provide complete protection. In the event of influenza infection, 
cell-mediated immune responses become important clearing virus infection. Cell-mediated 
responses may be measured by examining proliferative response of PBMC to appropriate 
antigen. Studies have shown that the proliferative response of PBMC is correlated with 
influenza-stimulated production of IL-10 in older adults [23]. IL-10 also appears to be 
necessary for the development of specific antibody subclasses in response to influenza vaccine 
[36]. Based on our results, it is possible that the Echinacea-associated increase in IL-10 may 
direct antibody subclass development if Echinacea had been administered at the time of 
vaccination and/or improve response to infection by promoting proliferation of appropriate cell 
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populations. However, clinical trials will be necessary to determine whether Echinacea may 
alter vaccine efficacy and/or modulate immune responses to influenza virus infection. 
Seven species of Echinacea were employed under the same experimental conditions, 
allowing us to make comparisons across taxa. The most consistent responses were seen from 
cells stimulated with PAL: in all cases, PAL induced decreases in cytokine production (Table 
2). Extracts from two other species, PAR and SAN, also decreased production of IL-2 and 
IFN-γ, but not IL-10. ANG, PUR, SIM, and TEN augmented production of IL-10 and 
diminished production of IL-2; no effects were seen on IFN-γ. These results imply that not all 
Echinacea species influence cytokine expression in similar fashions, supporting previous 
results from our lab [5] as well as others [37], [38], [39]. More specifically, extracts from 
certain species, such as PAL, PAR, and SAN, tend to show repressive effects regardless of the 
cytokine being assayed, whereas others, such as ANG, PUR, SIM, and perhaps TEN, stimulate 
cytokine-specific responses. Intriguingly, the three species employed for commercial 
preparations are E. angustifolia, E. pallida, and E. purpurea, alone or in various combinations 
[3], [40]. Our results may indicate that these three species do not have similar effects, and may 
warrant a re-assessment of which species are included in commercial preparations and in what 
particular combinations. 
In conclusion, the results from this study suggest that Echinacea roots stored dry for 
sixteen months maintain cytokine-modulating capabilities. Additionally, they suggest that 
different Echinacea species may act on cytokine expression in different fashions. Whether or 
not Echinacea extracts may have utility as influenza vaccine boosters and/or a beneficial role 
during actual influenza infection is not addressed directly by this study; however, our in vitro 
findings do suggest the plausibility of such an application. Finally, more studies are needed to 
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examine relationships between the phytochemical composition of extracts and extract fractions 
and immunomodulatory activities of these materials to identify possible bioactive molecules 
and their associated effects. 
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Figure 1. Cytokine production (in pg/mL) by PBMC stimulated with various levels of 
endotoxin: (A) IL-1β, (B) TNF-α, (C) IL-10, (D) IL-2. Bars represent standard errors.
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Figure 2. IL-10 production (in pg/mL) by Echinacea tinctures under H1N1 (A), and 
H3N2 (B) stimulation. Bars represent standard errors. Note the direction of 
significance. Species abbreviations: ANG (E. angustifolia var. strigosa), PAL (E. 
pallida), PAR (E paradoxa var. neglecta), PUR (E purpurea), SAN (E. sanguinea), SIM 
(E. simulata), and TEN (E. tennesseensis). 
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Figure 3. IL-2 production (in pg/mL) by Echinacea tinctures under HIN1 (A), and 
H3N2 (B) stimulation. Bars represent standard errors. Species abbreviations: ANG (E. 
angustifolia var. strigosa), PAL (E. pallida), PAR (E. paradoxa var. neglecta), PUR (E. 
purpurea), SAN (E. sanguinea), SIM (E simulata), and TEN (E tennesseensis). 
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Figure 4. IFN-γ production (in pg/mL) by Echinacea tinctures under H1N1 (A), and 
H3N2 (B) stimulation. Bars represent standard errors. Species abbreviations: ANG (E. 
angustifolia var. strigosa), PAL (E. pallida), PAR (E. paradoxa var. neglecta), PUR (E. 
purpurea), SAN (E. sanguinea), SIM (E simulata), and TEN (E tennesseensis). 
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Table 1. Phytochemical profile of Echinacea extracts used in this paper as determined 
by HPLC 
Compound ANG PAL PAR PUR SAN SIM TEN 
amide 1 ND ND ND 0.0456 0.0718 ND ND 
amide 2 0.0059 0.0008 ND 0.0159 0.0175 ND ND 
amide 3 0.0059 0.0087 ND 0.031 0.2011 ND ND 
amide 4 0.0059 ND ND ND 0.0213 ND ND 
amide 5 0.0124 ND ND 0.0156 ND ND ND 
amide 7 0 ND ND 0.0092 0.0559 ND ND 
amide 8 0.2798 ND ND 0.2912 1.3138 ND ND 
amide 9 0.0343 ND ND 0.0396 0.3387 ND ND 
amide 10 0.0368 ND ND 0.0102 0.0378 ND ND 
amide 11 0.0486 ND ND 0.0106 0.0286 ND ND 
amide 12 0.0371 ND ND ND 0.2782 ND 0.0024 
amide 13 0.0449 ND ND ND 0.1444 ND 0.0098 
amide 14 0.0141 ND ND ND 0.4444 ND 0.0085 
ketone 22 ND 0.054 0.0029 ND ND 0.0148 ND 
ketone 24 ND 0.1668 0.0301 ND ND 0.0093 ND 
caftaric acid ND 0.0535 ND 0.1568 0.0113 0.0359 ND 
chlorogenic 
acid 0.0137 0.0079 0.0266 0.0157 0.0509 0.0069 0.0088 
cichoric acid ND 0.0141 ND 1.0147 ND ND ND 
Cynarin 0.0223 ND ND ND ND ND 0.0094 
echinacoside 0.031 0.0885 0.1472 ND ND 0.0476 0.0436 
Species abbreviations: ANG (E.. angustifolia var. strigosa), PAL (E. pallida), PAR (E.. paradoxa var. neglecta), 
PUR (E.. purpurea), SAN (E.. sanguined), SIM (E.. simulato), and TEN (E.. tennesseensis). ND = Not detectable. 
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Table 2. Summary of significant effects of Echinacea tinctures on cytokines. Arrows 
indicate direction of effect 
 IL-2 IL-10 IFN-γ 
ANC ↓ ↑  
PAL ↓ ↓ ↓ 
PAR ↓  ↓ 
PUR ↓ ↑  
SAN ↓  ↓ 
SIM ↓ ↑  
TEN ↓ ↑  
 
Species abbreviations: ANG (E. angustifolia var. strigosa), PAL (E. pallida), PAR (E. paradoxa var. neglecta), 
PUR (E. purpurea), SAN (E. sanguinea), SIM (E simulata), and TEN (E tennesseensis). 
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